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The Characterization of Non-Ionic Surfactant Vesicles: A Release Rate Study for
Drug Delivery
Kristina Dearborn
ABSTRACT
Drug delivery methods for the treatment of brain tumor cells have been both
inefficient and potentially dangerous for cancer patients. Drug delivery must be done in a
controlled manner so that the effective amount of medication is delivered to the patient
and ensure over-dosage does not cause adverse side reactions in the patient. The focus of
this investigation is to design a drug delivery system that would allow for site-specific
administration of the drug, protection of the drug from the surrounding environment, and
controlled sustained release of the drug. We have proposed a model that incorporates a
niosome, which is a non-ionic surfactant vesicle, within a biodegradable polymer
hydrogel. The drug is encapsulated in the niosome, and the niosome is embedded within
a three-dimensional hydrogel network. It is therefore critical that the release rate of the
drug from the niosome be studied. This investigation provides information about the
release rate and behavior of the drug within the niosome as it is placed in a semipermeable membrane. The niosome and dye solution in the cellulose membrane are
placed in contact with water or PBS.

Intensity measurements are taken using

fluorescence spectrometry, and the readings are converted to concentration and moles
values. The release rates of the dye from of the niosome and across the membrane are

x

studied as the concentration data is collected over time. The results indicate that most of
the niosomes will release their dye within ten hours. The water will create instability in
the niosomes, while the PBS solution will maintain the stability of the niosomes. The
concentration that diffuses across the cellulose membrane will steadily increase and can
be predicted well by a simple diffusion model. We hope to use the information provided
in this study to continue to design a drug delivery method that will stabilize the niosomes
and allow for the maximum control over the release rate of the drug.

xi

Chapter One

Introduction

1.1.

Brain Tumor Disease
Brain tumor disease refers to the disease that is caused by the presence of

undesirable tissue or the abnormal formation of tissue in the brain. In 2000, it was
estimated that approximately 40,900 people living in the United States had developed a
primary brain tumor, either malignant or benign [1]. Remarkably, 3,140 of those patients
were under the age of 20 years. In 2004, approximately 18,400 new patients were
diagnosed with brain cancer and other nervous system tumors [1, 2]. In that same year,
approximately 12,690 patients died of brain/nervous system cancer [2].

Of that

population, approximately 75% of the people were living with a benign brain tumor, 23%
with a malignant brain tumor, and about 2% are uncertain of the tumor type [3]. Brain
tumors effect all ages, races, ethnic backgrounds, genders, and religions. However, it is
reported that women have a higher incidence rate (15 per 100,000) than men (14 per
100,000) [4]. Brain tumor disease is the second leading cause of cancer death in men
ages 20-39 years and the fifth leading cause of cancer death in women in that same age
bracket [5]. The three most common types of primary brain tumors are: astrocytomas
(12%), meningiomas (27%), and glioblastomas (23%) as shown in Figure 1 [4].
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Figure 1. Primary Brain and Central Nervous System (CNS) Tumors by Histology
1998-2002 (n=63,698)

Primary tumors originate in the brain [1]. These tumor types differ in location in the
brain in which the tumor is found and in the grade development of the tumor. Metastatic
brain tumors are tumors that originate from other tumors in the body, commonly from
breast cancer or lung cancer, and spread to areas in the brain. They have an incidence
rate that is four times greater than primary tumors [1]. In 1992-1999, the five-year
survival rate of people diagnosed with malignant brain tumors was 33% [2].
Glioma tumors can often result in the most severe types of brain tumors. Glioma
refers to any type of tumor that involves the glial cells, which are the supportive tissue in
the brain that help to keep the brain neurons functioning properly [1]. Approximately
70% of brain tumors are glioma tumors [6]. The five- year survival rate for patients
diagnosed with a glioma is less than three percent, and the risk increases as age increases
[6]. The recurrence of glioblastoma is between six and twelve months and between 182

36 months for astrocytoma [7].

Astrocyte glial cells lead to astrocytoma tumors,

oligodendrocyte cells lead to oligodendrogliomas tumors, and ependymal cells lead to
ependymomas tumors. The astrocyte cells are properly named so due to their long
branch arms and star-like appearance [1]. Figure 2 illustrates the location and shape of
these cells [8].

Figure 2. Illustration of Astrocyte, Oligodendrocyte, and Ependyma Glial Cells

Astrocytoma is a type of brain tumor that can range from a Grade I to a Grade IV tumor
with Grade IV being the most severe. There are several types of astrocytoma tumors that
include cerebella (located in the cerebellum), desmoplatics infantile (Grade I), pilocytic
(Grade I), subependymal giant cell, diffuse astrocytoma (Grade II), anaplastic Grade III),
and the astrocytomas Grade IV (glioblastoma multiforme) [1]. The treatment for these
tumors can range from surgery, radiation therapy, and chemotherapy. The chemotherapy
drugs that are often used are Carmustine (BCNU), Procarbazine, and Temozolomide
(Temodar). Oligodendroglioma is a type of brain tumor that can range from a Grade II to
a Grade IV tumor. The oligodendroyte cells have short branch arms and have a “fried
egg” like shape [1]. This tumor is frequently located in the cerebral hemisphere and
3

about half are found in the frontal lobe [1]. The treatment for this type of tumor is
usually by surgically removing the tumor and possible radiation or chemotherapy to
follow up. Ependymoma is a type of brain tumor that can range from a Grade I to a
Grade IV tumor. These tumors line the ventricles of the brain and center part of the
spinal cord [1]. These tumors are relatively rare as about 2-3% of primary brain tumors,
but comprise the most common type of brain tumor in children [1]. The treatment for
this type of brain tumor is surgery and radiation.
The causes and risk factors for developing a primary brain tumor are still not well
confirmed.

Environmental and genetic factors have been identified that may be

associated with the disease, but no one factor can predict if someone is at risk of
developing a brain tumor. It has been shown that exposure to ionizing radiation increases
the risk of a brain tumor [1, 6]. Several other environmental factors that may be linked to
brain tumor disease include, but are not limited to, exposure to vinyl chloride, diet,
common infections and viruses, smoking, exposure to agricultural work, exposure to air
pollution, and history of head trauma [1, 6]. It has been shown that only about 5-10% of
brain tumors are caused by genetic disorders [1]. In addition to the genetic syndromes
associated with brain tumors, researchers have identified several other genes in brain
tumors that do not function properly. These genes include tumor suppressor genes
(inhibit tumor growth), oncogenes (create tumor growth in an uncontrolled manner),
growth factors (normal cell growth), cyclin-dependent kinase inhibitors (normal growth
cell cycle), DNA repair genes (control repair of DNA), carcinogen metabolizing genes
(break down toxic chemicals), and immune response genes (controls virus and infection
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response) [1]. Certain chromosomes have been identified and associated with brain
tumors including chromosomes 1, 10, 13, 17, 19, and 22 [1].
The treatment for brain tumors includes surgery to remove the tumor,
chemotherapy, and radiation therapy. These treatments can be used as the primary
treatment alone for the tumor or in combination with the other two treatment methods.
Surgery, of an average 5 cm diameter tumor, can increase survival time up to six months
[9]. Surgery can often be difficult with brain tumors due to the lack of well-defined
boundaries of the tumor and its location to critical areas in the brain [7]. Chemotherapy
refers to the use of certain drugs to kill existing tumor cells and prevent the growth of
more cells [1]. The drug works by inhibiting cell duplication or replication. They may
either be cell-cycle specific targeting drugs (Procarbazine, Temozolomide) or non cellcycle specific targeting drugs (BCNU) [1]. Chemotherapy drugs may be administered
either by systemic delivery (injected into the bloodstream via an artery, muscle, or vein)
or by local delivery (implanted on or around the actual tumor) [1]. The blood brain
barrier is the protective layer that surrounds and protects the brain from foreign species.
Systemic delivery can overcome the blood brain barrier by using the drug Mannitol to
break through this barrier. Local delivery can be delivered directly between meninges
spaces (intrathecal) or into the cavity that the tumor left behind (intracavitary), brain
tissue (interstitial), tumor by gravity (convection enhanced), tumor (intratumoral), or a
ventricle (intraventricular) [1]. The use of chemotherapy drugs can cause normal cells in
the body to be exposed to the doses of medicine given to treat the tumor cells. Side
effects are often experienced by the patients in response to the effect of the drug on their
normal cells.

Side effects of Temozolomide include nausea, vomiting, headache,
5

constipation, diarrhea, weakness, fatigue, seizures, bleeding, and a decrease in white
blood cell count [1]. Some patients may also develop a resistance to the chemotherapy
drugs and the over-dosage that must be used to overcome this [7]. Radiation therapy is
also used in the treatment of brain tumors. Radiation uses an external beam of light to
slow the growth or shrink tumors [1]. Patients can only tolerate so much radiation, so
other treatment methods are used in conjunction with this technique. Side effects due to
radiation include nausea, fatigue, sexual side effects, hair loss, and changes in skin [1].
Researchers are investigating new treatment therapies that include gene therapy, viral
gene therapy, adenovirus vectors, adeno-associated virus vectors, herpes simplex virus
vectors, retroviral vectors, other viruses, hybrids, targeted viral vectors, and non-viral
vectors [7]. One particular gene therapy approach uses polymer microspheres to deliver
adenovirus vectors to the brain tumor [10]. The goal of this approach is to increase the
effectiveness of the gene transfer that is occurring and to decrease the amount of
subsequent doses that must be given [7].

1.2.

The System
The system that this thesis proposes as a novel drug delivery technique consists of

two components. The first component is a non-ionic surfactant vesicle that is made up of
a synthetic amphiphilic bilayer and cholesterol. This vesicle is commonly referred to as a
niosome.

Niosomes are composed of synthetic amphiphiles that self assemble into

bilayers, while liposomes are composed of natural amphiphilc lipids that self assemble
into bilayers. Niosomes have been shown to be more chemically stable when used as a
vesicle, easier to store, safer to handle, and less expensive than liposomes. The polar
6

core in niosomes can entrap hydrophilic solutions, while the non-polar shell can
accommodate hydrophobic solutions. A dye that represents the drug to be delivered can
be encapsulated into the vesicle by thin film sonication. The dye that is used is 5(6)carboxyfluorescein. The second component of the system is the biodegradable polymer
hydrogel. The hydrogel is a three dimensional polymer network that can form a gel-like
solution based on ionic crosslinking. The main feature of hydrogels is their ability to
swell in water but still resist dissolution. The polymer that is proposed for use in the
hydrogel is chitosan with a β-glycerophosphate polyol salt. Chitosan is derived from the
natural polysaccharide chitin and is created by deacetlyation. Chitosan has shown to be
biocompatible and biodegradable in the body. The advantage to using a chitosan polymer
is that it can be made to respond to changes in environmental conditions such as
temperature and pH. The hydrogel will begin to gel at 37°C and a pH of 6.8-7.2 [11].
The pH of the brain is 7.32 [12] and the temperature of the brain ranges from 37.84+/1.03°C to 38.39+/-0.33°C, depending on the distance from the scaffold [13]. These
conditions suggest the chitosan hydrogel will begin to gel once implanted inside of the
brain.
The in vitro experiments will involve the use of a semi-permeable membrane that
is designed specifically for dialysis experiments.

The semi-permeability of the

membrane will prevent larger molecules from crossing the membrane and allow smaller
molecules to cross. The system will be placed within this membrane and submerged in a
bulk liquid solution.

Two bulk liquid mediums will be used: Milli-Q water and

phosphate buffer solution (PBS). The niosomes will break or burst when they come into
contact with the water due to the osmotic pressure difference between the niosomes and
7

the water. Water in used so that the study of the effect of pH and ionic strength can be
made in later studies. Water is also present in the body, so the behavior of the niosomes
with water is very important. PBS is also studied to observe the behavior of the niosomes
in a buffer solution with constant pH of 7.4 and ionic strength of 281 mOsm [14]. This
thesis explored the behavior of the niosome solution alone in this environment. Future
studies will be conducted incorporating the niosomes inside the polymer hydrogel.
The main goal of the system is to be used in drug delivery to brain tumor cells.
After a malignant tumor is removed, malignant cells can still exist within the brain and
the tumor cavity. These cells can reproduce and cause a recurrence of the cancer. The
proposed system would be injected into the tumor cavity directly after surgery. The
solution would gel once inside of the brain, and the opening to the brain would be closed
and sealed. This eliminates contamination that may occur due to transport and the use of
other instrumentation.

The stability of the system would be known at the time of

injection, thus providing better knowledge of when the drug will actually be released.
The solution would take the shape of the cavity, reaching the entire surface of the cavity.
The system aims at prolonging the time that the available drug is in its therapeutic range.

1.3.

Significance of This Work
This thesis proposes a “package within a package” system that would allow for

the maximum control over the release rate of the drug being delivered to brain tumor
sites. The goal is to convert the basic insight of nanopackaging to design a more
authentic device that would deliver drugs more accurately in order to reduce the cost of
expensive drugs and the toxicity of the drug with other organs. The system proposed
8

involves a nanostructured drug delivery system that can control release rates from the
nanoscopic to the macroscopic scales. The hydrogel medium can either play a static role
as a passive scaffold or an active role as a stimuli-responsive network for the stability and
release of the niosomes. The anticipated opportunities with the system include:
1. Packaging of different type of vesicles with respect to size, membrane
composition, or loaded cargo to determine the controlled release time-scales
and chemical composition of the vesicles.
2. Packing of vesicles with gradient properties such as crosslink density and
chemical composition to alter the release profiles for identical groups of the
vesicles.
3. Packaging the vesicles so that they are sensitive to micro-environmental
changes such as temperature and pH to allow for another control parameter.
A fundamental aspect of this project is to study the relation between the chemical
composition, of both the niosome and hydrogel, to the resulting physical properties and
its effect on the transport of molecules embedded in the hydrogel. It is proposed to see if
alterations on the nanoscopic scale can control for the release behavior of the system at
the macroscopic level.
The first control over the release rate of the drug is the release of the niosomes
from the biodegradable hydrogel.

The interactions between the properties of the

niosomes and the properties of the hydrogel will provide insight on how to improve or
modify the composition of either one separately. The hydrogel will also allow for a
protective vehicle for the niosomes as the system is injected into the body. The hydrogel
will protect the integrity of the niosome, thus, allowing the preservation of the drug inside
9

of it. This, in turn, will allow for the most effective delivery of the drug to the tumor site.
The system will also allow for the control of when to release the niosomes and drug.
This is important because release of the niosome and drug too early could result in
medication being delivered to other parts of the body that do not require treatment. The
hydrogel component of the system allows for the niosomes and drug to be delivered
directly to the tumor site and control at what time the drug is released. This, in turn,
reduces the side effects often experienced from toxicity to other parts of the body. The
hydrogel is also a gel solution so it can be molded to any desired shape or size. This
feature allows for custom designed delivery systems that will ensure for the entire area of
the tumor cavity to be filled and exposed to medication. The other advantage to this
system is that the variability of each tumor found in the brain. Some tumors are quite
large, while other tumors can present themselves as very small. The size control allows
for the determination of the optimal amount of drug needed and also decreases the
toxicity problem mentioned earlier.
The second control over the release rate of the drug is the release of the drug from
the niosome.

The niosome also provides protection to the drug from the outside

environment, and prevents premature exposure to other organs in the body. The niosome
can also provide protection of the drug from adversely interacting with the monomer
from the hydrogel. It has been shown that this interaction, in the past, has caused the
integrity of both the hydrogel and niosome to degrade. The concentration of drug within
the niosome can be controlled so that the appropriate dose is being provided to the
patient. Control can also be given to the composition of the niosomes and various
concentrations of them can be explored. The niosome component also allows for the
10

control of the size of the vesicles. It has been shown that different size vesicles result in
different release rates. This is another way in which we may gain greater control over the
release rate of the drug.
The significance of this system is that it will allow for the understanding of the
release process of the niosome and polymer system.

It will also allow for the

understanding of the reaction process that is also occurring in the system.

By

understanding the release/reaction process of the system, the best conditions for the
niosomes’ performance can be determined. Factors that account for the release behavior
will be manipulated. This concept can be used for the further design of delivery systems
that will increase efficiency and decrease toxicity to other parts of the body.
The system that will be studied in this thesis will involve the measurement of
fluorescence intensity readings that can be translated into concentration values. The
concentration gradient can be determined by comparing the concentration in the dialysis
tubing with the concentration of the bulk solution in which it is submerged.

The

concentration gradient can be analyzed over several days to determine the behavior of the
system. This analysis will allow for the determination of the behavior of the dye when
the medium comes into contact with the vesicles. The concentration on each side of the
membrane will be determined to see the amount of dye is being released over time.
These concentrations are important in the design of this system because they provide
information on the amount of drug that will actually be delivered to the site of infection
and provide insight into how alternations to the system can be made to improve this
amount.
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Chapter Two
The Components

2.1.

Niosome
Since 1965, amphiphilic vesicles that are able to self-assemble have been used as

vehicles for drug transport and drug delivery [15]. The first of these vesicles was the
liposome.

A liposome is an amphiphilic, spherical membrane that consists of a

phospholipid bilayer. The aqueous core is able to encapsulate hydrophilic drugs, while
the hydrophobic membrane is able to transport non-polar solutions [15]. Liposome drug
delivery systems have been reported to increase the stability of the encapsulated drug,
promote the effectiveness of the drug, increase circulation time, and support the rate at
which the body accepts the drug [16-23]. However, liposomes in drug delivery have their
setbacks. Drug degradation by hydrolysis of the phospholipid molecule has been a
problem in aqueous solutions [15]. There have also been some stability problems of the
liposome suspensions [15]. It has been suggested that liposomes be prepared and stored
in a vacuum or nitrogen environment to prevent phospholipid do not oxidation [15].
Alternatives to liposome drug delivery have been suggested. Niosomes, in particular, are
an attractive alternative to liposomes in drug delivery. Niosomes were first used in the
cosmetic industry by L’Oreal in 1972 [24]. Niosomes consist of a non-ionic surfactant
dissolved in an aqueous solvent. Niosomes self-assemble from non-ionic amphiphiles
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and form spherical bilayers [25]. Energy in the form of heat or physical agitation is
usually required in niosome synthesis [25]. Similar to liposomes, the aqueous core is
able to store hydrophilic molecules, while the non-polar membrane can accommodate
hydrophobic solutions as seen in Figure 3 [25].

Figure 3. Illustration of a Niosome

Niosomes have many advantages over liposome for the use in drug delivery.

For

example, they are more chemically stable in solution, less expensive to make, easier to
store [25]. They also have a greater choice of non-ionic surfactants to choose, reduce the
side effects in patients, prolong the release of the drug, and perform transdermal
procedures well [15]. There are reports of niosomes used successfully in transdermal
drug delivery, and the delivery of anticancer, anti-tubercular, anti-leishmanial, antiinflammatory, hormonal, and oral drugs [26-33].

Niosomes consist of non-ionic

surfactants that may derive from alkyl ethers, alkyl esters, alkylamides, fatty acids, or
amino acid compounds [15]. There are several factors that affect the properties of
niosomes. Figure 4 illustrates these factors and their relationship to one another [25].
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Figure 4. Factors that Influence the Properties of Niosomes

These factors may be used to formulate niosomes specific for a particular application and
control the design of them.
2.1.1. Self-Assembly of Niosomes
Structure of Surfactant: The structure of the non-ionic surfactant affects the selfassembly of niosomes. Niosome formation involves an amphiphile and an aqueous
solvent [25]. Cholesterol is also needed in most cases to prevent the aggregation of the
vesicles that occurs due to the repulsive steric or electrostatic interactions between
molecules [25]. An example of steric stabilization is the addition of Solulan C24, a
cholesteryl poly-24-oxyethylene ether, in doxorubicin (DOX) sorbitan monostearate
(Span 60) [26]. An example of electrostatic stabilization is the addition of diacetyl
phosphate in 5(6)-carboxyfluorescein encapsulated Span 60 niosomes [34]. Sorbitan
monoester niosomes consists of alkyl esters. Figure 5 shows some common structures of
these surfactants [35].
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A = Sorbitan Monolaurate (Span 20), B = Sorbitan Monopalmitate (Span 40), C =
Sorbitan Monostearate (Span 60)
Figure 5. The Structure for Sorbitan Monoester Vesicle Forming Surfactants
The alkyl chain group of the surfactant commonly ranges from C12 – C18 [34, 35]. The
hydrophobic head group was investigated and designed to create new niosomes with
unique properties [25]. The hydrophilic lipophilic balance (HLB) is a number that
indicates the ability of any surfactant to form a vesicle [25]. Sorbitan monostearate
should have an HLB of about four to eight in order to be a good vesicle forming
surfactant [34, 35].
Membrane Additives: The critical packing parameter (CPP) was formulated by
Israelachvili [36] and takes into account the geometric features of the amphiphilic
monomer aggregation [35]. It is a dimensionless number that predicts the ability of the
amphiphile to form aggregates and is calculated by Equation 1 [35]:

CPP =
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υ
I c ao

Eqn. 1

where υ = hydrocarbon chain volume, Ic = critical hydrophobic chain length (the length
above which the chain fluidity of the hydrocarbon may no longer exist), and ao = area of
hydrophilic head [25, 35]. Israelachvili [36] reports that a CPP value of 0.5 – 1.0 predicts
that the amphiphile will form a vesicle. Additives must often be incorporated in the
preparation of niosomes to stabilize the vesicles [25]. Cholesterol and diacetyl phosphate
are the most common additive to niosome solutions to increase their stability [25]. The
bilayer of the niosome membrane may exist in the gel state or the liquid crystal state [25].
The liquid state exists at a higher temperature than the gel state, and thus requires an
increase in temperature [25]. The increase in energy increases the enthalpy and entropy
of the system [25]. The overall free energy of the system decreases [25, 35]. Van der
Waals interactions, hydrophobic forces, hydrogen bonding formation, and electrostatic
interactions all play a role in the self-assembly of niosomes [37].

The Effect of Cholesterol: The addition of cholesterol results in more stable
niosomes. Cholesterol has shown to eliminate the gel to liquid phase transition of
niosomes [38] by affecting the chains in the bilayers when present in certain
concentrations [38]. The ultimate effect is that the niosomes will be less leaky, and thus
more stable. Studies have shown that an equimolar ratio of cholesterol to surfactant is
optimal [25]. Cholesterol can affect several biological membrane properties such as ion
permeability, aggregation, elasticity, size, and shape [39-41]. Cholesterol also shows
several mechanical properties such as cohesion, stiffness of membranes, and membrane
permeability to water [40].

Figure 6 shows how the cholesterol and sorbitan

monostearate may interact in the niosome bilayer [42].
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Figure 6. The Interaction of Cholesterol and Sorbitan Monostearate in the Niosome
Bilayer

The small 3 β-hydroxyl of the cholesterol head group is able to come parallel to the acyl
chain of the sorbitan monostearate surfactant ester group [42]. A study has shown that a
29 mol% amount of cholesterol added to vesicles resulted in a 50-100% increase in
encapsulation efficiency [43].

Surfactant and Lipid Levels: The surfactant/lipid level to make niosomes is
usually about 10-30 mM [41, 44-52]. The properties of the niosome system can be
changed by using different ratios of surfactant to water during hydration of the niosomes
[25]. The surfactant/lipid level may also have an effect on the encapsulated drug. An
increase in surfactant/lipid level will increase how much drug will be encapsulated [25].
Figure 7 illustrates how the selection of surfactant may affect the properties of the
niosome system [25].
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Figure 7. The Effect of Surfactant on the Properties of Niosomes

Temperature: The temperature at which the niosome system is hydrated during
the niosome preparation should greater than the gel to liquid phase transition temperature
of the system [25].
2.1.2. Nature of Encapsulated Drug
The nature of the encapsulated drug can affect the stability of the niosome. For
example,

Span

60

niosomes

with

diacetyl

phosphate

were

loaded

with

carboxyfluorescein, and the resulting system formed a homogeneous dispersion [53].
However, when the amphiphathic drug DOX was loaded into the same system,
aggregation occurred [53]. This is an indication that the CPP number must consider
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hydrophobic and amphiphathic drugs that could be incorporated into the niosomes [35].
Figure 8 shows the effect the encapsulated drug may have on the niosome system [25].

Figure 8. The Effect of the Encapsulated Drug on Niosome System

The stability of liposomes has been evaluated using dialysis methods [54, 55]. Peer &
Margalit [54] developed a novel procedure to entrap drugs in liposomes that involved the
preparation and lyophilization of regular and surface-modified drug-free liposomes and
drug encapsulation during liposome reconstitution via rehydration of the drug in an
aqueous solutions. It was found that the properties of the different drug determined the
diffusion coefficient as evaluated using a dialysis membrane assay.

Encapsulation Efficiency and Stability:

The encapsulation efficiency of the

niosomes is the result of the stability of the niosome dispersion, the loading of the
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vesicles, and the intrinsic properties of the niosomes [35]. The stability of the niosome
dispersion depends on the stability of the encapsulated drug, the retention the membrane
has for the drug, the stability of the surfactant, and the structure of the vesicles [35]. The
loading of the drug and efficiency are based on the nature of the solute, the temperature
of hydration, and the method used for loading [35]. The intrinsic properties that affect
the encapsulation efficiency include vesicle size, cholesterol levels, and the composition
of the membrane [35]. The stability of the system is based not only on the aggregation of
the vesicles but also on other factors such as osmotic behavior and other size and shape
change of the system [35]. Cholesterol has been demonstrated to enhance the retention of
the solute, which is a measure of encapsulation efficiency [35]. The nature of the
hydrophilic head group also increases the stabilization of the system [35]. The nature of
the hydrophilic head group and the hydrophobic tail may be varied in order to increase
the drug loading [25]. Stable niosomes will also have constant particle size, constant
levels of entrapped drug, and possess no membrane precipitation [25]. The encapsulated
drug must be compatible with the components that make up the bilayer membrane [25].
Smaller niosomes are less stable than large niosomes due to the high amount of energy
needed to break them [25]. Niosomes are considered thermodynamically stable and can
exist in the metastable state that includes an excess of energy [56]. Micelles are soluble
surfactants and are not compatible with niosomes; they will disrupt the system and a
mixture of micelles and aggregates will form [41, 46, 47, 57, 58].
The length of the alkyl chain has an effect on encapsulation efficiency as shown
in Table 1 [35].
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Table 1. The Effect of Alkyl Chain Length on Encapsulation Capacity

The table indicates that with longer the alkyl chain length, the encapsulation capacity
increases. Sorbitan monoester niosomes with 5(6)-carboxyfluorescein and DOX have
shown better encapsulation with C18 alkyl chains than C12 chains [34]. Span 60 (C18) and
Span 80 (C16) have shown excellent CF and DOX encapsulation efficiency and are the
least leaky due to their high phase transition temperature [34]. Figure 9 illustrates the
encapsulation efficiency and size of CF loaded niosomes [35].
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Figure 9. A Comparison of Sorbitan Monoesters on Encapsulation Efficiency. The
Solid Bars Represent the Size and the Shaded Bars Represent the Encapsulation
Efficiency

The stability of niosomes may be improved in other ways such as decreasing the air water
interface [59], adding a polymerized surfactant, including charged molecules [38], and
the inclusion of hydrophobic drugs [60].

Osmotic activity: The osmotic activity of niosome systems is observed in the
dispersion of hypotonic mediums [25, 38, 45]. There is an observed change in the size of
the niosome during this occurrence.

Toxicity: The toxicity of the niosome system was observed when there was an
increase in the alkyl chain and gel to liquid transition. There was an observed decrease in
the toxicity of the system and gel to liquid phase transition when there was increase in the
polyoxyethylene chain length [61].
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2.1.3. Preparation of Niosomes
The preparation of niosomes involves the self-assembly of the vesicles through
the addition of energy, which aids the process. The most common way to prepare
niosomes is through the hydration of a mixture of the surfactant at high temperatures
[25]. Size reduction is then performed to get the final dispersion [25]. Centrifugation,
gel filtration, or dialysis is then performed to separate the unentrapped dye from the
encapsulated dye [25]. Niosomes have been produced on the industrial scale through a
technique called Novasome® [25].

Hydration: The following hydration techniques are commonly used in laboratory
settings.
1. Injecting the surfactant organic solution into an aqueous solution of the drug and
heating above the boiling point of the organic solvent [45].
2. Creating a surfactant film by evaporating the organic solvent in which the
surfactant is dissolved. The film is hydrated with the drug solution [45, 62].
3. Emulsifying the surfactant solution and aqueous solution of the drug in an oil in
water emulsion. The niosomes are left in the dispersed aqueous phase after the
organic solvent is evaporated [25].
4. Adding a heated aqueous phase to the surfactant solution [24]. Note: the use of an
organic solvent is not required.
5. Using enzymatic activity in a mixed micellar solution to form niosomes [63].
6. Homogenizing the surfactant mixture and bubbling nitrogen gas through it [64].

Reduction of Niosome Size:

Niosomes prepared by hydration are usually

produced in the micron size range [24, 62]. Sub-micron sizes are used for intravenous
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and transdermal delivery; sizes up to 10 µm are used for intraperitoneal, intramuscular,
and intracavity administration; and sizes greater than 10 µm are used for drug delivery to
the eye [11]. The following are ways in which the size of the niosome may be reduced,
after hydration, which may play an important role in the function of the niosome.
1. Probe sonication to obtain 100-140 nm niosomes [45, 62].
2. Use of 100 nm Nucleopore filters to obtain 140 nm niosomes [65].
3. Combination of sonication and filtration to obtain 200 nm niosomes [26].
4. Microfluidizer to obtain sub-50 nm niosomes [25].
5. High pressure homogenization to obtain 100 nm niosomes [25].

Separation of Unentrapped Drug: A final step of removing an unentrapped drug
is necessary because not all of the drug gets encapsulated. The methods that have been
described to separate the unentrapped dye from the encapsulated dye include: exhaustive
dialysis [45, 66], gel filtration [34, 53], and centrifugation [67].
2.1.4. Drug Delivery Applications
Niosomes have been used in a variety of drug delivery applications. They have
been used intravenously as anti-infective agents, particularly for the treatment of
leishmaniasis [66].

They have also been used to deliver anticancer drugs such as

methotrexate (intravenously or orally), DOX (cardiotoxic drug), and NDOX N(2hydroxypropylmethacrylamide) (tumors) [25]. Niosome have also been used as antiinflammatory agents and in diagnostic imaging. Niosomes were first demonstrated in
oral administration by Azmin in 1985 [62]. It was reported that the delivery of drugs in
niosomes resulted in higher levels of the drug in targeted areas when compared to the free
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drug alone [25]. Niosomes have also been used in transdermal drug delivery. The
flexibility of their bilayers aids in the transdermal transport [68]. Niosomes have also
been used in ophthalmic drug delivery [25].
Niosomes have been studied for use in drug delivery due to their attractive selfassembly and amphiphilic properties. There seems to be an endless number of different
non-ionic surfactants that can be used, and the manipulation of several factors that make
them ideal for any situation. The stability of niosomes has been explored and factors
such as the nature of the surfactant, the encapsulated drug used, and temperature all must
be considered. In terms of encapsulated efficiency, factors such as the stability of the
niosome dispersion, the loading of the drug, and intrinsic properties are all very
important. The use of niosomes in drug delivery applications is virtually unexplored.

2.2.

Hydrogels
Hydrogel networks have become increasingly important for use in many

biomedical and pharmaceutical applications. In particular, the use of biodegradable
hydrogels coupled with drug-encapsulated niosomes has received attention for use in
drug delivery. Hydrogels are crosslinked, three-dimensional polymer networks that swell
in water but do not dissolve[69]. These hydrogels often undergo a volume change due to
their swelling characteristics in response to surrounding stimuli such as temperature, pH,
light, ionic strength, electric field, or even some chemicals [69, 70]. Hydrogels can be
used in nanostructures and Figure 10 summarizes these applications.
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Figure 10. Hydrogels in Nanopackaging

The most commonly used polymer in hydrogel networks is poly(N-isopropylacrylamide)
(PNIPA), which has the ability to transition from a swelling characteristic to a collapsed
characteristic at temperatures greater than 33°C [71].

Specifically, this means that

PNIPA has a lower critical solution temperature (LCST) of 33°C.

Below this

temperature, it can dissolve in water. However, at temperatures above the LCST, the
polymer precipitates out of solution due to the interruption of the hydrogen bonding and
the hydrophobic interactions of the isopropyl groups [70]. This alteration, based on
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temperature and pH, allows for better control over the system and can be used for such
applications as protecting drugs from degradation and for delivery of drugs to specific
sites in the body [71]. There have been quite a few number of research papers devoted to
incorporating co-polymers into the PNIPA network to improve the properties of the
system. The use of co-polymers allows the hydrogel network to take on advantageous
properties of both polymers and improve upon the function of the hydrogel as a whole.
2.2.1. Properties of Hydrogels

Structural Parameters:

There are three important structural parameters in

biomedical hydrogels: the volume fraction of the polymer in the swollen state, v2,s, the
number average molecular weight between cross-link units, M c , and the correlation
length, ξ [72]. The correlation length represents the distance between cross-links in the
hydrogel network [72]. The volume fraction of the polymer in the swollen state can be
determined by the volume of the polymer and the volume of the swollen gel as shown in
Equation 2:

v 2 ,s =

Vp
Vgel

= Q −1

Eqn. 2

where Vp = volume of the polymer, Vgel = volume of the swollen gel, and Q = volume
swelling ratio [72]. The number average molecular weight between crosslink units is
equal to the molecular weight of the repeating unit (Mo) divided by two times the degree
of crosslinking (X) [72] as shown in Equation 3:

Mc =
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Mo
2X

Eqn. 3

Models for Network Prediction: Models that predict the formation of the network
structure of hydrogels systems have been developed. There are currently three models
that are used with confidence and include kinetic models, statistical models, and Monte
Carlo simulations [72]. The kinetic models uses differential equations to predict the
properties of the gel such as the final conversion of polymer to hydrogel and the average
molecular weight [72]. The component mass balance is represented by the differential
equations [72]. These models can predict average values for the properties of biomedical
hydrogels and so statistical and Monte Carlo simulations have been developed that
provide a more in depth analysis to the structure formation. They can determine the
process of network formation, information on heterogeneities, and sol and gel regions
[72].
Swelling Properties: Polymer networks will swell when placed into contact with
an aqueous solution because of the thermodynamic compatibility between the polymer
chain and water [72]. The swelling behavior of a polymer network is very important and
can affect the properties of the network.
Diffusive Characteristics: The diffusion of a drug or solute through a hydrogel
network is very important in many biomedical applications. The diffusion coefficient of
the solute can describe how a solute molecule will behave and takes into account the
structure and size of the gel pore, the composition of the polymer, the amount of water
present, and the behavior and size of the drug [72]. The diffusion of the solute through
the gel solvent is dependent on interactions between the drug, the gel polymer, and the
solvent [72]. The diffusion process may be slowed down from interactions between the
drug and gel polymer [72]. Large drugs will diffuse very differently than small, rigid
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drugs [72]. It is thus important to consider the diffusive characteristics of the hydrogel
system under consideration.
Surface Properties:

Hydrogels have been described as behaving similar to

“polymer brushes” due to the various polymer chains that stem from the attacked end of
the network [73].

This property makes hydrogels adjust to different solvent

environments [74]. The frictional properties of hydrogels have been studied [75], and it
was determined that hydrogels have a lower frictional coefficient than most solids, which
may be due to the water solvation of the hydrogel [72].
2.2.2. Chemical and Physical Hydrogels

Hydrogels can be classified in two categories: chemical hydrogels or physical
hydrogels. Chemical hydrogels, also referred to as “permanent” hydrogels, are gels that
are formed from irreversible covalent links between different polymer chains [76-78].
Physical hydrogels, also referred to as “reversible” hydrogels, are gels that are formed
from several different reversible links and physical interactions [76-78]. They are held
together by secondary forces such as ionic bonding, hydrogen bonding, and hydrophobic
forces [77]. Chemically crosslinked hydrogels can be made in several different ways: 1.
crosslinking by radical polymerization; 2. crosslinking by chemical reaction of
complementary groups such as aldehydes, crosslinking by addition reactions, or
crosslinking by condensation reactions; 3. crosslinking by high energy irradiation or; 4.
crosslinking using enzymes [77].

Physically crosslinked hydrogels can be made in

several different ways as well: 1. crosslinking by ionic interactions; 2. crosslinking by
crystallization in homopolymer systems and stereocomplex formation; 3. physically
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crosslinked hydrogels from amphilphilic block and graft copolymers; 4. hydrophobized
polysaccharides; 5. crosslinking by hydrogen bonding or; 6. crosslinking by protein
interactions [77]. Figure 11 is an illustration of the difference between a chemical
hydrogel and a physical hydrogel [79]:

Figure 11. Differences Between a Chemical Hydrogel and a Physical Hydrogel

Chemical hydrogels can be synthesized by the following methods: 1. the polymer can
crosslinked in the solid state or in solution with radiation, chemical crosslinkers, or multifunctional reactive compounds; 2. a monomer and crosslinker in solution can be
copolymerized; 3. a monomer and a multi-functional macromer can be copolymerized; 4.
a monomer can be copolymerized within a different solid polymer to form an
interpenetrating polymer network (IPN) or; 5. a hydrophobic monomer can be chemically
converted to a hydrogel [77]. Physical hydrogels can be synthesized by the following
methods: 1. a polymer solution can be warmed to form a gel; 2. a polymer solution can
be cooled to form a gel; 3. crosslink a polymer in an aqueous solution; 4. two different
polymers in the same aqueous solution can form a hydrogen-bonded gel by lowering the
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pH; 5. a polyanion and a polycation can be mixed together to form a coacervate gel or; 6.
a polyelectrolyte solution and a multivalent ion can gel together [77].
2.2.3. Free Radical Polymerization

Hydrogels can be formed with or without the addition of a crosslinking agent.
The crosslinking agent is very important in the formation of a hydrogel because it
interconnects the polymeric chains and forms the 3-D structure of the gel [76].
Crosslinkers are generally much smaller in molecular weight than the monomer chains
they connect, and the selection of a crosslinker is critical for the properties that the gel
will exhibit [76]. Crosslinked chitosan hydrogels may be linked either covalently or
ionically. The synthesis of both will be discussed in this paper. There are several
different notable macromolecular structures for covalently crosslinked hydrogels [77]:
chitosan crosslinked with itself, hybrid polymer networks (HPN), semi- or fullinterpenetrating polymer networks (IPN) [76], block or grafted copolymers, or physical
blends.

The IPN and the grafted copolymers are the most popular examples of

chemically crosslinked hydrogels in the literature and will be discussed further.
Physically crosslinked ionic hydrogels will be discussed later.
The difference between a semi-IPN and a grafted chitosan hydrogel is that the
semi-IPN hydrogel traps unreacted chitosan within a polymer matrix, while the grafted
chitosan hydrogel is functionalized by grafting another polymer. Both hydrogels are
desired because the hydrogel will exhibit the characteristics of both polymers. Figure 12
is an illustration of a semi-IPN and a grafted chitosan hydrogel [11].
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Figure 12. Differences Between a Semi-IPN Hydrogel and a Graft Hydrogel

The polymerization of the hydrogel is usually done via a free radical polymerization or
gamma-irradiation. UV light is a common initiator of the polymerization. Covalent
crosslinked

chitosan

requires

multifunctional

molecules

as

crosslinkers

[76].

Dialdehydes, such as glutaraldehyde, is one common crosslinker used in the
polymerization of chitosan hydrogels. Figure 13 illustrates the mechanism from which
chitosan is able to crosslink with glutaraldehyde to form a Schiff’s base [80].

Figure 13. Mechanism of Chitosan Crosslinking with Glutaraldehyde
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The nitrogen of the amino group acts as a nucleophile and attacks the carbon of the
aldehyde. A C=N bond, a Schiff’s base, is formed when a water molecule is lost due to
the displacement of the oxygen from the aldehyde [80].
2.2.4. Ionic Crosslinking

Ionically crosslinked chitosan hydrogels contain reversible links. The chitosan
polymer contains a positive charge and can react with ions or molecules that are
negatively charged. These anions or anionic molecules create ionic bridging between
chitosan chains and form the hydrogel network [76]. This type of chitosan hydrogel is
often preferred over the covalently crosslinked chitosan hydrogels, especially in
biomedical applications, due to the toxicity that most crosslinkers posses.

Ionic

crosslinking requires chitosan in solution and at least one charged ionic crosslinker [76].
The ionic crosslinker must have multivalent counter-ions [76]. The crosslinking process
is very simple and easy compared to the covalent crosslinking procedure, and a catalyst is
not required for ionic crosslinking [76].

Crosslinking can occur when the ionic

crosslinker is added to chitosan; this can be done by dipping strips of chitosan into the
crosslinker solution or by adding them together with a syringe [76]. Figure 14 illustrates
the interactions in an ionic crosslinking hydrogel network [81].
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Figure 14. Ionic Crosslinking in Hydrogel

Ionically crosslinked chitosan hydrogels can be used in a variety of biomedical and
pharmaceutical applications such as controlled drug delivery, films, gel beads, and bone
regeneration [76].

These hydrogels are also able to swell in acidic and basic pH

solutions; however, they are extremely sensitive to pH conditions [76].
2.2.5. Proposed Hydrogel

The literature suggests many different options and choices for the number and
type of hydrogels available. It is desired to choose a physical hydrogel over a chemical
hydrogel to eliminate the need for a toxic crosslinking agent. Many chemical hydrogels
also undergo free radical polymerization which often requires the use of UV light to
initiate the process. It is desired to use a physical hydrogel that will form from physical
interactions and will not require the use of any external energy. Alginate hydrogels and
chitosan hydrogel are of the most common physical hydrogels in the literature. The use
of alginate hydrogels requires the presence of a divalent metal cation to form the gel [82,
83]. These hydrogels have also shown limitation in degradation [81]. These properties
are not attractive as the presence of a divalent metal cation could be challenging to find in
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the body in enough concentration to induce gellation. Another disadvantage is that the
hydrogel must be degradable in the body.

Chitosan hydrogels have been used in

biomedical applications and have shown to be both biodegradable and biocompatible.
They can be synthesized to be temperature or pH sensitive and have shown to gel at body
temperature. I have chosen to study chitosan hydrogels because it has the potential to be
a good hydrogel for our system. At this point, the choice of chitosan is only theoretical in
nature as in depth investigations of its properties will be studied in the future work of this
project.
2.2.6. Chitosan

Chitosan contains a hydroxyl group and an amino functional group from the
deacetylation of chitin [70, 71, 79, 84, 85]. Figure 15 illustrates the chemical structure of
chitosan [70].

Figure 15. Chemical Structure of Chitosan

It is biocompatible, pH-dependent, cationic, and water soluble up to pH 6.2 [11].
Chitosan can be dissolved in acidic solutions, thus protonating the amino group and
creating a polycation [70, 85]. Chitosan behaves as a polycation at physiological pH [71]
and is pH sensitive due to the many amino groups it contains [69, 70]. Chitosan’s
reactivity makes it ideal for chemical reactions, salt formation [79], and the formation of
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intermolecular complexes with carboxylic and polycarboxylic acids [85]. Chitosan is
also an attractive polymer for use in drug delivery because it has shown to be highly
biocompatible and biodegradable [70, 71, 76, 85], nontoxic [70, 71], abundant [86],
cheap to produce [86], cell growth stimulator and protein absorber [84], affinity for cells
[5], bioadhesive [71, 76],

and hydrophilic [79].

Chitosan has been used in such

applications as topical ocular applications [86], implantation [86], injection [86], drug
delivery carriers [69-71] surgical thread [70], wound healing [69, 70, 86], anticoagulant
[69], thickening and film forming [71], penetration enhancer [86], and is metabolized by
enzymes in the body such as lysozyme [86]. The molecular weight and degree of
deacetylation govern the way that chitosan will behave [86].
2.2.7. Chitosan Hydrogel Synthesis

One particular chitosan hydrogel uses the polyol counterionic monohead salt βglycerophosphate (GP) as the ionic crosslinker.

Chitosan/β-GP hydrogels can be

prepared by preparing the chitosan solution by itself in deionized water at room
temperature. The chitosan powder is added to the DI water and continued to stir and mix
for one hour [11, 87, 88]. The solution is sterilized in an autoclave. A chilled solution of
β-GP is also prepared in deionized water. It is sterilized by filtration. The two solutions
are chilled in an ice bath for about 15 minutes. The β-GP solution is added drop wise to
the chitosan while stirring. The entire solution is stirred for about ten more minutes [11,
87, 88]. The β-GP lowers the temperature at which chitosan will begin to gel; it creates a
shield around the chitosan molecules that allows them to retain their shape until large
amounts of energy is added to break them apart. Once the temperature is raised, the
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carbon-carbon bonds will be disturbed. The gellation process occurs due to the following
interactions: electrostatic attraction between the ammonium group of the chitosan and
the phosphate group of the glycerophosphate, the hydrogen bonding between the chitosan
chains, and the chitosan-chitosan hydrophobic interactions [11]. Upon gellation, the
neutralized chitosan amine groups will begin hydrogen bonding and hydrophobic
interactions after the repulsive electrostatic forces are gone [11].
2.2.8. Intermolecular Interactions

Temperature and pH Sensitivity
As stated above, there are three interactions that occur between chitosan and βGP:

electrostatic attraction between the ammonium group of the chitosan and the

phosphate group of the glycerophosphate, the hydrogen bonding between the chitosan
chains, and the chitosan-chitosan hydrophobic interactions [11]. The chitosan/β-GP will
remain a liquid at low temperatures and a pH up to 6.2 [89]. An increase in temperature
will begin the gellation process. Chitosan chains are stable at low temperatures and
weakened at high due to repulsive forces between the chains [11, 89]. It is suspected that
the polyol part of the β-GP prevents the gellation of chitosan at low temperatures [11,
89]. The polyol most likely forms a shield of water around the chitosan molecules [90],
thus increasing the transition temperature of the solution [91, 92]. This, in turn, requires
more energy, or temperature to break through this barrier. Ruel-Gariepy [11] suggested
that the addition of β-GP would prevent the gel formation of the chitosan network at low
temperatures and neutral pHs. They postulated that when the temperature was raised,
there would be an increase in chitosan-chitosan hydrophobic interactions and gellation
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would occur at this point. The chitosan would lose its water shields and the chitosan
chains would be allowed to bond [89]. The stability of the chitosan at room temperature
and the time of gellation increases as the degree of deacetylation of the chitosan
decreases [89]. One study showed that an 84% deacetylation could remain stable stored
for three months at 4°C [89].
2.2.9. Biomedical Applications

Hydrogel systems have been used in a variety of biomedical applications.
Hydrogels have been used in applications where a controlled release of a drug is needed.
They have been used in systems where a target concentration of the drug must be
maintained in the blood stream for extended periods of time [72]. They can be used for
drug diffusion, environmental sensitivity applications, and incorporation of functional
groups to target specific sites [72]. They have been used in swelling-controlled release
systems where controlled release is desired [72]. They are attractive for environmental
response systems due to their response to change in pH, temperature, ionic strength, and
solvent composition [72].

They have been used as blood-compatible hydrogels, in

contact lenses, as artificial tendons, artificial kidneys, membranes for plasmapheresis,
artificial liver, artificial skin, mammaplasty, vocal cord reconstruction, sexual organ
reconstruction, ophthalmic applications, and articular cartilage [72].

2.3.

Cellulose Membrane

A cellulose membrane is used to mimic the brain cavity in vitro in the
experiments performed in this thesis. It is used in dialysis experiment in which the
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behavior of the cell membrane is desired.

Cellulose is a natural linear natural

polysaccharide polymer that consists of (1 Æ 4) – linked β-D-glucopyranosyl unit [9395]. Figure 16 illustrates the chemical structure of cellulose [94].

Figure 16. The Chemical Structure of Cellulose

A typical cellulose polymer chain will contain about 7,000 to 15,000 repeat units [94].
Cellulose is the world’s most abundant natural resource and can be found in vegetable
matter, plants, trees, cell walls, and cotton fibers [94]. Cellulose is the main structural
component of the cell wall of most plants [94]. Cellulose was originally used in the
paper-making industry and sparked the interest of chemists and biologists [96]. Cellulose
can be manufactured into cellulose derivates such as ethers and esters or into regenerated
materials such as fibers, films, membranes, sponges, and food casing [93].
Cellulose derivatives have been used in the manufacturing of membranes [97].
Microfiltration and ultrafiltration membranes have been made from cellulose acetate and
reverse osmosis membranes have been manufactured from cellulose triacetate [97].
Cellulose acetate can be made from acetic anhydride, acetic acid, and the catalyst sulfuric
acid to produce a degree of substitution of about 2.4 [94]. Regenerated cellulose has
been a very attractive source for dialysis membrane due to its high hydrophilic nature
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[97]. The cellulose membrane is also resistant to dissolving in water, which makes it an
ideal choice in dialysis analysis [97]. Regenerated cellulose membranes have a high
degree of swelling due to their hydrophilic tendency and negative fixed charge created
from the –COOH group [98]. The semi-permeability of the cellulose membrane allows
for the transport of small molecules such as ions and low molecular weigh substances
through the pores of the membrane [99]. The molecular weight cut off (MWCO) of the
membrane will prohibit larger molecules or high molecular weight macromolecules from
diffusing [99]. The control of molecules across the regenerated cellulose membrane can
be attributed to the crystalline nature of the cellulose as well as the hydrogen bonding that
takes place between the hydroxyl groups of the molecule [97]. The behavior of transport
across a cellulose membrane is based on the permeability of the solute, the water, and
vapour [100]. The transport of molecules across the membrane can also be characterized
by electrical parameters, when dealing with an electrolytic solution, and include
conductivity, ion transport, and concentration of fixed charge in the membrane [101].
The carboxylic acid group (-COOH) in the structure of cellulose makes the membrane
weak to cation-exchange [101, 102].

2.4.

5(6)-Carboxyfluorescein

A fluorescent dye, 5(6)-carboxyfluorescein, can be encapsulated in the aqueous
core of niosomes.

The dye can be an indication of how similar molecular weight

molecules will behave under the same conditions. The advantage of using a fluorescent
species is that fluorescent spectroscopy methods can be used to measure the intensity of
the dye. The 5(6)-carboxyfluorescein dye that will be used in the experiments performed
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in this paper is obtained from Biotium Inc. The chemical formula for it is C21H12O7. The
molecular weight of the dye is 376 g/mol. Figure 17 illustrates the chemical structure for
5(6)-carboxyfluorescein [103].

Figure 17. Chemical Structure of 5(6)-Carboxyfluorescein

The 5(6)-carboxyfluorescein molecule will form a trivalent anion when the pH is
increased (physiologic and alkaline) due to the deprotonation of the hydroxyl groups
[103]. The carboxyl group will attacked at either the 5 or 6 carbon in the structure [103].
5(6)-Carboxyfluorescein is a yellow orange solid that can be dissolved in water with a pH
that is greater than 6 [103]. It should be stored at a temperature of 4ºC and have minimal
exposure to light [103]. When the dye is in solution, there should be special care taken to
avoid extended periods of light exposure. At pH 9, the excitation/emission wavelength
(λex/λem) of 5(6)-carboxyfluorescein is 492 nm/514 nm [103].
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Chapter Three
Problem Presentation

The following chapter will discuss a current method that is used for the treatment
of brain tumors and a controlled drug delivery method that uses liposomes in hydrogels
that could be designed for brain tumor treatment applications. The chapter will then
compare these treatments to my proposed drug delivery system. I will then present the
goals and aims of the project.

3.1.

Previous Work One

3.1.1. Gliadel Wafer

The challenges of drug delivery to brain tumor sites have been investigated in
several instances. There is a general understanding that a controlled delivery system
would eliminate some of the complications that are often associated with brain tumors.
The most significant of the contributions to this field of work would be the use of
biodegradable polymer wafers. A chemotherapeutic drug is incorporated into a polymer
and implanted in the cavity of a brain tumor after surgery. The wafers slowly release the
drug over a two week time period as the polymer slowly degrades [104, 105]. The
Polymer-Brain Treatment Tumor Group was one particular group involved in some of the
early studies of implanting these wafers in patients. Studies first began with patients who
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required surgery and treatment after a tumor had reoccurred. Later studies conducted by
various other research groups have been studied on the effect of the wafers after a first
surgery [106]. The motivation for the use of this delivery system was the high recurrence
rate of brain tumors, the limitations of drug delivery through the blood stream to the
brain, and the risk of exposing other parts of the body to the drug [107]. The average
survival time for a patient diagnosed with a high-grade glioma, even after surgery and
subsequent therapy, is less than one year [107]. The idea to implant a biodegradable
polymer offers sustained release to the targeted site and eliminates the need to cross the
blood brain barrier [108].
The wafers consisted of the polymer poly(carboxyphenoxypropane/sebaic acid)
anhydride. This polyanhydride polymer is commonly called BIODEL and consists of a
20/80 ratio of poly-carboxyphenoxypropane and sebaic acid [109]. Methyl chloride was
used to dissolve the BIODEL and the drug.

The hydrophobic environment of the

polymer protects the drug from hydrolysis [108]. The chemotherapy drug that was used
in the wafers was carmustine (BCNU). The resulting solution was sprayed into 1.4 cm
(diameter) by 1.0 mm (thickness) microspheres and sterilized with gamma irradiation
[110]. The polymer was loaded with 50 μg carmustine/mm3 and resulted in wafers that
contained 7.7 mg of the drug [108]. There could be up to eight wafers placed in the
tumor cavity so that the maximum patient dose was 62 mg [108]. The Polymer Brain
Tumor Treatment Group administered these wafers to 222 patients in 27 at medical
centers [108]. The selection criterion was based on patients who needed to be reoperated on due to a recurrent malignant brain tumor [108]. The results of this study
showed that the six-month survival time in polymer disc treated patients was 50% greater
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than those patients treated with a placebo pill [108]. From early studies, the wafer
appeared to be easy to implant, safe from adverse side effects, and clinically effective for
treatment of high grade gliomas [104, 108, 109].
Recent studies suggest that the earlier optimism associated with the Gliadel
wafers was premature. Implantation has shown to cause extensive local edema and
inflammation [111]. The could lead to complications such as seizures, cerebral edema,
tumor bed cyst formation, abnormal wound healing, and increase for infection [108, 112,
113]. Earlier studies report an infection rate of less than 5%, while recent studies suggest
that the rate of infection was as high as 15%-23% [114, 115]. A study conducted at the
University of Pennsylvania (Philadelphia) compared the risk of patients developing a
surgical site infection (SSI) based on their use of Gliadel wafers. They found that 9 out
of the 32 patients included in the study developed a surgical site infection [111]. The
28% of patients who developed an infection after Gliadel wafer implantation is the
highest percentage reported [111]. The infections that developed included one patient
with cellulitis, one patient with subgaleal abscess, four patients with bone flap ostetitis,
two patients with epidural abscesses, four patients with parenchymal brain abscesses, and
one patient with meningitis [111]. The average time from the time of implantation to the
time of infection was 23 days, and there were four patients who developed more than one
infection [111]. The study suggest that Gliadel wafers may contribute to the formation of
these abscesses due to the prolonged exposure of drug to the surrounding tissue, extended
inflammation, and continued edema [111]. The wafers are believed to contribute, along
with other factors such as radiation therapy and subsequent operations, to the
development of infections [111]. Gliadel wafer were first approved for clinical use on
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September 24th, 1996 by the US Food and Drug Administration [116]. They were
approved for use in the treatment of brain recurrent brain tumors.

The FDA later

approved the wafers for use in newly diagnosed patients with high grade gliomas on
February 26, 2003 [117]. The most recent study by Westphal (2003) [118] indicated that
the average survival of a patient treated with Gliadel wafers was 13.9 months compared
to 11.6 months for those patients receiving a placebo pill.

3.2.

Previous Work Two

3.2.1. Liposomes in Hydrogels

Liposomes alone have been investigated for use in drug delivery, particularly for
chemotherapy applications. It has been shown that normal chemotherapy involves the
administration of very toxic drugs to the brain and that only about 1% of the drug will be
delivered to the infected site [119]. The remainder drug will cause toxicity to other
organs of the body. Liposomes have been used to encapsulate the drug to reduce toxicity.
However, the reduced toxicity is actually due to the quick uptake of the liposomes by the
immune system [119]. Therefore, treatment with liposomes resulted in reduced toxicity
but also a reduced in therapeutic efficacy [119]. However, the development of sterically
stabile liposomes reduced the uptake of the vesicles.

This phenomena is due to

opsonization, which is the adsorption of proteins based on tagging foreign particles for
the uptakes by the body’s immune system [119]. Sterically stable liposomes are effective
in brain tumor treatment due to the nature of the tumor tissue. The tumor tissue is
comprised of poorly formed and leaky vasculature [119]. Small, stable vesicles are
allowed to gather in these sites. Liposomes alone have show n promise for drug delivery;
45

however, other suggestions in drug delivery have been made incorporating these
characteristics of liposomes with other mechanisms.
There have been several suggestions for the use of in-situ forming systems for use
in drug delivery [120-124]. Photoinitiation methods have been suggested for use in
injured arteries [120], but requires the use of a photoinitiator and laser [87]. Selfassembling amino acids gels have to be carefully selected due to their tendency to gel at
room temperature [121], The idea of incorporating a water soluble polymer in a watermiscible solvent and initiating a precipitate polymer implant [125, 126] poses the
possibility of premature release of the drug due to the risk of partial precipitation [87].
Thermosensitive systems have been suggested to eliminate the need for organic solvents
and copolymerization components [87]. The polymer must be carefully selected to be
biodegradable and biocompatible. A formulation that involves the in-situ gel forming of
a biodegradable and biocompatible polymer has been suggested that can be heated to
about 45°C and will gel when cooled to body temperature [127]. However, this method
is impractical because it involves the burdensome step of heating the solution. RuelGariepy [87] discussed one particular formulation that addresses this problem and
involves the formation of a gel when the temperature is raised to body temperature. He
also decided to incorporate liposomes in these temperature sensitive hydrogels in order to
sustain the release of hydrophilic molecules. It was shown that drugs incorporated
directly into the hydrogel system have a high release rate due to the presence of pores
created by the high water content of the hydrogel [87].
Ruel-Gariepy [87] previously demonstrated that the release of small hydrophilic
compounds incorporated into a chitosan-β-glycerophosphate occurs within 24 hours [11].
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The concentration and the nature of the polymer did not improve on the release time.
Therefore, Ruel-Gariepy [87] decided to load the hydrophilic compounds into liposomes
and incorporate them into the hydrogel network. The researchers investigated what
effects the liposomes would have on the gelling behavior of the hydrogel. It was shown
that the liposomes decreased the sol-gel lag time and increased the strength of the gel
[87]. It was observed that high concentrations of liposomes disrupted the crosslinks of
the polymer [87]. The authors also studied the viscoelasticity of the system, as well as
the release kinetics of encapsulated dye [87]. They found that the release rates of the dye
was strongly dependent on the size of the liposome and the composition of them [87].
For example, certain amounts of cholesterol were added to the liposomes to determine the
effect it would have on the system. The authors found that they were able to produce a
controlled release rate over a two week time period [87].
Murdan

[128]conducted

research

that

uses

niosomes

and

sorbitan

monostearate/polysorbate 20 organogels. This work was primarily used to study these
vesicle-in-water-in-oil (v/w/o) gels for the delivery of vaccines [128]. The v/w/o gels are
formed from an emulsion process at high temperatures. The gel forms when the solution
is cooled.

The aqueous niosomes are dispersed throughout the oil medium.

niosomes form mixed surfactant films at the interface of the water and oil.

The
A

thermosensitive semi-solid gel was formed upon cooling and the niosomes selfassembled themselves into tubular and fibrillar aggregates [129, 130]. The organogel
consisted or sorbitan monostearate and polysorbate 20 dissolved in an organic solvent
such as hexadecane or isopropyl myristate. The results showed that the v/w/o gel showed
strong properties after intramuscular administration [128]. The w/o and v/w/o gels were
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shown to improve the primary and secondary humoral immune responses to
haemagglutinin antigen [128].

3.3.

Comparison to Smart-Packaging

The smart-packaging system is an improved design of the Gliadel wafer system
for several reasons. Although the proposed system of this thesis seeks to be applied for
drug delivery in a similar manner, the design addresses several factors that make these
wafers undesirable. The proposed design improves upon the over exposure and toxicity
problems that these wafers cause because the delivery of the drug from the wafer is done
only in a semi-controlled fashion. Once the wafers are implanted, they will degrade over
a set period of time, depending on how many wafers are placed in the cavity. The smartpackaging system will allow us to have maximum control over the release of the drug and
could be designed specifically for each individual. The smart-packaging design allows
for the controlled release of the drug, thus, eliminating the exposure of other organs in the
body to unneeded medication. The drug delivery design also incorporates the use of a
flexible, moldable hydrogel that will fill the shape of the entire cavity, thus, allowing for
maximum contact area between the drug and the tumor cells. The wafers possessed a
predetermined shape, thus, reducing the contact surface area between the drug and the
cavity [108]. The smart-packaging system has a similar end-goal in mind; however, the
design greatly increases the delivery of the drug to the tumor cavity while eliminating
harmful side effects. The Gliadel wafers have also been shown to increase survival by
only a couple of months. The smart-packaging design wishes to not only increase the
survival of these patients, but would eliminate the risk of death due to the tumor
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altogether. Any increase in survival time is an improvement, as the Gliadel wafers
currently offer. The novel control system that is being proposed will hopefully increase
survival to a significant amount of time and eliminate the tumor completely.
Liposomes have shown positive potential in drug delivery, especially for
chemotherapy applications. However, the steric stability of the liposomes plays a major
role in the efficacy of the system. In the proposal, it is suggested to use a non-ionic
surfactant vesicle which has shown better stability than liposomes. It is the intention that
this advantage will improve the current systems available based on liposomes. The
publication that discusses the use of liposomes and chitosan/β-glycerophosphate
hydrogels

for

the

delivery

of

low

molecular

weight

compounds

such

as

carboxyfluorescein dye is similar to our design; however, there are several differences
and improvements in the smart-packaging design [87]. The authors found great success
in their design.

However, the smart-packaging design is different in that synthetic

amphiphilic surfactants, niosomes, will be used instead of liposomes. Niosomes have
shown to be more chemically stable in the vesicle state. This could provide for a better
release rate of the drug. Niosomes have also been shown to be easier to store and handle.
This ultimately means that they will be more convenient and user-friendly than liposomes
for use in drug delivery applications. Niosomes are also less expensive than liposomes.
This is advantageous because it means that we can design a better, improved system for
less money. For the consumer, this means that a life-saving procedure can be performed
at a lower cost and be more effective, thus, increasing the demand from the market if
more people are able to afford it and have it improve their quality of life. The authors of
the liposome/hydrogel system are also interested in observing the behavior of release
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based primarily on changes in the niosome composition. For example, they altered the
amount of cholesterol content, the size of the niosomes, and added an enzyme in some
cases. The smart-packaging system will be interested in observing the behavior of the
system when both or either the hydrogel or niosome component is altered. The proposed
plan is to determine how the composition of the hydrogel changes the release behavior
and what is the best composition for interaction between the niosome and hydrogel. The
proposed system is interested in the niosome and hydrogel as they work together and not
as individual pieces. It is the intent to treat the niosome and hydrogel as separate but
equal entities, but moreover, how they behave as one. The mentioned article also did not
have a specific aim in mind. They noted that their system could have the potential to be
used in drug delivery. The advantage and improvement of the proposed smart-packaging
design is that there is a specific market that it is targeting. The system will be able to be
custom designed to be used in brain tumor surgeries. Although the desire to remain
broad and multifunctional is also intended, the proposed system suggests one particular
application for the invention that will enable the testing of the design in specific in vivo
samples.
The work concerning the niosomes in organogels only slightly compares to the
proposed smart-packaging design. The focus of the niosome/organogel was to use that
system for the delivery of antigens. There are different considerations that must be
addressed when comparing both systems. The main focus of the proposed system is a
controlled delivery system of the drug, while the main focus of their system was to
determine whether the niosome/organogel would actually delivery the antigen to the
respective site. It is known that the niosome/hydrogel will make it to the desired site; it is
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desired to focus on controlled delivery at the site. The niosome/organogel system was
also prepared by heating the mixture and cooling it to gel. This heating factor in their
design process is impractical and neither time nor cost effective.

3.4.

Research Objectives

3.4.1. First Objective

The first objective of this thesis is to study the behavior of the release of the 5(6)carboxyfluorescein from the niosomes. This is a critical, initial step towards the design
of the smart-packaging system that includes the hydrogel because the behavior of the
niosomes must first be understood. It is desired to observe how the dye will act when
encapsulated in the niosomes and how the dye will behave once released from the
niosomes. The release behavior will provide crucial information about the system such
as the concentration, volume, and size of the vesicles that will result in the most efficient
design.

The release behavior will also provide information about the interactions

between the niosomes in the solution and the bulk solution that comes into contact with
them. The majority of the dye initially released and the behavior of the dye over time can
be determined. Any equilibrium tendencies the high concentration of the niosomes
solution has with the neutral concentration of the surrounding bulk fluid can also be
observed.
3.4.2. Second Objective

The second objective of this thesis is to run the system with in vitro experiments.
It is desired to do this because this system is being designed to one day be used in brain
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tumor patients. By creating an in vitro environment, a better understanding of how the
system will behave under similar conditions can be seen. It is important to run the
experiment in vitro because there are unforeseen problems that may occur during
traditional bench top experiments that in vitro experiments will expose before in vivo
experiments are performed. There are more specific conditions of the brain that will need
to be addressed for future work; however, it is desired to create several in vitro conditions
in this thesis that will provide information on how the system will work when run at
comparable situations of the brain environment.
3.4.3. Third Objective

The third objective of this thesis is to look ahead to the future of the system. The
objective is to one day create the perfect system for drug delivery to tumor patients by
increasing survival time and lowering side effects. The information obtained from this
thesis will provide insight as to the next step in the project. The purpose of this thesis is
not to save the world overnight, but make a contribution to the understanding of the
design of a delivery system that will one day be flawless. There are several different
complex components of the smart-packaging system that are proposed and time must be
spent on each of them to ensure that all factors are considered. The information obtained
here will provide a better perspective on what is essential for the future of the project and
the possibility that what was once considered important may not be significant after all.
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3.5.

Research Aims
3.5.1. First Aim

The first aim of this thesis attempted to achieve the first objective of the thesis: to
determine the release rates of the dye.

This was done by setting up bench top

experiments and observing the diffusion of the dye into a bulk fluid separated by a semipermeable membrane. The change in concentration of the bulk fluid and the initial
solution over several time intervals was determined. The use of fluorescent dye allowed
for the use of fluorescence spectrometry to measure the intensity of the dye. These
intensities were translated into concentration measurements and the change in
concentration provided information on the release of the dye from the niosomes. The
experiments were run at different time intervals to determine the crucial release time
behavior of the dye that should be noted. The moles of the dye were considered with the
concentration of dye because the number of moles is a direct indication of the amount of
dye present.
3.5.2. Second Aim

The second aim of this thesis attempted to address the second objective of this
project: to run the experiments in vitro.

This was accomplished by setting certain

environmental conditions that were similar to the conditions of the brain. For example, a
semi-permeable membrane was used to mimic the cell membrane of the body that will
only allow certain molecules from passing through it. Regenerated cellulose has been
used in previous dialysis experiments and will be used to observe the behavior of the dye
across it. The fluorescent dye that was chosen based on the molecular weight of the drug
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that will one day be loaded it its place. The molecular weight of the CF dye is about 376
g/mol, while the molecular weight of the drug that will be considered (Temozolomide) is
about 194 g/mol.

Different dosages of Temozolomide were found [131] and the

concentration encapsulated in the niosomes was determined based on similar amounts.
The niosomes were initially loaded with a 5mM concentration of CF dye. Different
concentrations of the CF dye that were comparable to the loading of drug that are already
used for treatment were considered.
3.5.3. Third Aim

The third aim of this thesis attempted to accomplish the third objective of this
thesis: to design, for the future, the perfect drug delivery system. This was accomplished
by 1) gathering information on past systems that failed and addressing the downfalls of
them; 2) obtaining information on potential components that have shown to be
successful; and 3) using the information from the experiments performed in this thesis to
decide on what information was still needed and what information needed to be revised.
The design of a perfect system will take time to develop, but by considering aspects of
each of the components, crucial information can be obtained. It is the hope of this thesis
to gain valuable information from the trials and tribulations of the experiments and to
move forward in an efficient direction.
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Chapter Four
Experimental and Characterization Techniques

4.1.

Concentration Characterization Technique

The main interest of this thesis was to determine the change in concentration over
an elapsed amount of time. This information would allow us to determine the behavior of
the release of the 5(6)-carboxyfluorescein dye from the niosomes and the time it took to
diffuse into the beaker. The use of fluorescence spectroscopy was used to obtain the
concentration changes based on intensity reading from the dye. The following chapter
discusses the method of fluorescence spectroscopy and how it was used to determine
concentration.
4.1.1. Fluorescence Spectroscopy

Fluorescence spectroscopy is the class of spectroscopy in which absorbing energy
from an external source excites samples and the intensity of the energy is observed as the
atoms transition back to the ground state [132]. Luminescence is the general term that is
used to describe all forms of light emission that is not from an increase in temperature
[133].

The process involves the loss of energy from the system, where energy is

provided from an external source to make the emission continuous. Photoluminescence
occurs when the emission of light is caused by the absorption of infrared, ultraviolet, or
visible light [133, 134]. Chemiluminescence occurs when the emission of light is based
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on a chemical reaction, and bioluminescence is from enzymes in living systems [133].
Photoluminescence can either be categorized as fluorescence of phosphorescence.
Fluorescence involves the immediate release of absorbed energy, about 10-8 second,
while phosphorescence involves the delayed release of absorbed energy, about 10-6 – 102
second [133]. The absorption and emission of light is referred to as energy being
absorbed in definite units called quanta [134]. The quanta are usually referred to in terms
of N (where N = 6.023 x 1023 molecules) quanta, or an Einstein. Appendix A shows the
approximate sizes of quanta for certain radiation types. Fluorescence spectroscopy is
only concerned with the ultraviolet and visible regions of the spectrum where absorption
results in the excitation of the outermost electrons [134]. The absorbed light spectrum is
similar to the excitation spectrum; however, the emission spectrum has a longer
wavelength than the absorbed light [133]. The intensity that is emitted is proportional to
the concentration of dilute solutions that allows for quantitative measurements [133].
There are several advantages to fluorescence spectroscopy that include the sensitivity that
is allowable in the pictogram range, the selectivity from two characteristic wavelengths,
and the variety of methods available for sampling such as dilute, concentrated, and
suspended solutions [133]. The phenomena that occur in fluorescence are a result of the
electromagnetic nature of light, the molecular structure of the species, and the
environment in which the species has been exposed [135].
The electronic absorption spectrum represents graphically the intensity of light
absorbed when electrons transition in a molecule [135]. This is a function of frequency
or wavelength of the light [135]. Strong absorption bands result from regions of intensity
where absorbed light is high, while weak absorption bands result from regions of
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intensity where absorbed light is low [135].

Most molecules occupy the lowest

vibrational level of the ground state when at room temperature [134]. When the molecule
absorbs light, it may be excited to the first state, S1, or second state, Ss, vibrational levels.
Figure 18 shows the transition that the molecule may follow when excited to higher
vibrational states [134].

Figure 18. The Transition from Ground State to Higher Vibrational Levels. The
Return to the Ground State Produces Fluorescence
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The molecule may be excited to any of the levels within each electronic state. It should
be noted that Figure 18 does not account for any rotational levels that may be associated
with the molecule due to the fact that such inclusion would result in numerous absorption
bands that would make any individual absorption band indistinguishable [134]. The
molecule has absorbed a high amount of energy to excite it to the higher levels of each
electronic state and will eventually loose energy and fall to the lower levels of each
excited state.
Most molecules that occupy higher than the second excited electronic state will
undergo internal conversion, causing them to fall from the lowest level of one excited
state to the highest level of the next lowest level. All molecules will eventually loose
enough energy to fall to the lowest level of the first electronic state. They will occupy
this level for approximately 10-8 seconds until they fall from the excited state back to the
ground state [135]. During this transition, they will emit energy in the form of visible or
ultraviolet fluorescence [134, 135].

The lifetime of fluorescent molecules is

approximately of the order of 10-8 seconds, but the actual fluorescence occurs in
approximately the order of 10-5 seconds [135].
A fluorescence instrument consists of generally six components [134, 135]:
1) Light source – to excite the sample.
2) Monochromator – to separate the light of the source from the light of the sample.
3) Sample compartment – to place the sample to be analyzed.
4) Second monochromator – to separate the energy of excitation from the energy of
the sample’s fluorescence.
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5) Photodetector – to interpret the fluorescent light into an recordable electrical
signal.
6) Readout system with an amplifier – to obtain the intensity of the fluorescent light
that was emitted from the molecule.
Slits are also present on both sides of the monochromator to unify the exciting and
fluorescent light and to control the wavelength range of exciting light from the sample
and fluorescent light that the photodetector receives [135]. Fluorescent spectrometers can
either have filters or gratings as monochromators to control the wavelengths of the
species. Figure 19 represents a typical fluorescent spectrometer [135].

Figure 19. General Schematic Diagram of a Fluorescence Spectrometer

The excitation, or light, source should possess the following characteristics: be relatively
intense, contain wavelengths in the ultraviolet to visible range, have continuum radiance,
and be stable [135]. Xenon sources may provide a good continuum from 250 to 500 nm.
59

The disadvantage to a xenon source is that stability can only be obtained when an
expensive highly regulated D.C. power supply is used [135].
Devices must be used to control the amount wavelength that is allowed to excite
the sample and control the wavelength that is emitted by the sample.

Filter or

monochromators may be used to fulfill this responsibility. Filters allow for a broader
range of wavelengths to excite the sample and that are emitted by it [135].
Monochromators allow a smaller range of wavelength to pass. They usually consist of
diffraction gratings and slit arrangements to control the wavelengths.

The user is able to

select both the excitation and emission wavelength for each sample by changing the
width of the slits independently [134].

Gratings limit the wavelengths by using

destructive and constructive principles of interferences of light [135]. The slits focus the
light onto the monochromators and are responsible for the wavelength that will be read
by the detector. Therefore, the width of the slits is crucial when it come to the resolution
of the machine and the selectivity that will be employed. Sample compartments are
where the sample to be studied is placed. It usually consists of a cell that is painted black
to minimize any stray exciting light and is covered when in use to prevent outside light
from entering [135]. The compartment is usually positioned so that the emitted light
leaves at a 90° angle from the angle that light is excited to the cell. This minimizes any
stray exciting light that may interfere with the reading. The cells are typically 1 cm2 can
be made of Pyrex glass, quartz, or fused silica [135].

The detector consists of a

photomultiplier. The photomultiplier is a phototube that is able to effect the emission of
the photocathode to obtain a linear amplification of primary photocurrent within the tube
[135]. The photomultiplier produces an electrical current that can be amplified to levels
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that can be measured, when exposed to light. The readout device is where the output
from the detector is sent and displayed [134]. They may be galvanometers, recorders, or
oscilloscopes [135].
The fluorescence spectrometer that is used in this procedure can measure the
fluorescence in a continuous scan over the range of wavelength of the machine or at
specified points within a range [133]. Figure 20 illustrates the schematic of the LS-3B
luminescence spectrometer that is used in the experiments in this thesis [133].

Figure 20. Schematic of the LS-B Luminescence Spectrometer

The instrument has two reflection grating monochromators and a photomultiplier
detector. The output from the detector is proportional to the level of emission produced
from the sample [133]. The excitation source is a pulse xenon flash tube. The ellipsoidal
mirror collects the energy from the source, and the toroid reflects it onto the entrance slit
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of the excitation monochromator.

The excitation monochromator consists of and

entrance slit 2, 1200 lines per mm grating, a spherical mirror, and an exit slit 1 [133].
The grating diffracts a narrow wavelength of energy that exits at slit 1 and is determined
by the setting of the grating. A stepper motor controls the angle. The toroidal and plane
mirrors direct the energy from slit 1 to the sample. Upon emission, the toroidal and plane
mirrors direct the energy into the entrance slit to the emission monochromator. The
emission monochromator is similar to the excitation monochromator in that it consists of
a entrance slit 1, a spherical mirror, a 960 line per mm grating, and a slit 2 that transmits
the energy to the detector. The stepper motor controls the angle of the grating and
determines the narrow wavelength that is allowed to be detected by the photomultiplier
[133]. Figure 21 illustrates the optical system of the LS-3B fluorescence spectrometer
[133].
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Figure 21. Optical System of the LS-3B Fluorescence Spectrometer

The emission and excitation monochromators can be made independent or synchronized
over their ranges or set to certain points within their range [133]. The slits are 10 nm in
width but can be adjusted to 5 nm (excitation) or up to 20 nm (emission). The excitation
range is from 230 nm to 720 nm. The emission range is from 250 nm to 800 nm.

4.2.

Calibration Curve Technique

The topic of interest in measuring the fluorescent intensity of solutions was to
obtain the concentration from these readings, for the purpose of this thesis. The intensity
measurements taken from the fluorescent spectrometer were interpreted into
concentration values based on a calibration curve for intensity versus concentration that
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was generated. The idea behind the calibration curve was to prepare several known
concentrations of a sample and measure the fluorescent intensity of those samples. A
plot of concentration versus intensity was made. For dilute solutions (up to about 5x10-7
M), the relationship between concentration and intensity were directly proportional and
therefore create a linear curve in this region. In the case of the experiments performed in
this thesis, 5(6)-carboxyfluorescein dye was the dilute solution that was used and studied.
Samples of unknown concentrations of 5(6)-carboxyfluorescein were placed in the
fluorescent spectrometer, and their intensities were taken. This was the crucial procedure
of this thesis, because the diffusion of the dye from the niosomes and into the beaker
created concentrations that were unknown and required calculated. Referring back to the
concentration curve and finding the values graphically or analytically determined the
concentration of these samples.
A sample of dye that was encapsulated in the niosomes was provided to create the
calibration curve. The dye was given as the concentration that was in the niosomes and
required dilution.

For example, if 5mM (5x10-3 M) dye was encapsulated in the

niosomes, the first diluted sample was made as 5x10-5 M. If 10 ml of this new dilution
was desired, Equations 4 and 5 were used.
C1V1 = C 2V2

(5x10

−3

Eqn. 4

)

M * (V1 ) = (5 x10 −5 M ) * (10 ml )

Eqn. 5

V1 = 0.1 ml of 5 x10 −3 M in 9.9 ml PBS

It was desired to create five samples of known concentrations: 1x10
2.5x10

–7

M, 3.5x10

–8

M, 5x10

–8

–8

M, 1x10

–7

M,

M. In order to make these samples, five dilutions of

the 5x10-5 M sample had to be made. Those five dilutions were diluted further when
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placed in the fluorescence spectrometer in a 1:100 ratio with PBS to yield the five desired
concentrations. Table 2 illustrates the preparation of the dilutions and the concentrations
that were obtained when 5mM was encapsulated in the niosomes. Table 2 was used to
prepare these dilutions.
Table 2. Preparation of Dilutions and Concentrations for Calibration Curve
Measurements
Dilution

Volume of 5x10-5
M CF dye (ml)

Volume of PBS
water (ml)

1
2
3
4
5

0.02
0.2
0.5
0.7
1

0.98
0.80
0.50
0.30
0

New Dilution (M)

1x10-6
1x10-5
2.5x10-5
3.5x10-5
5x10-5

New
Concentration (M)

1x10-8
1x10-7
2.5x10-7
3.5x10-7
5x10-7

Intensity was plotted on the y-axis, while concentration was plotted on the x-axis. The
calibration curve yielded an equation for the line in the form of y = mx + b, where b in
this case was zero. The fluorescent intensity of the unknown sample was equal to y, and
the concentration was equal to x. The unknown concentration of the sample wa simply
be found by dividing the fluorescent intensity by the slope of the calibration curve.
Figure 22 illustrates a typical calibration curve. In this case, more than five known
samples were made and tested.
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CF Concentration versus Intensity Calibration Curve
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y = 3.3711E+08x
R2 = 9.9655E-01

160
140

Intensity
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3.00E-07

4.00E-07
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6.00E-07

Concentration (m ol/L)

Figure 22. Typical Calibration Curve Using 5mM CF Dye

A new calibration curve was made each time a new batch of dye was encapsulated in the
niosomes. For dye that did not come from a new batch of dye, testing one known
concentration was made to verify that the intensity and concentration were consistent
with the previous dye.
The linear relationship between intensity and concentration was only observed for
dilute concentrations. At high concentrations, the curve did not behave linearly, but
rather parabolic. Therefore, in order to obtain the concentrations for unknown samples,
their concentration had to lie in the linear range of the concentration curve. If the
concentration was too high, they were diluted so that they fell in the linear range. The
linear range was observed to be concentrations up to about 5x10-7 M, which corresponded
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to an intensity of about 160. The linear relationship was been observed for intensity
readings up to about 250. Therefore, an intensity of much greater than 250 required
diluted. The corresponding calculations accounted for the dilution.
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Chapter Five
Experimental Design and Procedure

The reagents, equipment, and instruments used in the experiments are described
in Table 3, Table 4, and Table 5, respectively.

5.1.

Reagents

Table 3. Primary Reagents Used. Gray Shaded Area Denotes Reagents That Were
Used by Dr. VanAuker’s Lab Group to Prepare Niosomes
Reagent

Common

Concentration

Name

Serial

Manufacturer

Number

Lot

Description

Number

Milli-Q water

H2O

pH ~ 7.1

N/A

Millipore

N/A

Temperature:
22.6°C;
TOC: 5 ppb
@ 25°C;
18.2 MΩ.cm

Dulbecco’s
Phosphate Buffer
Saline (Modified)
without calcium,
magnesium
5-(6)Carboxyfluorescein

PBS

9.55 g/L;
pH ~ 7.3

Catalog
#:
1760426

MP
Biomedical,
Inc.

17604014

Storage 2°C
to 8°C;

C21H12O7

MW 376 g/mol

Cat #
51013

Biotium

N/A

C14H22O;
Ethoxylated
p-tertoctylphenol

10%
MW: 628 g/mol

Cat #
BP151500

Fisher
Scientific

33078

Store at 4°C.
Protect from
light,
especially
when in
solution; pH
~ 7.3
Storage code
gray G;
Shake well
before using

Triton-X-100
Electrophoresis
grade
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Table 3 (Continued)
Chloroform HPLC
grade

CHCl3

99+ %
Chloroform
0.75 % Ethyl
Alcohol

FL-141296

Fisher
Scientific

42013

Dicetyl Phosphate
(Dihexadecyl
phosphate)

C32H67O4P

MW: 206.1534
g/mol

D2631

Sigma Aldrich

112K1306

Sephadex® G-50

N/A

N/A

G508050G

Sigma Aldrich

Sorbitan
Monostearate

C24H46O6;
Span 60

MW: 430.62
g/mol

S-7010

Sigma Aldrich

Cholesterol (5Cholesten-3β-ol)

C27H46O;

MW: 386.65

C-8503

Sigma Aldrich

Equivalent
to USP/NF

g/mol
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C606-1; RQ
Chloroform
UN1888; UV
cutoff 244
nm; Storage
code blue B

CAS #:
2197-63-9;
Store at less
than 0°C;
EC#218-5947;
085K1268
CAS #:
9048-71-9;
Don’t
breathe dust,
moisture
sensitive; Dry
bead
diameter: 2080 μm, Bed
volume: 9-11
mL/g;
SL05374
023K1171
CAS #:
1338-41-6;
EC # 215664-9; Store
at room
temperature
032K0060

CAS #: 5788-5;
Approx. 95%
(GC);
EC#200-3532

Table 3 (Continued)
Phosphate
Buffered Saline

5.2.

PBS

pH 7.4

P-3813

Sigma Aldrich

025K8208

Avoid
contact and
inhalation;
Target
organs:
heart; 10
packets; Dry
powder
dissolved in
1L deionized
water will
yield 0.01 M

Equipment

Table 4. Primary Equipment Used. Gray Shaded Area Denotes Reagents That Were
Used by Dr. VanAuker’s Lab Group to Prepare Niosomes
Equipment

Manufacturer

Model

Serial Number

Range

Description

Liquid volume: 100,
500, 1000; Accuracy:
±1.0 %, ±0.8 %, ±0.7
%; Reproducibility:
<0.5 %, <0.3 %, <0.2
%; Adjustable
increment: 1.0 µL;
Accuracy: +/- 2.0 to
+/- 8.0 µL;
Reproducibility CV: <
0.5 to < 0.3
Liquid volume: 20,
100, 200; Accuracy:
±1.0 %, ±0.8 %, ±0.8
%; Reproducibility:
<0.5 %, <0.3 %, <0.2
%; Adjustable
increment: 1.0 µL;
Accuracy: +/- 0.6 to
+/- 2.0 µL;
Reproducibility: < 1.0
to < 0.3

Number
Autoclavable
Nichiryo,
Oxford®
Benchmate TM
Micropipette
8885-500945

Oxford
Worldwide

Cat # 8885501945

N/A

100 ~
1000 μL

Autoclavable
Nichiryo,
Oxford®
Benchmate™
Micropipette
8885-500937

Oxford
Worldwide

Cat # 8885501937

N/A

20 ~ 200
μL
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Table 4 (Continued)
Autoclavable
Nichiryo,
Oxford®
Benchmate™
Micropipette
8885-500911

Oxford
Worldwide

Cat # 8885501911

N/A

2 ~ 20 μL

Redi-Tip™

Fisher Scientific

Cat #
211978A

N/A

101- 1000
μL

ART100® Tips
(Aerosol
Resistant Tips)

Molecular
Bioproducts

Cat # 2065

Lot # 72101

101 μL

Disposable
Serological
Pipettes

Fisher Scientific

Cat #
1367610K

N/A

25 ml in
2/10 ml

Regenerated
Cellulose
Dialysis
Membrane

Fisher Scientific

Cat # 21152-18

N/A

Nominal
MWCO
1200014000
Dalton
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Liquid volume: 2, 10,
20; Accuracy: ±5.0
%, ±1.0 %, ±1.0 %;
Reproducibility: <3.0
%, <1.0 %, <0.4 %;
Adjustable increment:
0.1 µL; Accuracy: +/0.16 to +/- 0.4 µL;
Reproducibility: < 3.0
to < 0.5
General purpose tips;
Fisherbrand;
Nonsterile; Volume:
201-1000 μL;
Package: 10 racks of
100 each
Prevent
contamination even
under the most
demanding
conditions; Nuclease,
nucleic acid, and
pyrogen free; Presterilized; certified
pure 96 tips/10 tray/5
packs/case
Individually wrapped;
50 Pipettes; Fisher
Brand; Sterile
plugged; Polystyrene
disposable
serological pipettes
with magnifier stripe
Dialysis tubing;
regenerated
cellulose;
Fisherbrand; Type T3
membranes; 20 μm
wall thickness;
EOT#7933; Flat
width: 25 mm, vol/cm:
1.98 ml, dry cylinder
diameter: 15.9 mm

Table 4 (Continued)
Spectrum ®,
Spectra/Por ®
closures

Spectrum
Laboratories

Cat # 142152

N/A

N/A

Elastic Bands

Goody®

71291

1712911W0

75 pieces

Disposable
Centrifuge
Tubes

Fisher Scientific

Cat # 05539-1

N/A

15 ml (in
2-14.5 ml)

Fisher
Isotemp®
Ceramic Top
Stirring
Hotplates

Fisher Scientific

Cat # 11600-49SH

312N3531

Stir: 60 –
1200 rpm

CimarecTM
Digital Stirring
Hot Plates

Barnstead
International

Model
SP131325

1313050139770

50 to 1200
rpm
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Red closures for
cellulose membranes;
Gripping width: 50
mm; Quantity: 10;
Strong leak proof
seal; Polyamide 6.6
from DuPont (Nylon);
Maximum operating
temperature: 90°C;
Minimum operating
temperature: 0°C;
Sanitation: Ethylene
oxide, gamma
irradiation, ethanol, or
formaldehyde; Nonautoclavable
Ouchless Goody hair
bands
Sterile; Fisher brand;
Polypropylene; Plug
seal cap; O.D x L: 17
x 119 mm; Max RCF:
6000xG; Graduated
in 0.5ml subdivisions
from 2 to 14.5 ml
Hot top: 30 – 550°C;
Laboratory
Instruments
(1000186); 120 volts,
7.5 amps, 60 Hz;
Isotemp reflective
white ceramic plate
(7x7 in, 17.8x17.8
cm); Acid/alkali
resistant; Load
capacity: 40 lb.
(18.1kg); heating
surface area: 49 sq in
(316cm2)
Phase 1; Amp: 8.9,
120 volts, 60 Hz;
Aluminum
top/ceramic top;
Adjustable in 5°
increments, from 5°540°C

Table 4 (Continued)
Corning® PC410 Stirrer

Corning®

PC-410

04050569

60 to 1100
rpm

Corning® PC353 Stirrer

Corning®

PC-353

N/A

80 to 1000
rpm

Vortex Genie
2™

Fisher Scientific

Cat # 12-812

2-148767

Parafilm®M

Fisher Scientific

Cat # 13374-16

N/A

2in W x
250 ft L

Aluminum Foil

Reynolds

N/A

N/A

200 ft2

Rotary
Evaporator

Buchi

Rotavapor R200

N/A

N/A

AKTA Prime

Amersham
Bioscience

Hiload
Superdex™
30

Lot #: 216902

N/A

120 V, 60 Hz, 73
Watts; Top size: 5 x 7
in; Top style:
pyroceram; Weight:
6.5 lbs; Dimensions
(H x W x D): 4.4 x 5.8
x 9.6 in
Top: 5 x 7 in; Ceramic
top resistant to
scratches, chemicals,
and corrosion; Base:
epoxy coated
aluminum
Scientific Industries;
Model G-560; 0.5
amps, 120 volts, 60
Hz
American National
Can PM 992; 1 in
diameter core;
Flexible, moldable,
self sealing, odorless,
thermoplastic,
moisture resistant,
semi-transparent,
practically colorless,
waterproof
(66 2/3 yds x 12 in)
18.5 m2 (60.9 m x
304 mm)
Buchi-Vacuum
Controller V-800;
Heating Bath B-490
N/A

All of the water that was used in these experiments was generated from a Millipore Water
(Milli-Q) water station. The water was ultra purified and meet the requirements of
resistance < 18 MΩ.cm and organic contents < 5 ppb [136]. The purification process
involveed three components: the Elix® water system (Serial # 495000240926), the
Automatic Sanitation Module (Serial # 495000240927), and the Milli-Q Synthesis A10
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system (Serial # 495000240928).

Tap water was passed through to a Progard™

pretreatment pack where particles and chlorine were removed from the water [137]. The
water was pressurized and reverse osmosis was used to purify the water. The reverse
osmosis water was then passed through to an electrodeionisation module where the
organic and mineral content was brought down to an acceptable level [137].

5.3.

Instruments

Table 5. Instruments Used
Instrument

Manufacturer

Model
Number

Serial
Number

Range

Description

AccuSeries
II® Electronic
Toploading
Balance

Fisher Scientific

Accu-2202

Cat # 13265-225

0 to 2200
g

Accumet 1003
pH Meter

Fisher Scientific

Accumet 1003

N/A

-6 to 20
pH

Accumet Gelfilled Polymer
Body pH/ATC
DoubleJunction
Combination
Electrode

Fisher Scientific

SN4175147P2

Cat # 13620-111

0 to 14
pH

Readability: 0.01 g;
Tarring; Repeatability: 0.01
g; Linearity: ±0.02 g;
Stabilization time 2 sec;
Pan Size: 7x7 in (18 x 18
cm); Dimensions: 14 ½ x 9
3/8 x 3 ¾ in; 115 Volts,
50/60 Hz; Single range
Resolution: 0.1, 0.01;
Accuracy: 0.002; Buffer
Values:
1.68,4.00,7.00,10.00,12.45;
mV Range: -999 to 999;
Temperature Range: 0°C
to 100°C; Dimensions: 6.5
in x 2.88 in x 1.2 in;
Weight: 9.3 ounces
Temperature: -5°C to
80°C; Accuracy: <±0.05pH
at 25°C; Efficiency: >95 at
25°C; Sodium Ion Error:
<±0.05 pH 13 and 25°C;
Response Time: 30
seconds; Diameter: 3/8 in.
(body) and 5/8 in. (cap)
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Table 5 (Continued)
Lab Fume
Hood
Safeaire®

Fisher Hamilton

Part # 70864

LS-3B
Fluorescence
Spectrometer

Perkin Elmer

C659-0000

5.4.

54L
PL822;
Serial
110000
6999403

N/A

12 Volts,
60 Hz

Hood type: bench,
prewired; Fumehood
monitor: Phoenix Controls
Corporation (part FHM610)
Monochromator = 488 nm
Excitation Filter to 515 nm
Emission Filter

Experimental Procedure

The experimental procedure consists of a series of diffusion experiments. The
experimental procedure requires several steps. The first step was to weigh out and
measure the materials and reagents that were used in the experiment. This included the
components for the membrane and the components for the medium. The next step was to
incorporate the two components together. The experiments were allowed to run for an
elapsed time and the final samples were taken to the fluorescence spectrometer.
From previous experience, the best design for in vitro experiments was
determined.

Two types of regenerated cellophane membranes were tested as a

membrane. They were manufactured in sheets of cellophane. The cellophane membrane
was secured to the bottom of a tube, and the tube was filled with a sample. Experimental
design showed that the cellophane membrane caused a pressure differential and
subsequently leakage from the membrane. The regenerated cellulose membrane was
manufactured in spools of tubing and was specifically used for dialysis experiment. The
end closures also allowed for a reliable and secure seal of the membrane. A 5(6)carboxyfluorescein dye was used because it has a similar molecular weight to
Temozolomide, a chemotherapeutic drug, and is the dye of choice in Dr. VanAuker’s
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laboratory. Temozolomide is the chemotherapeutic drug that is currently used in vivo at
Moffitt Cancer Center, where it is intended to test this drug in vitro and in vivo. The
concentrations encapsulated in the niosomes were 4mM, 5mM, and 14mM.

These

concentrations were based on similar amounts of Temozolomide used in experimental
testing.

Span 60 niosomes were prepared due to their great stability, which reduced

leaking. TX-100 was the traditional surfactant that was used to break niosomes in
fluorescence spectrometry. Time intervals were used based on previous experiments.
Several time intervals were originally made, and it was decided that intermediate points
were needed for comprehensive data. Earlier experiments were performed at the original
time intervals and later experiments were performed at the modified time points. The
experiment was performed at a room temperature. The pH of the Milli-Q water used was
approximately 7.1 and the pH of the PBS used was 7.3-7.4.
5.4.1. Niosome Preparation

The niosome solutions were prepared in the laboratory of Dr. VanAuker. The
students who prepared the niosomes in the lab provided the following procedure [138].
Niosome Films:

The niosomes were prepared in a 1:1:0.105 molar ratio of

surfactant : cholesterol : dicetyl phosphate (DCP).

A 10x solution for 3 films of

niosomes required 0.294 g of Span 60 surfactants, 0.264 g cholesterol, and 0.039 g DCP.
The components were then added to 9 ml of chloroform and swirled until all of the
chemicals are dissolved. The flask was covered to avoid evaporation of the chloroform.
Too much mass would be aliquoted if excessive evaporation occurs and additional
chloroform could be added if necessary during the film-making process.
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Three

millimeters of the solution was added to 1 ml of chloroform in a 50 ml round bottom
flask.

The flask was attached to the Buchi rotary evaporator (removing the large

collection flask) and allowed to slowly rotate at a near flat angle. The solution was put
into a rotary evaporator. Nitrogen gas was pumped into the flask at 3 L/min. The
chloroform evaporated to reveal the film. The film was allowed to dry for at least 10
minutes after the last liquid is gone. The flask was then covered with Parafilm®M and
placed upside down in a dish in the fume hood where it was allowed to dry for 8-24
hours.
Hydration of the Thin Films: The hydration of the thin films was done with 1X
PBS solution. Span 60 has a gel phase transition temperature of 56-58°C. The hydrating
temperature must be 60°C to make a stable ordered lamellar membrane [139]. The rotary
evaporator was filled with a deionized water bath and the temperature is set to 60°C.
Three ml of the hydrating solution was added to the think film flask. Three milliliters of
the deionized water was added to a blank place-filling flask. The flask was secured with
a clip on the wide side of the flask. The flasks were allowed to slowly spin in the water.
After one hour, the flasks were taken off the rotary evaporator and agitated. They were
covered with Parafilm®M and mixed on a vortex mixer that removed the lipids evenly by
moving around the outer surface.

The flask was then returned to the evaporator.

Hydration was continued for one more hour and sonicated for 60 minutes in a sonicator.
The sonicator bath was filled three quarters of the way full with deionized water. The
flask, covered with Parafilm®M, was suspended in the water bath using a clamp stand. The
bulk niosome solution was filtered and heated before it was GEC injected into the Akta
Prime system. The plunger of a 10 ml disposable syringe was removed. Two filter discs
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(5/8”) were put into the syringe and pushed to the bottom of the syringe. The syringe was
held over a flask while 2.25-2.5 ml of the bulk solution was added to it. The plunger was
pushed back into the syringe and forced the bulk solution through the filter. Another
syringe was used to take about 2.0 ml of the bulk solution, and the tip of that syringe was
wrapped in Parafilm®M. The contents of that syringe were swirled in the heated water
bath at 60°C.
5.4.2. Membrane Measurements

The first step in the experimental procedure was to prepare the components of the
membrane system. The procedure is discussed in terms of using water as the medium,
but the procedure for using PBS instead is analogous; one would simply substitute the
PBS information in for the water information. A five to seven centimeter strip of
regenerated cellulose dialysis membrane was cut from the reel of membrane. A 250 ml
beaker (Beaker A) was placed on the AccuSeries II® Electronic Toploading Balance
Accu-2202 mass balance and zeroed. The membrane was placed in the zeroed beaker,
and the mass of the membrane was taken. All mass measurements were taken in grams,
g. Beaker A was later used in the measurement of the entire membrane system and
offered a contained environment for the components of the membrane system to be
recorded in. A solution of PBS was prepared by dissolving the entire container of
Dulbecco’s Phosphate Buffer Saline (Modified) without calcium, magnesium powder in
one liter of Milli-Q and stirred. A 100 ml beaker was filled with approximately 100 ml of
the PBS solution. The membrane strip was placed in the PBS solution and allowed to
soak for approximately ten minutes. Beaker A was zeroed again, and two Spectrum ®,
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Spectra/Por® closures were placed in the beaker to be weighed. The beaker and closures
were removed from the balance. The balance was zeroed again, and the two Goody®
elastic bands were placed directly on the balance to be measured. Due to the small mass
of the elastic bands, they were placed directly on the balance. This eliminated any
disturbances that may have altered the reading of such a lightweight component. The
membrane strip also had a small mass; however, the delicate nature of the membrane
required that it be measured in the beaker. The closures did not require being measured
directly on the balance and could be measured in the zeroed beaker because their mass
was not greatly affected by disturbances from the zeroed beaker. Elastic bands were used
to ensure proper closure of the membrane and eliminate the reduced tension of the
closures that could result over time. The total mass of the dry membrane system could be
calculated by adding the mass of the dry membrane, the two dialysis-membrane closures,
and the elastic bands.

mmembrane system dry = (mdry membrane − mclosures − melastic bands ) Eqn. 6
Beaker A, the two closures and elastic bands were placed aside while the components of
the beaker are prepared. Please see section 5.4.2. After the beaker measurements were
completed, the next step was to add the niosomes to the membrane.

The soaked

membrane was taken out of the PBS solution with tweezers and placed onto
approximately three sheets of Kimwipes® paper tissue. Three more Kimwipes® paper
tissues were placed on top of the membrane and the excess moisture from the PBS
solution was allowed to be absorbed. The membrane was gently opened by delicately
rubbing the sides of the membrane back and forth. Once the ends of the membrane were
opened, the tweezers were inserted into the membrane and expanded the remaining
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length of the membrane. This was an essential step in the procedure because otherwise,
the bottom section of the membrane would have remained closed and the niosomes
solution would have spilled out of the top when added. One dialysis-membrane closure
was placed at one end of the membrane and securely shut. Over time, the closures could
loose their firmness and leak due to an unsecured closure. The elastic bands were
wrapped around the closures to ensure maximum security. A Redi-Tip™ (101-1000 μl)
pipette tip was fitted to the Autoclavable Nichiryo Oxford® Benchmate

TM

(~100-1000

μl) micropipette. The micropipette was used to add 2 ml (2000 μl) of the niosomes to the
membrane. The tweezers were used to hold the membrane upright with one hand, while
the other hand measured out the 2 ml. The open end was then closed with the remaining
dialysis-membrane closure, and the remaining elastic band was wrapped around the end
of the closure. Beaker A was placed on the mass balance once again and zeroed. The
entire membrane unit was placed in the beaker and the mass was recorded. The weight of
the niosome solution was determined by subtracting this mass from the mass of the dry
membrane, two dialysis-membrane closures, and elastic bands.

mniosomes @ to = m membrane system total @ to − mmembrane system dry

Eqn. 7

This information was used to determine the density of the niosomes solution and
determined the final volume of the niosome solution in the membrane.
5.4.3. Beaker Measurements

The next step in the experimental procedure was to prepare the components of the
medium.

A 250 ml beaker (Beaker B) was labeled “Experiment N, t=x” and was

weighed on the Accu-2202 mass balance. The balance was zeroed and a stirring rod was
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placed in the beaker. This mass was recorded. The total weight of the empty beaker
system could be calculated by adding these two measurements together.

mbea ker r medium system dry = m Bea ker B − m stirring rod

Eqn. 8

A 500 ml beaker was filled with approximately 500 ml of the Milli-Q water. A 25 ml
disposable serological pipette was used to fill the Beaker B, with stirring rod, with 85 ml
of Milli-Q water. The filled beaker was weighed again. The mass of the 85 ml of the
Milli-Q water could be determined by subtracting this mass from the mass of the empty
beaker and stirring rod.

m water @ to = m bea ker system total @ to − mbea ker system dry

Eqn. 9

This information was used to determine the density of the water in the Beaker B and then
later to determine the final volume of the solution in the beaker. The pH of the medium
was taken, based on a sample from the medium in the 500 ml beaker, using the Accumet
1003 pH Meter with Accumet Gel-filled Polymer Body pH/ATC Double-Junction
Combination Electrode.
5.4.4. Density Calculation

The density of the both the niosome solution in the membrane and the water
medium solution in the Beaker B were calculated. The equation for density was equal to
the mass of the solution divided by the volume of the solution.

ρ=

mass
volume
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Eqn. 10

The density of the membrane was as follows:

ρ niosome solution @ t =
o

mniosomes
2ml

Eqn. 11

The density of the water in the beaker was as follows:

ρ water @ t =
o

m water
85ml

Eqn. 12

A list of the density values for the experiments performed can be found in Appendix B.
5.4.5. Incorporation of Two Units

The next step in the experimental procedure was to incorporate the two units
together: the membrane system and the beaker system. The membrane system was
submerged into the 85ml of Milli-Q water in Beaker B, with the dialysis-membrane
closures guiding the orientation of the membrane to face downward. This was necessary
to ensure that the entire area of the membrane is submerged in the water. Parafilm®M
was placed over the entire system and placed on the mass balance. The total weight of
the system was recorded and compared to the total weight of the system at the end of the
experiment to determine if the mass remained constant throughout the elapsed time. The
entire system was placed on the Fisher Isotemp® Ceramic Top Stirring Hotplate (1), the
CimarecTM Digital Stirring Hot Plate (3), the Corning® PC-410 Stirrer (1), or the
Corning® PC-353 Stirrer in the Lab Fume Hood Safeaire®. The rotation was placed on
approximately 300-350 rpm. The system was covered with Reynolds aluminum foil to

82

prevent any exposure to light that could result in bleaching of the dye. The system was
allowed to run for the specified elapsed amount of time.
5.4.6. Elapsed Time for Experiment

The experimental procedure was performed for each elapsed time desired. The
original experiment was run at 0, 24, 72, and 144 hours. The times of 6 and 12 hours
were then added. One experiment was performed to fill in intermediate data points to a
previous experiment. It was discovered later that the concentration that was thought to be
equal to the original concentration was not. The experiment was taken as a separate
experiment; only the times at 3, 6, 9, and 24 hours were obtained.

In the latter

experiment, it was determined that the times of 3, 6, 9, 12, 24, and 72 hours provided the
most comprehensive data. At the end of each experiment, the foil was removed from the
system and the stirring plate turned to zero. The total system was weighed to determine
the consistency in weight. The Parafilm®M was removed and Beaker A was placed on
the mass balance and zeroed. The membrane unit was taken out of the beaker system
with tweezers and as much excess liquid was shaken off. The membrane system was
placed in the beaker on the balance and the final weight of the system was determined.
The mass of the contents in the membrane (now consisting of both the original niosome
solution and the water from the beaker) could be found.

mmembrane @ t f = m membrane system total @ t f − mmembrane system dry Eqn. 13
The elastic bands and closures were removed and the contents of the membrane were
placed in a 15 ml disposable centrifuge tube and labeled “Experiment N, t=x,
MEMBRANE.” The mass balance was zeroed and Beaker B was placed on it to be
83

weighed. The contents of the Beaker B were placed in a 15 ml disposable centrifuge tube
and labeled “Experiment N, t=x, BEAKER.”

The pH was taken of the remaining

solution in Beaker B using the Accumet 1003 pH Meter with Accumet Gel-filled
Polymer Body pH/ATC Double-Junction Combination Electrode.
5.4.7. Fluorescence Spectrometer

The intensity of the 5(6)-carboxyfluorescein dye was taken using the LS-3B
Luminescence Spectrometer. A small sample of the original niosome solution was used
for the measurement. It is important to note that no volume was taken from the niosome
solution already in the dialysis membrane. The sample was taken from the bulk niosome
solution prepared in the plastic sample container. It was labeled, “Experiment N, t=0,
MEMBRANE”. A sample of Milli-Q water was also taken from the bulk Milli-Q water
in the 500 ml beaker, and no volume was removed from what was already in Beaker B. It
was labeled, “Experiment N, t=0, BEAKER.” The LS-3B fluorescence spectrometer was
turned on. The 5(6)-carboxyfluorescein dye excitation/emission range was 492/514 nm.
The excitation/emission wavelength was set to 488/515 nm which was sufficient for
detection of the dye. For the beaker sample, 1000 μl of PBS solution was added to a
quartz cuvette using the Autoclavable Nichiryo Oxford® Benchmate™ Micropipette
(~100-1000 μl) micropipette with a Redi-Tip™ (101-1000 μl) pipette tip. The cuvette
was placed in the sample cell. There was a small black “Q” marked on the cuvette. The
cuvette was placed in the fluorescence spectrometer with the “Q” facing the front right
hand corner of the machine. The “AUTO ZERO” button was pushed and the PBS was
taken as the zero. The PBS solution was discarded and 1000 μl of the sample from the
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beaker was added to cuvette using a 1000 μl micropipette. The outside of the pipette tip
was wiped with a Kimwipes® to prevent any excess sample from being measured. The
cuvette was placed in the sample cell.

The “INT” button was pressed and the

measurement was taken and recorded as “Intensity of the beaker @ t=0 before
surfactant.” This procedure was done until three consistent readings are taken. A
surfactant didnot need to be added to the sample because there were no niosomes present
in the initial milli-Q water in the beaker. The cuvette was cleaned each time between
readings with water, paper towels, and Kimwipes®. The same procedure was performed
for the sample from the beaker at each elapsed time except one step was added. A 10%
solution of TX-100 was prepared by diluting 1 ml of TX-100 in 9 ml of Milli-Q water.
The 10% TX-100 solution prepared was used in subsequent procedures. Ten microliters
of TX-100 are added to the 1000 μl of sample using the Autoclavable Nichiryo Oxford®
Benchmate™ Micropipette (~20-200 μl) micropipette, with an ART100® Tips (101 μl)
pipette tip, and the outside of the pipette tip with Kimwipes® are wiped.

The

Autoclavable Nichiryo Oxford® Benchmate™ Micropipette (~20-200 μl) micropipette
was able to read down to approximately 10 μl. The solution was allowed to mix for five
seconds on the Vortex Genie 2™ and placed back in the sample cell. The intensity was
allowed to stabilize, and the “INT” button was pressed. The recording was taken as
“Intensity of the beaker @ t=x after surfactant.”
The niosome readings were taken next. There are 990 μl of PBS added to the
cuvette using the 1000 μl micropipette. The cuvette was placed in the fluorescence
spectrometer, and the “AUTO ZERO” was pressed again. Ten microliters of the niosome
sample were taken using the Autoclavable Nichiryo Oxford® Benchmate™ Micropipette
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(~2-20 μl) micropipette with ART100® Tips (101 μl) pipette tip and placed in the
cuvette, wiping the outside of the pipette tip with Kimwipes®. The solution was mixed
for five seconds on the Vortex Genie 2™ and placed back in the cell. The reading was
allowed to stabilize and the “INT” button was pressed. The intensity was recorded as
“Intensity of the membrane @ t=0 before surfactant.” This reading represented the signal
from the small amount of free dye in the solution as well as about 70% of the signal from
the dye within the niosomes. There was about 30% quenching of the signal from the
niosomes. Ten microliters of TX-100 are added to the cuvette using the Autoclavable
Nichiryo Oxford® Benchmate™ Micropipette (~20-200 μl) micropipette (20-200 μl)
micropipette and wiping the outside of the pipette tip. The resulting solution was mixed
for five seconds on the Vortex Genie 2™, and the cuvette was again placed in the sample
cell. The reading was allowed to stabilize and the intensity was recorded as “Intensity of
the membrane @ t=0 after surfactant.”

This reading represented the signal from

supposedly all of the dye present. The TX-100 should have broken all of the niosomes
and just free dye should be left. It represented everything that was present, inside and
outside of the vesicles. The same procedure was performed for the sample from the
membrane at each elapsed time and recorded appropriately.
It is important to note a slight variation in the procedure when high concentrations
were to be tested. The linear relationship between intensity and concentration was only
observed for dilute concentration, about 5.00x10-7 M, which corresponded to around and
intensity of 160. The linear relationship would continue until intensity readings of about
250.

Higher concentrations would behave in a parabolic manner, reaching a high

intensity and then lowering back down. When high concentrations were observed, an
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added step to the procedure was included to dilute the sample. The concentration was
diluted by half by making a 1:1 ratio of the sample to PBS. If further dilutions were
needed, the same technique was used, dilution by PBS in a 1:1 ratio. The procedure in
the LS-3B fluorescence spectrometer was carried out in the same fashion as before by
adding 10 μl of the sample to 990 μl of PBS. However, in the calculations to follow, the
diluted sample was accounted for accordingly.
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Chapter Six
Results

The diffusion of a niosome solution through a cellulose membrane into a bulk
solution was studied for several different concentrations. The experiments consisted of 4
mM dye in 0.01 M PBS diffused into water; 5.0 mM dye in 0.01 M PBS diffused into
water; 14 mM dye in 0.01 M PBS diffused into water; and 5 mM dye in 0.01 M PBS
diffused into PBS. The 4mM ran for t = 0, 3, 6, 9, and 24 hours. The 5mM ran for t = 0,
6 12, 24, 72, and 144 hours. The 14mM ran for t = 0, 3, 6, 9, 12, 24, and 72 hours. The
5mM/PBS ran for t = 0, 24, 72, 144. The variation in time with the experiments was due
to the fact that it took several tests to determine the best times to run the experiment at.
However, the experiments that were not run at the formulated times behaved in a similar
manner, and therefore, their times were recorded as usual.

In some instances,

interpolation was necessary to extend the behavior to a greater time. There are several
important calculations that needed to be made that included the concentration, moles,
diffusion from the membrane to the medium, diffusion from the niosome to membrane,
and release rate of dye. The following section describes these calculations and presents a
comparison of the data.
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6.1.

Calculations

6.1.1. Volume

The final volume of the contents in the beaker containing the water/dye solution
was calculated using the density calculated for each experiment for each time run. The
final contents of the beaker are weighed. The weight of the water/dye solution can be
determined by:

mwater / dye @ t f = mbea ker system dry − mbea ker system total @ t f

Eqn. 14

The final volume of the water/dye solution can be determined from:

Vwater / dye @ t f =

mwater / dye @ t f

ρ water in bea ker @ t

Eqn. 15
o

The density of water in the beaker at t=0 can be used to determine the volume of the
water/dye solution at tf based on Equation 15 because the density of the dye was
approximately close to the density of dye. When the dye was in solution with the water,
the density of the solution could be approximated by the density of water. The final
volume of the contents in the membrane containing the noisome solution could be
calculated in a similar manner. The final contents of the membrane were weighed. The
weight of the noisome solution could be determined from:

m niosome solution @ t f = m membrane system total @ t f − m membrane system dry
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Eqn. 16

The final volume of the noisome solution could be determined from:

V niosome

solution

@ t

=

f

m niosome

solution

ρ niosome

@ t

f

Eqn. 17

@ to

The density of the niosome solution at t=0 could be used to determine the volume of the
niosome solution at tf based on Equation 17 because the density of the noisome solution
would be approximately close to the density of the noisome solution at the end of the
experiment. Table 6 represents the initial and final volumes of the 4mM, 5mM, 14mM,
and 5mM/PBS. It is very clear that the volume in the beaker initially decreases at the
beginning of the experiment, while the volume in the membrane initially increases. This
indicated that initially the medium rushes into the membrane. Volume after the first few
hours fluctuates as the system dynamics are changing, but it is important to observe that
in all cases, the bulk solutions influxes into the medium.
Table 6. Initial and Final Volumes for 4mM, 5mM, 14mM, and 5mM/PBS

4mM

5mM

14mM

5mM/PBS

Time
[hr]

Beaker
Final
Volume
[ml]

Membrane
Final
Volume
[ml]

Beaker
Final
Volume
[ml]

Membrane
Final
Volume
[ml]

Beaker
Final
Volume
[ml]

Membrane
Final
Volume
[ml]

Beaker
Final
Volume
[ml]

Membrane
Final
Volume
[ml]

0
3
6
9
12
24
72
144

85
84.02
83.88
84.05
83.71
-

2
2.78
2.91
2.65
3
-

85
84.04
83.18
84.12
84.24
84.39

2
2.71
2.67
2.51
2.47
2.27

85
83.83
83.64
83.90
83.69
83.80
83.31

2
2.95
3.11
2.83
3.01
2.81
3.25

85
84.34

2
2.445
2.365
2.485

90

84.455
84.265

6.1.2. Concentration

The calculation of concentration was needed to compare how the concentration
changes over time and with varying concentrations of dye entrapped within the niosomes.
The concentration was also directly related to the number of moles in the system, which
was also of interest. Concentration could be calculated initially, before the surfactant was
added, and after the surfactant was added to obtain a total concentration.

The

concentrations were directly related to the intensity readings and were based on a
concentration standard.

The three consistent intensity readings for the fluorescence

spectrometer were averaged. The calibration curve yielded an equation in the following
form:

y = mx + b

Eqn. 18

Intensity = ( slope of the curve ) * ( concentration ) + ( zero int ercept )
The initial and final concentrations could therefore be determined by dividing the
averaged intensity by the slope of the curve:
C [M ] =

Intensity
slope of the curve

Eqn. 19

This concentration represented the amount of original sample in the PBS in the cuvette.
Table 7 lists the slopes obtained from the calibration curves:
Table 7. Slope Obtained from Calibration Curve

Experiment
Slope from
calibration
curve

4mM

5mM

14mM

5mM/PBS

3.3711E8

6.125E8

4.733E8

3.3711E8
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It does not represent the actual concentration in either the beaker or the membrane.
Further calculations were performed to scale down this concentration to represent the
concentrations that are present within the two systems. Table 8– Table 11 represents the
initial (before TX-100 is added) and final (after TX-100 is added) concentrations of
4mM, 5mM, 14mM, and 5mM/PBS, respectively. It should be noted here that the
concentration, and subsequently the number of moles, in the beaker originally would be
zero because there was just water at the beginning of the experiment.
Table 8. Initial and Final Concentrations (4mM)

Time
(hr)
0
3
6
9
24

Initial Concentration [mol/L]
[Beaker]o
[Membrane]o

Final Concentration [mol/L]
[Beaker]f
[Membrane]f

0
1.517E-07
1.616E-07
2.319E-07
3.612E-07

0
1.535E-07
1.497E-07
2.297E-07
3.257E-07

2.140E-07
3.192E-07
3.012E-07
2.993E-07
2.427E-07

5.475E-07
4.662E-07
4.298E-07
4.316E-07
3.4604E-07

Table 9. Initial and Final Concentrations for (5mM)

Time
(hr)
0
6
12
24
72
144

Initial Concentration [mol/L]
[Beaker]o
[Membrane]o

Final Concentration [mol/L]
[Beaker]f
[Membrane]f

0
1.294E-07
2.008E-07
2.539E-07
5.557E-07
5.651E-07

0
1.864E-07
2.865E-07
3.250E-07
6.136E-07
5.744E-07

2.361E-07
2.597E-07
2.674E-07
2.822E-07
2.305E-07
3.816E-07

6.559E-07
5.645E-07
5.335E-07
5.497E-07
3.767E-07
4.513E-07

Table 10. Initial and Final Concentrations (14mM)

Time
(hr)
0
3
6
9

Initial Concentration [mol/L]
[Membrane]o
[Beaker]o

Final Concentration [mol/L]
[Beaker]f
[Membrane]f

0
5.226E-07
5.182E-07
8.820E-07

0
5.157E-07
4.899E-07
9.156E-07

6.439E-07
9.992E-07
9.311E-07
8.488E-07
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1.638E-06
1.351E-06
1.311E-06
1.211E-06

Table 10 (Continued)

12
24
72

6.612E-07
1.546E-06
1.902E-06

8.020E-07
6.932E-07
4.955E-07

6.238E-07
1.534E-06
1.799E-06

1.153E-06
1.062E-06
9.009E-07

Table 11. Initial and Final Concentrations (5mM/PBS)

Time
(hr)
0
24
72
144

Initial Concentration [mol/L]
[Beaker]o
[Membrane]o

Final Concentration [mol/L]
[Beaker]f
[Membrane]f

0
6.318E-08
5.717E-08
6.100E-08

0
6.575E-08
5.489E-08
4.263E-08

1.689E-07
1.785E-07
1.861E-07
2.223E-07

3.995E-07
3.860E-07
3.603E-07
3.405E-07

6.1.3. Moles in Cuvette

The moles in the cuvette could be calculated to determine how many moles were
present in the sample that was measured in the cuvette.

This was an important

intermediate step in calculating the total moles in the system. The moles in the cuvette
had to be scaled up to account for the actual moles in either the beaker or membrane
system. The moles in the cuvette represented the moles of the sample in the 1 ml (or 1.01
ml) sample in the cuvette. There was an initial (before TX-100 is added) and a final
(after TX-100 is added) value for the moles in the cuvette. The initial moles in the
cuvette for both the beaker and the membrane could be calculated by converting L to ml
and was multiplyed by the total volume in the cuvette initially (1 ml):

molesinitial in cuvette

⎡ mol ⎤
Co ⎢
L ⎥⎦
= ⎣
* (1 ml )
ml
1000
L
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Eqn. 20

The final moles in the cuvette for both the beaker and membrane were calculated in a
similar manner. However, the total volume in the cuvette was now 1.01 ml since 10 μl of
TX-100 was added. The calculation for the final moles in the cuvette for both the beaker
and the membrane was as follows:

moles final in cuvette

⎡ mol ⎤
Cf ⎢
L ⎥⎦
⎣
=
* (1.01 ml )
ml
1000
L

Eqn. 21

The initial and final moles in the cuvette are represented in Table 12–
Table 15 for 4mM, 5mM, 14mM, and 5mM/PBS, respectively.
Table 12. Initial and Final Moles in the Cuvette (4mM)

Time
(hr)
0
3
6
9
24

Initial Moles in Cuvette [moles]
[Beaker]o
[Membrane]o
0
1.517E-10
1.616E-10
2.319E-10
3.612E-10

2.140E-10
3.192E-10
3.012E-10
2.993E-10
2.427E-10

Final Moles in Cuvette [moles]
[Beaker]f
[Membrane]f
0
1.550E-10
1.512E-10
2.320E-10
3.289E-10

5.530E-10
4.708E-10
4.341E-10
4.359E-10
3.495E-10

Table 13. Initial and Final Moles in the Cuvette (5mM)

Time
(hr)
0
6
12
24
72
144

Initial Moles in Cuvette [moles]
[Beaker]o
[Membrane]o
0
1.294E-10
2.008E-10
2.539E-10
5.557E-10
5.651E-10

2.361E-10
2.597E-10
2.674E-10
2.822E-10
2.305E-10
3.816E-10

Final Moles in Cuvette [moles]
[Beaker]o
[Membrane]o
0.000E+00
1.883E-10
2.894E-10
3.283E-10
6.198E-10
5.801E-10
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6.624E-10
5.701E-10
5.388E-10
5.552E-10
3.805E-10
4.558E-10

Table 14. Initial and Final Moles in the Cuvette (14mM)

Time
(hr)
0
3
6
9
12
24
72

Initial Moles in Cuvette [moles]
[Beaker]o
[Membrane]o
0
5.226E-10
5.182E-10
8.820E-10
6.612E-10
1.546E-09
1.902E-09

6.439E-10
9.992E-10
9.311E-10
8.488E-10
8.020E-10
6.932E-10
4.955E-10

Final Moles in Cuvette [moles]
[Beaker]o
[Membrane]f
0.000E+00
5.208E-10
4.948E-10
9.247E-10
6.301E-10
1.549E-09
1.817E-09

1.655E-09
1.365E-09
1.324E-09
1.223E-09
1.165E-09
1.073E-09
9.099E-10

Table 15. Initial and Final Moles in the Cuvette for (5mM/PBS)

Time
(hr)
0
24
72
144

Initial Moles in Cuvette [moles]
[Beaker]o
[Membrane]o
0
6.318E-11
5.717E-11
6.100E-11

1.689E-10
1.785E-10
1.861E-10
2.223E-10

Final Moles in Cuvette [moles]
[Beaker]o
[Membrane]o
0.000E+00
6.640E-11
5.544E-11
4.305E-11

4.035E-10
3.898E-10
3.639E-10
3.439E-10

It is important to note that the moles in the cuvette for the beaker only represented 1 ml of
the sample. The moles in the cuvette for the membrane only represented 10 μl of the
sample. This information is important when the total moles of the beaker and membrane
are desired.
The moles in the vesicles were calculated by subtracting the initial moles in the
cuvette from the final moles in the cuvette. The final moles represented the presumably
total moles in the system after supposedly all of the niosomes had burst and there was just
free dye left. The initial moles in the cuvette represented the signal from the free dye and
about 30% of the reading of the dye within the niosomes. The difference between the
initial and final moles represented the moles that were entrapped within in the niosomes.
Table 16 shows the moles within the vesicles for 4mM, 5mM, 14mM, and 5mM/PBS.
The unusual observation was that the moles within the vesicles were negative for some
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certain times and experiments in the beaker. The behavior was due to the fact that the
TX-100 is not sufficiently breaking all of the niosomes and the final signal should be
much higher. Because it is not as high as it should be, negative numbers results. The
negative numbers also resulted from the fact that there were no vesicles with dye in the
beaker. The negative number was a result of an inaccurate mass balance as well as an
indication that there were zero moles of dye in the vesicles in the beaker.
Table 16. Moles in Vesicles (4mM, 5mM, 14mM, and 5mM/PBS)

4mM
Time
[hr]
0
3
6
9
12
24
72
144

5mM

14mM

5mM/PBS

Beaker
Moles in
Vesicles

Membrane
Moles in
Vesicles

Beaker
Moles in
Vesicles

Membrane
Moles in
Vesicles

Beaker
Moles in
Vesicles

Membrane
Moles in
Vesicles

Beaker
Moles in
Vesicles

Membran
e Moles in
Vesicles

0

3.390E-10

0

4.26362E-10

0

1.011E-09

0

2.345E-10

3.341E-12

1.516E-10

-

-

-1.745E-12

3.654E-10

-

-

-1.039E-11

1.330E-10

5.888E-11

3.10442E-10

-2.341E-11

3.926E-10

-

-

1.203E-13

1.366E-10

-

-

4.268E-11

3.747E-10

-

-

-

-

8.854E-11

2.71410E-10

-3.109E-11

3.626E-10

-

-

-3.228E-11

1.068E-10

7.437E-11

2.72986E-10

3.507E-12

3.794E-10

3.218E-12

2.114E-10

-

-

6.408E-11

1.49971E-10

-8.540E-11

4.144E-10

-1.735E-12

1.778E-10

-

-

1.504E-11

7.42231E-11

-

-

-1.795E-11

1.217E-10

6.1.4. Moles in the System

The total moles in the system provided information of interest. The moles in the
system represented the total number of moles present in both the beaker and the
membrane. It told us how much dye has diffused across the membrane and how much
dye has been released from the vesicles. The total moles in the system were determined
based off of the moles found in the cuvette. However, in order to calculate the total
moles, the moles found in the cuvette were scaled up by multiplying by the volume that
was found for each experiment and for each time run. It is important to note that 1 ml of
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the beaker sample was measured and 10 μl of the noisome solution was measured.
Therefore the number of moles in the cuvette for the beaker was only based on 1 ml. The
number needed to be multiplied by the volume of the system to determine the moles in
that particular system. The total moles in the system were calculated for the free dye
alone or for the total dye. The data for the total dye is shown below; however, the total
free moles are discussed in Chapter Seven. The total moles in the beaker system were
therefore be calculated by the following method:

moles

bea ker total system

=

moles

final in cuvette ( bea ker)

1 ml

* V water / dye

@ tf

Eqn. 22

The calculation for the number of moles total in the membrane was performed in a
similar manner. The number of moles in the cuvette for the beaker was only based on 10
μl. The conversion from μl to ml needed to be made. The number then needed to be
multiplied by the final volume of the membrane to determine the number of moles in that
particular system. The total moles in the membrane system were therefore be calculated
by the following method:

molesmembrane total system =

moles final in cuvette ( membrane) 1000μl
*
*Vniosome solution @ t f Eqn. 23
10μl
1ml

The total moles in the beaker and noisome system were calculated and are represented in
Table 17– Table 20 for 4mM, 5mM, 14mM, and 5mM/PBS, respectively. The gray
shaded areas represent extrapolated points.
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Table 17. Total Moles in the System (4mM)

Time
(hr)
0
3
6
9
24
72

Total Moles in the System [moles]
Beaker
Membrane
0.000E+00
1.302E-08
1.268E-08
1.950E-08
2.753E-08
5.213E-08

1.106E-07
1.309E-07
1.263E-07
1.155E-07
1.048E-07
5.948E-08

Table 18. Total Moles in the System (5mM)

Time
(hr)
0
6
12
24
72
144

Total Moles in the System [moles]
Beaker
Membrane
0.000E+00
1.572E-08
2.396E-08
2.761E-08
5.221E-08
4.896E-08

1.325E-07
1.716E-07
1.439E-07
1.393E-07
9.398E-08
1.035E-07

Table 19. Total Moles in the System (14mM)

Time
(hr)
0
3
6
9
12
24
72

Beaker

Total Moles in the System [moles]
Membrane

0.000E+00
4.366E-08
4.138E-08
7.758E-08
5.273E-08
1.298E-07
1.514E-07

3.309E-07
4.026E-07
4.116E-07
3.462E-07
3.505E-07
3.014E-07
2.957E-07

Table 20. Total Moles in the System (5mM/PBS)

Time
(hr)
0
24
72
144

Total Moles in the System [moles]
Membrane
Beaker
0.000E+00
1.121E-08
9.364E-09
7.256E-09

1.614E-07
1.906E-07
1.721E-07
1.709E-07
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6.1.5. Diffusion from Membrane to Medium

The analysis of the diffusion of the proposed system was separated into two subsystems: the diffusion from inside the cellulose membrane to the medium (the term
beaker will now be referred to in terms of the medium) and the diffusion from inside the
niosome outside into the membrane area. The diffusion of the dye from the membrane
to the medium was important to understand because it allowed for the determination of
what the concentration was in the medium and how many moles were released to the
surroundings. The diffusion also allowed for the determination of a relationship between
the concentrations in the membrane with the concentration in the medium. A model was
developed to see if it would predict this information, or where the model would begin to
deviate from the experimental data. The diffusion through the membrane was also
important because provided insight into the behavior of the system. Fick’s First Law of
Diffusion was used and described the flux of a chemical species through a membrane
[140]:

J cellulose = Dcellulose

(C

1( membrane final )

− C2 ( medium final ) )

hcellulose

Eqn. 24

where C1 [=] mol/m3 was the concentration in the membrane, C2 [=] mol/m3 was the
concentration in the beaker, h [=] m was the thickness of the membrane, D [=] m2/hr was
the diffusion coefficient of the dye, and J [=] mol/hr/m2 was the flux of the dye across the
membrane. The thickness of the cellulose membrane was 40 µm. The concentration in
the membrane was the total concentration in the membrane, not jus the free dye in the
membrane, because it was of interest to see what the maximum effect the concentration
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in the membrane had on the flux across the membrane. Theoretically, if all of the
niosomes were to break, the total concentration would affect the flux. In this case, only
the free dye was moving across the membrane. It was decided it would be better to
include the other dye in the niosomes than not to include them due to the fact that there
was still some uncertainty of the actual free dye at any given moment.

The niosomes

were constantly breaking and the dye was constantly diffusing across the membrane so it
was very hard to determine the actual free dye at any given moment. The diffusion
coefficient can be determined from the following equation [141]:

Dcellulose

⎛ Co ( membrane final @ t ) ⎞
Acellulose
o ⎟
* log⎜
=
⎜ Ct ( membrane final @ t ) ⎟
Δt
f
⎝
⎠

Eqn. 25

where A [=] m2 was the area of the membrane, t [=] hours was the time of the
experiment, C0 [=] mol/m3 was the initial concentration in the membrane, and Ct [=]
mol/m3 was the concentration in the membrane at time, t. The length of our membrane
was approximately 7 cm, which was equivalent to 0.07 m. The width of our membrane
was approximately equal to 25 mm, which was equivalent to 0.025 m. The area of the
membrane is therefore:

Acellulose = 2 * L * W = 0.07m * 0.025m = 0.0035m 2

Eqn. 26

The initial concentration in the membrane was constantly changing due to the breaking of
the niosomes in the membrane. Therefore, the quantity (Co/Ct) was determined by taking
the initial concentration from the previous time over the concentration at the current time.
Since the initial concentration was constantly changing, the previous concentration at
time, t, will be the new initial concentration at our new time. Several values were
100

obtained for the diffusion coefficient based on the concentration and time. An average of
the positive diffusion coefficients was taken to determine one diffusion coefficient for the
system. Negative values were obtained for the diffusion coefficient in some cases. This
meant that the initial concentration from the previous time was not greater than that final
concentration at time, t. This was very possible, as each different experiment ran at each
different time could result in a variation in the actual concentration present at each time.
More niosomes may have been breaking from one set-up to the next that could account
for this variation. The negative values were not used to calculate the average diffusion
coefficient.

The equation for the diffusion coefficient assumed that either the

concentration in the medium or the concentration in the membrane was kept relatively
small to determine the diffusion coefficient for the system. It was assumed that the
concentration in the medium was relatively small compared to the concentration in the
membrane (1E-2 vs. 1E-4 mol/m3). The concentration in the membrane, C1 and C0/Ct,
and the concentration in the medium, C2, were scaled up based on the volume of the
system. The concentration in the system was found by taking the intensity measurements
and dividing by the slope of the calibration curve. However, this was the concentration
based on the amount of sample was measured, either 10 µl for the membrane or 1 ml for
the medium. In order to scale this concentration up to account for the concentration in
the volumes we actually have, the total moles in the system was used that were found for
each. The total moles in the system were divided by the total volume in the system to
obtain the final concentration scaled up:
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C scaled up =

molestotal in system
Vtotal in system

Eqn. 27

The values for D and J were obtained. The diffusion coefficients and fluxes for 4mM,
5mM, 14mM, and 5mM/PBS are shown in Table 21.
Table 21. Flux and Diffusion Coefficient for Cellulose (4mM, 5mM, 14mM, and
5mM/PBS)

Time
[hr]

4mM

5mM

14mM

5mM/PBS

Diffusion Coefficient
m2/hr = 4.175E-5

Diffusion Coefficient
m2/hr = 2.143E-5

Diffusion Coefficient
m2/hr = 3.226E-5

Diffusion Coefficient
m2/hr = 1.849E-6

Flux [mol/hr/m2]

Flux [mol/hr/m2]

Flux [mol/hr/m2]

Flux [mol/hr/m2]

0.0577
0.0490
0.0451
0.0453
0.0361
-

0.0355
0.0338
0.0287
0.0296
0.0201
0.0241

0.133
0.110
0.106
0.098
0.093
0.085
0.072

3.730E-3
3.598E-3
3.359E-3
3.176E-3

0
3
6
9
12
24
72
144

It was also desired to obtain theoretical values of the concentration in the beaker based on
a known concentration in the membrane. A relationship between the concentration in the
membrane and flux was determined by plotting the experimental values for the
concentration in the membrane versus the experimental values just calculated for the flux.
The relationship was a linear relationship and an equation for the line was easily obtained
in the form of:

y = mx + b

Eqn. 28

where y = flux, m = slope, x = concentration in membrane, and b = y-intercept. A list of
concentrations in the membrane was generated and plugged into the above equation to
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obtain theoretical values for flux. The theoretical values for the concentration in the
medium was obtained by rearranging Equation 24 to solve for C2:

C2 ( medium final ) = C1( membrane final ) −

J cellulose * hcellulose
Dcellulose

Eqn. 29

The average diffusion coefficient was used in Equation 29 to obtain the theoretical values
of C2. A list of the theoretical values for flux and the concentration in the medium are
not presented here but will be commented on in Chapter 7.
It is also of interest to determine whether this model was able to predict the
concentration in the medium (and perhaps the flux) over a certain period of time. To do
this, Equation 25 was rearranged to solve for Ct:

Ct ( membrane final @ t f )

⎛C
⎞
⎜ o ( membrane final @ to ) ⎟
=⎜
⎟
Dcellulose *Δt
⎜
⎟
Acellulose
10
⎝
⎠

Eqn. 30

The original Co was the total concentration at t = 0 hrs. Subsequent concentrations, Ct,
were determined and acted as the new C0 in the following time interval. These were
predicted concentrations in the membrane. These predicted concentration were then
plugged into Equation 28 to solve for the predicted flux of the experiment at time, t. The
predicted concentration in the medium was determined using Equation. 29, plugging in
the predicted values for C1 and J. The predicted values are not presented here but will be
commented on in Chapter 7.
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6.1.6. Diffusion/Release from Niosome to Membrane

The diffusion/release of the dye from within the niosome to the membrane was
important to understand because it allowed for the determination of the behavior of the
niosomes throughout the experiment. The concentration that was being released and
available to diffuse through the membrane into the surroundings was determined. This
allowed for the determination of how the concentration being released was changing and
the relationship between the concentration in the niosomes and the concentration being
released. A model was developed to see how well that model predicted the experimental
data. The actual system consisted of a certain number of niosomes containing a specified
concentration of dye (i.e. 5 mM) in a specific total volume with a certain amount of
moles. Fick’s First Law of Diffusion modeled the diffusion of a species of higher
concentration into an area of lower concentration. However, in for this particular case,
the dye was not diffusing across the niosome membrane appreciably. The real dye
release mechanism was the breaking of the surfactant membrane layer. It was proposed
that the real system can be related to an analogous counterpart that included that total
surface area of all of the niosomes in the real system, the concentration of the real system,
and the membrane thickness of the real system.

The new model consisted of one

continuous “theoretical” membrane with a thickness of the niosome membrane, the total
surface area of all of the niosomes in the system, and was filled with dye at the
concentration inside of the niosomes. It was assumed that the theoretical membrane
thickness was equal to the thickness of the niosome because the dye would never have to
go through a thickness larger than that in the real system. The diffusion out of the
theoretical membrane would be the same as the rate of dye released due to the breaking
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niosomes in the real system. The concentration in the theoretical membrane was the
concentration in the real system that was still contained in the niosomes left in tact. The
concentration in the theoretical membrane changed the same as the concentration in the
real system changed due to dye being released from the breaking niosomes.
The missing pieces were obtained to solve Fick’s First Law of Diffusion. The
total volume of the niosomes in the membrane was determined so that the calculation of
the total concentration in the niosome membrane at any given time was determined.
(Please note that the niosome membrane now refers to the theoretical niosome
membrane). In order to do so, the total number of niosomes present in the niosome
membrane was calculated. For this, the dimensions of a single niosome were taken. The
diameter of Span 60 niosomes that were made for these experiment were determined by a
particle sizer/counter to be about 800 nm, or 8x10^-7 m. The radius was therefore r = d/2
= 4x10^-7 m. The thickness of the niosome membrane has rarely been cited in the
literature. The literature reports the thickness of a niosome membrane to be between 915 nm [35]. The maximum thickness was used to determine what the maximum possible
diffusion or release would be. The number of total moles that are within the niosome
membrane was known. It was obtained from subtracting the initial moles of free dry in
the cellulose membrane system from the total moles in the cellulose membrane system.
The difference between the two will provide the number of moles that were not free, but
were contained in the niosome membrane.

To determine the concentration in the

niosome membrane, the total volume of the niosomes in the niosome membrane were
determined.

The total volume [m3] of the niosomes required the total number of

niosomes in the system and the volume of one niosome:
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Vniosome membrane total = V1 niosome * nniosomes total

Eqn. 31

The volume of one niosome was determined by the following equation for the volume of
a sphere:

V sphere =

4 2 4
πr = π ( 4 E − 7 m) 2 = 2.682 E − 19 m 3
3
3

Eqn. 32

The total number of niosomes was determined from the following Equation 33:

nniosomes total =

moles niosome membrane total
Cniosome membrane

*

1
V1 niosome

Eqn. 33

The total moles in the niosome membrane at each time were known, and the initial
concentration in the niosome membrane was known based on the requested concentration
of dye encapsulated in the niosomes, i.e. 5 mM. The number of niosomes was then
calculated based on a known concentration of dye originally encapsulated in the
niosomes. The actual original concentration was determined by dividing the total number
of moles in the niosome membrane by the total volume of the niosome in the membrane
Equation 31. The total volume can be determined from Equation 31. The concentration
[mol/m3] within the niosome membrane at each time was determined from the following
equation:

C niosome membrane =

molestotal in niosome membrane
V total in niosome membrane
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Eqn. 34

The total moles represent the total number of moles in the niosomes membrane was
determined by the difference between total moles in the membrane and free moles in the
membrane. Fick’s Law was used:

J niosome = Dniosome

(C

1( niosome membrane )

− C 2 ( membrane initial ) )

hniosome

Eqn. 35

where C1 [=] mol/m3 was the concentration in the niosome membrane, C2 [=] mol/m3
was the concentration released into the cellulose membrane, h [=] m was the thickness of
the niosome membrane, D [=] m2/hr was the diffusion coefficient of the dye across the
niosome membrane, and J [=] mol/hr/m2 was the flux of the dye across the niosome
membrane. The diffusion coefficient was determined using:

Dniosome =

Aall niosomes
Δt

⎛ Co ( niosome membrane @ t ) ⎞
o ⎟
* log⎜
⎜ Ct ( niosome membrane @ t ) ⎟
f
⎝
⎠

Eqn. 36

where A [=] m2 was the total surface area of the all of the niosomes, t [=] hours was the
time of the experiment, C0 [=] mol/m3 was the initial concentration in the niosome
membrane, and Ct [=] mol/m3 was the concentration released into the cellulose membrane
at time, t. The total surface area of all of the niosomes was used because the system is
modeled with one theoretical membrane, but in the real system that is of interest was the
dye that was bursting from all of the niosomes so total surface area was used. The initial
concentration in the niosome membrane was constantly changing due to the breaking of
the niosomes.

Therefore, the quantity (Co/Ct) was determined by taking the initial

concentration from the previous time over the concentration at the current time. Since
the initial concentration was constantly changing, the previous concentration at time, t,
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was the new initial concentration at the new time. Several values for the diffusion
coefficient were obtained based on the concentration and time. The average of the
positive diffusion coefficients was taken to determine the one diffusion coefficient for the
system. Negative values of the diffusion coefficient were obtained in some cases. This
meant that the initial concentration from the previous time was not greater than that final
concentration at time, t. This was very possible as each different experiment run at each
different time could have resulted in a variation in the actual concentration present at
each time. More niosomes may have been breaking from one set-up to the next that
could account for this variation. The negative values were simply not used to calculate
our diffusion coefficient because a negative value did not fit the Fick’s Law model. The
equation for the diffusion coefficient assumed that either the concentration in the niosome
membrane or the concentration in the released into the cellulose membrane was kept
relatively small to determine the diffusion coefficient for the system. It was assumed that
the concentration released into the cellulose membrane was relatively small compared to
the concentration in the niosome membrane. The initial concentration in the cellulose
membrane, or the free dye in the membrane, had to be scaled up in a similar fashion as
was done for the final concentrations in the medium and membrane in Section 6.1.5. The
initial concentration was used as the concentration in the cellulose membrane in Fick’s
First Law. The concentration in the system was originally found by taking the intensity
measurements and dividing by the slope of the calibration curve. However, this was the
concentration based on the amount of sample was measured, 10 µl. In order to scale this
concentration up to account for the concentration in the actual volume, the total moles in
the system had to be found and the divided by the actual volume:
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molesmembrane initial system =

molesmembrane initial cell 1000μl
*
*Vmembrane total
10μl
1ml

Eqn. 37

The new concentration was determined by dividing the total number of moles by the
volume of the system:

Cscaled up =

molesmembrane initial system
Vmembrane total

Eqn. 38

The values for D and J were be obtained. The diffusion coefficients and fluxes for 4mM,
5mM, 14mM, and 5mM/PBS are shown in Table 22.
Table 22. Flux and Diffusion Coefficient of the Niosomes (4mM, 5mM, 14mM, and
5mM/PBS)

Time
[hr]
0
3
6
9
12
24
72
144

4mM

5mM

14mM

5mM/PBS

Diffusion Coefficient
m2/hr = 8.152E-24

Diffusion Coefficient
m2/hr = 1.815E-24

Diffusion Coefficient
m2/hr = 7.683E-24

Diffusion Coefficient
m2/hr = 1.803E-25

Flux
[mol/hr/m2]
2.149E-15
9.488E-16
8.309E-16
8.544E-16
6.671E-16
-

Flux
[mol/hr/m2]
0.023E-16
4.375E-16
3.820E-16
3.858E-16
2.101E-16
1.007E-16

Flux
[mol/hr/m2]
7.137E-15
2.541E-15
2.738E-15
2.615E-15
2.531E-15
2.657E-15
2.915E-15

Flux
[mol/hr/m2]
5.990E-17
5.395E-17
4.534E-17
3.091E-17

The theoretical values of the concentration released into the cellulose membrane wee
desired based on a known concentration in the niosome membrane. A relationship
between the concentration in the niosome membrane and flux was determined by plotting
the experimental values for the concentration in the niosome versus the experimental
values just calculated for the flux. The relationship was a linear relationship and an
equation for the line was easily be obtained from Equation 28 where y = flux, m = slope,
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x = concentration in niosome membrane, and b = y-intercept. A list of concentrations in
the niosome membrane was generated and plugged into the above equation to obtain
theoretical values for flux. The theoretical values for the concentration released into the
cellulose membrane was obtained by:

C2 ( membrane initial ) = C1( niosome membrane ) −

J niosome * hniosome
Dniosome

Eqn. 39

The average diffusion coefficient was used in Equation 37 to obtain the theoretical values
of C2. A list of the theoretical values for flux and the concentration in the medium are
not presented here but will be commented on in Chapter 7.
It is also of interest to determine whether this model was able to predict the
concentration released into the cellulose membrane (and perhaps the flux) over a certain
period of time. Equation 40 was used:

Ct ( niosome membrane @ t f )

⎛
⎜ Co ( niosome membrane @ to
=⎜
Dniosome *Δt
⎜
A
⎝ 10 total of all niosome

⎞
⎟
⎟
⎟
⎠

Eqn. 40

The original Co was the total concentration at t = 0 hrs. Subsequent concentrations, Ct,
were determined and acted as the new C0 in the following time interval. These are the
predicted concentrations in the niosome membrane. These predicted concentrations were
then be plugged into Equation 28 to solve for the predicted flux of the experiment at time,
t. The predicted concentration in the membrane was determined using Equation 37,
plugging in the predicted values for C1 and J. The predicted values are not presented here
but will be commented on in Chapter 7.
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6.1.7. Release Rate from Niosomes

Section 6.1.5 and 6.1.6 described calculations in which the total system was
separated into two separate systems to determine if Fick’s First Law of Diffusion
modeled and predicted the concentrations in the experiments well. However, the release
rate of the niosomes could be determined based on a total mole balance of the system.
The rate of change of the free dye in the membrane (not entrapped in the niosomes) was
determined from the rate of change in concentration over time:

∂Vβ C β
∂t

= S gen −

k
* ΔC
l

Eqn. 41

where β represented the free dye in the cellulose membrane, Sgen represented the
burst/leak rate of the dye from the niosomes, l represented thickness of the membrane, k
represented the diffusion coefficient, and ΔC represented the concentration difference
across the cellulose membrane. The collective third term in the equation represented the
diffusion across the cellulose membrane. The rate of change of dye in the medium was
determined based on the third term for the diffusion across the membrane:

∂Vγ Cγ
∂t

=

k
* ΔC
l

Eqn. 42

where γ represented the dye outside in the medium. The rate of change of dye entrapped
in the niosomes was represented by Sgen being the burst/leak rate:

∂Vα Cα
= S gen
∂t
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Eqn. 43

where α represented the dye entrapped in the niosomes. The combination of Equation 41,
Equation 42, and Equation 43 yielded the governing equation:

∂Vα Cα ∂Vβ Cβ ∂Vγ Cγ
+
+
=0
∂t
∂t
∂t

Eqn. 44

The rate of release of dye from the niosomes was therefore determined based on data that
was known for the free dye in the cellulose membrane (β) and the dye in the medium (γ).
The values are not presented here but will be commented on in Chapter 7.
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Chapter Seven
Discussion

The results from the experiments provided a myriad of information open for
discussion. The discussion section will comment on the behavior of the system as it
relates to the activity of the moles in the system, the concentration in the system, the flux,
and the release rate of the niosomes.

7.1.

Moles of Dye in the Membrane

The behavior of the free moles of dye in the membrane was of particular interest.
Figure 23 depicts the behavior of the free moles of dye in the membrane over time for
4mM, 5mM, and 14mM.
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Figure 23. Moles of Dye in Membrane vs. Time (4mM, 5mM, and 14mM)

The number of free moles dye in the membrane initially increased and reached a peak
very early on during the experiment. The moles then gradually decreased steadily over
the 72 hours time period. This indicated that initially an influx of water was entering
from the beaker across into the membrane. The water was creating an osmotic pressure
gradient and causes the niosomes to burst open, and released any encapsulated dye that
was within. This occured during the first ten hours of the experiment, in some cases
sooner than this time. The peak in moles indicated that the initial influx of water was
responsible for the large majority of the niosomes to burst. The moles in the membrane
eventually decreased as the bursting decreased due to the fact that there are less intact
niosomes present. The moles in the membrane decreased as the dye diffused from the
membrane into the water medium. The similar behavior of the moles in the membrane of
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all three experiments indicates that the concentration of the dye encapsulated in the
niosomes does not affect the overall behavior of the system.

The affect that the

concentration did have was the point at which each system has its major decrease in
moles. For 4mM and 5mM, there was a gradual decrease in moles after the first 12
hours, but a greater slope was observed from 24 hours to 72 hours. The dashed line for
4mM at 72 hours indicates an extrapolated point. The 14mM had a greater slope from 12
hours to 24 hours and a more constant decrease from 24 hours to 72 hours. Overall, the
behavior of the three systems is similar. The concentration was directly proportional to
the number of moles present; however, the behavior of the system was not dependent on
the concentration of the dye encapsulated. This means that one can encapsulate of a
variety of concentrations of drugs in our niosomes, and would see a peak during
approximately the first six hours when most of the bursting is occurring, followed by a
gradual decrease in drug in the membrane as the drug is released across the membrane
starting at about 12 hours. This data indicates the general behavior of the system as well
as supports the consistency of the behavior of the system with different concentrations.
The data indicates that a higher initial concentration of dye encapsulated in the niosomes
will ultimately result in a higher amount of moles present in the system, but the general
behavior is not affected by the concentration.
The free moles of dye in the membrane have also been compared for 5mM and
5mM/PBS. Figure 24 illustrates the behavior of the moles over time.
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Figure 24. Moles of Dye in Membrane vs. Time (5mM and 5mM/PBS)

It is important to note that these experiments were both carried out over 144 hours, but is
illustrated only for 72 hours. The moles in 5mM increased to a maximum at about 24
hours and the gradually decreased until about 72 hours. After 72 hours, the moles began
to increase again. The moles initially increased due to the breaking of the niosomes in
the membrane and then gradually decreased as moles of dye are diffusing across the
cellulose membrane. The important point to note here is the comparison of 5mM/PBS.
The moles in 5mM/PBS did not do a sudden increase at the beginning of the experiment,
but more of a gradual increase over time. This indicates that the free moles in the PBS
experiment did not increase and that PBS stabilized the breaking of the niosomes better
than the water. The niosomes were released gradually over time due to natural instability
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of the niosomes, but it clear that the water medium is the solution that creates instability
and causes the niosome to release dye.

7.2.

Moles of Dye in the Medium

The behavior of the moles in the medium was also of importance when analyzing
the system. The moles in the medium were an indication of how many moles actually
diffuse across the cellulose membrane.

This was important because it provide

information on the number of moles, or amount of drug that will cross the membrane and
be exposed to the surroundings. Figure 25 depicts the behavior of the moles in the
medium over time for 4mM, 5mM, and 14mM. The plot shows that the behavior of the
moles in the membrane over time is a clear increase in the number of moles over time.
The 4mM and 5mM both began with relatively similar concentrations of dye
encapsulated in the niosomes, and their behavior of moles in the medium followed a
similar pattern. There was a steady gradual increase in the number of moles that diffused
into the medium. The dashed line for the 4mM at 7 hours indicates an extrapolated point.
During the first six hours, the behavior of the moles in the medium was somewhat
variable; however, the overall behavior was a constant increase. This was in agreement
with the data of the moles in the membrane. Most of the niosomes broke during the first
ten hours at which time, as indicated in Figure 25, there was a steady increase in moles in
the medium as the dye from those broken niosomes diffused across the membrane.
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Figure 25. Moles of Dye in Medium vs. Time (4mM, 5mM, and 14mM)

The moles in the membrane began to steadily decrease at about 12 hours, while the moles
in the medium began to steadily increase at 12 hours.
The 14mM initially had a higher concentration of dye encapsulated in the
niosomes. The behavior of the moles in the medium was somewhat variable during the
first ten hours when the bursting of the niosomes reaction was dominant. This variability
could be due to the system trying to reach equilibrium while more niosomes are bursting,
keeping the concentration variable until about ten hours when the moles do not fluctuate
as dramatically. Once the majority of the niosomes have broken, there was a sharp
increase in the moles that diffused into the medium followed by a steady increase in the
moles after about 24 hours. After the majority of niosomes burst at approximately ten
hours, there was a sharp decrease in the moles in the membrane and a sharp increase in
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the number of moles in the medium. This was due to the system’s attempt to balance the
concentration gradient and reach equilibrium. After about 24 hours, the attainment of
equilibrium reached an approximate steady behavior. The overall behavior of the three
systems was similar and indicates the stability of the niosomes with varying
concentrations. The absolute values of moles in the system will of course be different,
and the intermediate path of the system may vary, but the behavior of the system was
more or less consistent regardless of the concentration of dye encapsulated.
The moles in the medium of 5mM and 5mM/PBS are shown in Figure 26.

Figure 26. Moles of Dye in Medium vs. Time (5mM and 5mM/PBS)

This plot clearly indicates that the water in 5mM forced the niosomes to burst and the
released dye was diffusing across the cellulose membrane. The steady increase in moles
in the medium indicates that dye from the membrane was diffusing out, and this can only
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happen if dye was begin released by the niosomes. In contrast, the moles in the medium
for 5mM/PBS indicates that the there was only a small rise in concentration at the
beginning. This was when the dye released naturally from the niosomes diffused across
the membrane. The fact that the moles in the medium did not increase over time
indicates that the there was minimal release of dye from the niosomes in the membrane.
This indicates that the medium of PBS did not induce the niosomes to break. It would
therefore be recommended that if one desired the niosomes to be forced to break, water
would be the preferred medium over PBS.

7.3.

Experimental Concentration of Dye vs. Time

7.3.1. Niosomes

The concentration in the niosome and the concentration released were plotted on
the same graph versus time for 4mM in Figure 27 from 0-24 hours. The concentration for
all plots in this section are viewed in the log scale so that a clear comparison can be
made.
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Figure 27. Experimental Concentration of Dye vs. Time Plotted on the Log-Scale
(Niosome-4mM)

The plot indicates that concentration in the niosomes was sharply decreasing in the first
three hours. This means that there was an initial burst and release of niosomes at the very
beginning of the experiment.

During this time, the concentration released into the

cellulose membrane was increasing as indicated by that initial release. There was a
period in which the concentration in the niosome membrane was practically constant
from three hours to nine hours. During this time of niosomes not constant concentration,
the concentration released decreased as that dye was diffusing across into the medium.
After about nine hours, the concentration in the niosomes decreased again. The release
rate of the niosomes was approximately constant over this time as indicated in Section
7.7.

This decrease in concentration could be explained by several reasons.

The

concentration may have begun to decrease as more stable niosomes began to break over
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this time. The larger, more unstable niosomes burst first, and the smaller, more stable
niosomes broke after time. The decrease in concentration could be misleading since there
are two separate sub-systems that have been modeled. The decrease could really just be a
constant concentration but did not recognize the other diffusion that was occurring in the
cellulose membrane sub-system. The decrease in concentration could also possibly be
due to a concentration differential between the concentration in the niosome and the
concentration outside of the niosomes. When this differential is too low, the niosomes
may not burst until the differential increases and promotes bursting again.

The

concentration released continued to decrease as the dye continued to diffuse into the
water medium.
The concentration in the niosome and the concentration released were plotted on
the same graph versus time for 5mM in Figure 28 from 0-144 hours.
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Figure 28. Experimental Concentration of Dye vs. Time Plotted on the Log-Scale
(Niosome-5mM)

This plot indicates that the concentration in the niosomes decreased over the entire time
range. There was an initial decrease in concentration as water initially bursts the vesicles,
at which time the concentration released into the cellulose membrane increased as the dye
moves into the membrane. Like with the 4mM, there was a time interval in which the
niosomes appeared to not be releasing dye as indicated by a steady line from 12 hours to
24 hours. The concentration then decreased. This again can be explained by several
reasons. The concentration may begin to decrease as more stable niosomes begin to
break over this time. The larger, more unstable niosomes burst first, and the smaller,
more stable niosomes will broke after time. The decrease in concentration could be
misleading since the system was separated into two sub-systems. The decrease could
really just be a constant concentration but did not recognize the other diffusion that was
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occurring in the cellulose membrane sub-system. Another possible reason could be the
initial burst of dye created an environment outside of the niosomes that was too
concentrated, and the niosomes did not want to release any more dye until this
concentration decreased.

It is noted again that the concentration released into the

membrane greatly decreases over this time of no release from the niosomes as the dye is
diffusing across the cellulose membrane to try to decrease that concentration the
niosomes detect outside. It is also important to note that this time of niosomes not
breaking occurs later in the time interval and for a longer amount of time that of the
lower concentration, 4mM. This could be due to the fact that more stable niosomes will
burst later during the experiment at the higher concentration. This difference could also
be due to the fact that the higher concentration release provided a higher concentration
outside of the niosomes and the rate through the membrane was approximately the same,
so it took a little longer to diffuse that higher concentration in the water medium. The
niosomes then began to release dye constantly from 24 hours to 72 hours, while the
concentration released in the membrane gradually increased over this time as the dye was
released and was now steadily diffusing into the medium. At 72 hours, the slope of rate
of the niosomes releasing dye changed; it became slower. The majority of niosomes
broke at the beginning of the experiment, but at 74 hours there were even less niosomes
to break and so the rate of breaking may have decreased again. This shift in niosomes
that broke occurred at 72 hours and remained constant thereafter. The concentration
released into the membrane followed the behavior of the niosome released change by also
increasing at a slower rate.
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The concentration in the niosome and the concentration released are plotted on the
same graph versus time for 14 mM in Figure 29 from 0-72 hours.

Figure 29. Experimental Concentration of Dye vs. Time Plotted on the Log-Scale
(Niosome-14mM)

This plot indicates a similar behavior as the 4mM and 5mM. There was an initial release
of dye from the niosomes at the beginning of the experiment, as shown by a decrease in
concentration in the niosomes and an increase in concentration in released dye to the
membrane.

This was again followed by a period of constant concentration in the

niosomes which was explained by the several possibilities discussed earlier. The higher
concentration, again, resulted in a longer time of this constant behavior from 12-72 hours.
This again, could be due to the fact that for higher concentrations, the niosomes mostly
all broke at the beginning and that the smaller, more stable niosomes took even longer to
break. It may be that there were no more niosomes to break. It could also mean that it
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took longer for the concentration differential to reach a point again that promotes
breaking. The concentration outside still decreased over time as it was continuously
release into the membrane. Concentration was the driving force behind the breaking and
release of the niosomes in this experiment as well, and indicates the independence of
original concentration encapsulated on this phenomena.
The concentration in the niosome and the concentration released are plotted on the
same graph versus time for 5mM/PBS in Figure 30 from 0-144 hours:

Figure 30. Experimental Concentration of Dye vs. Time Plotted on the Log-Scale
(Niosome-5mM/PBS)

This plot indicates that PBS was not inducing a release of dye from the niosomes
as indicated by the constant decrease in niosome concentration and the constant increase
in released concentration. There was no indication of an initial burst of niosomes or any
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significant change in how the dye was released from them. In the experiment, the only
dye that was being released from the niosomes was the dye released over time due to
natural instabilities in the niosomes structure. This supports the theory that osmotic
interactions of water caused the niosomes to break, while PBS did not have an effect on
the release.
7.3.2. Diffusion from Membrane to Medium

The concentration in the membrane and the concentration in the medium are
plotted for 4mM in Figure 31.

Figure 31. Experimental Concentration of Dye vs. Time Plotted on the Log-Scale
(Membrane-4mM)

The data indicates that as the niosomes burst, the dye from them was being released into
the tubing, but then diffused out across the cellulose membrane. The concentration in the
127

membrane decreased as the moles of dye diffused out into the beaker and as water
entered into the membrane and created a dilution of the existing dye in the membrane.
The dye in the medium was increasing gradually as the dye diffused out into it. There
was a significant increase in the concentration in the medium at the beginning of the
experiment as the concentration gradient was much higher at the beginning. Over time,
the concentration gradient deceased and both sides changed in concentration steadily. It
was important to observe that the concentration in the membrane and the concentration in
the medium complimented each other throughout the experiment. This meant that as one
concentration increased, the other one decreased. It is important to note that 4mM was
only run for a maximum of 24 hours. Extrapolation was not performed for this plot
because these plots are strictly experimental measurements only. Predicted values were
determined and are discussed later.
The concentration in the membrane and the concentration in the medium were
plotted for 5mM in Figure 32.
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Figure 32. Experimental Concentration of Dye vs. Time Plotted on the Log-Scale
(Membrane-5mM)

It is clear that 5mM behaves similarly to 4mM during the first 72 hours. The niosomes
are initially breaking, releasing dye, and diffusing across the membrane.

The

concentration in the membrane decreased as the niosomes diffused out and the water
diffused inward, while the concentration in the medium increased as the dye diffused out
into it. There was a significant increase in the concentration in the medium at the
beginning of the experiment as the concentration gradient was much higher at the
beginning. Over time, the concentration gradient deceased and both sides changed in
concentration steadily. After 72 hours, the concentration in the membrane increased,
while the concentration in the medium decreased. It was here that the moles of free dye
in the tubing (5.693x10-8 moles) was very close to the moles of dye in the beaker
(5.221x10-8 moles). Although the data indicates that the moles in the tubing was slightly
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greater than the moles in the medium, based on the difference between these values at
different times, it was safe to say that moles in the beaker could very well be greater at
t=72 hours than the moles in the membrane. If the system sees more moles in the
medium than in the membrane, the equilibrium shifted and the moles in the medium
began to flow back into the membrane to create equilibrium. After a certain amount of
time, the moles in the membrane will again be greater than the moles in the beaker and
expected diffusion will occur. The reason for the shift in equilibrium at this time in the
experiment may be due to the fact that the niosomes after 72 hours decreased their rate of
release, as indicated in Figure 28. The free dye in the membrane was not increasing as
steadily as it was in the past, so the moles in the medium at this point would be greater
than in the membrane. Once the system adjusts to the new slightly slower release of dye
from the niosomes, the system will again recognize that the concentration in the
membrane was higher than in the medium and the dye will again diffuse into the medium
until equilibrium is reached.
The concentration in the membrane and the concentration in the medium are
plotted for 14mM in Figure 33.
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Figure 33. Experimental Concentration of Dye vs. Time Plotted on the Log-Scale
(Membrane-14mM)

This plot indicates the same behavior as the 4mM and 5mM over 72 hours.

The

concentration in the membrane was slowly decreasing over time while the concentration
in the water medium was slowly increasing over time as the dye diffuses across the
cellulose membrane. The dye was diffusing steadily from 12-72 hours as this is the time
that the niosomes were not breaking and waiting for the concentration in the membrane to
decrease. There was a significant increase in the concentration in the medium at the
beginning of the experiment as the concentration gradient was much higher at the
beginning. Over time, the concentration gradient deceased and both sides changed in
concentration steadily.
The concentration in the membrane and the concentration in the medium were
plotted for 5mM/PBS in Figure 34.
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Figure 34. Experimental Concentration of Dye vs. Time Plotted on the Log-Scale
(Membrane-5mM/PBS)

This plot indicates that the concentration in the membrane decreased slightly as the dye
from the niosomes was slowly released over time. There was no dip in concentration
anywhere, which indicates that there was no sudden increase in dye from the niosomes.
The concentration almost appeared constant, or at least was changing very slightly over
the long time interval. This supports the fact that PBS was not inducing breaking of the
niosomes. The concentration in the PBS medium appeared to be decreasing over time;
however, it was suspected that the sensitivity at such low concentration resulted in
fluctuations in the measurements. It was believed that the concentration in the medium
increased where there concentration in the membrane decreased and that there was error
in the measurements of the experimental data.
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7.4.

Experimental vs. Theoretical Concentration of Dye

7.4.1. Membrane

The theoretical concentration in the membrane and medium were calculated using
Fick’s First Law of Diffusion as a model. The experimental concentrations were plotted
as stray data points on the same plot. The results for the 4mM, 5mM, and 14mM were
plotted together in Figure 35.

Figure 35. Experimental vs. Theoretical Concentration of Dye Using Fick's First
Law of Diffusion (4mM, 5mM, and 14mM)

The plot indicates that the theoretical model of Fick’s First Law predicted the
experimental data well. The r2 value for 4mM was 0.9338, for 5mM was 0.934, and for
14mM was 0.8675. The average diffusion coefficients were 4.17x10-5 m2/hr, 2.14x10-5
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m2/hr, and 3.23x10-5 m2/hr, respectively for the three experiments. An average diffusion
coefficient was found to be 2.98x10-5 ±7.46x10-6 m2/hr. Figure 35 is plotted using the
individual diffusion coefficients; a plot using the average diffusion coefficient yields a
similar behavior. Fick’s First Law of Diffusion predicted that as the concentration in the
membrane decreased, the concentration in the medium increased in a constant manner.
This was in agreement with the experimental data. The data indicates that the change in
concentration in the membrane and the change in concentration in the medium would
always be the same regardless of the initial concentration.
Figure 36 shows the theoretical and experimental concentrations for the
5mM/PBS.

Figure 36. Experimental vs. Theoretical Concentration for 5mM of Dye in PBS
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This plot indicates that the theoretical model was not able to fit the experimental data
well due to the inaccurate measurements in data that suggest a decrease in the
concentration in the medium. It was most likely that the data points were not indicative
of what was actually occurring, and so the theoretical model appeared to be a bad fit. If
the data points were measured with better confidence, it is predicted that the
concentration in the medium would increase, and the theoretical model would fit it well.
7.4.2. Niosome

The experimental and theoretical concentration in the niosome and concentration
released into the membrane for 4mM were plotted in Figure 37.

Figure 37. Experimental and Theoretical Concentration of Dye Using Fick's First
Law of Diffusion (4mM)
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This plot indicates that the theoretical model fits this plot moderately well. The error in
the theoretical model was that is did not recognize the point in the experiment when the
niosomes were not breaking. The concentration in the niosome was constant at that point
and Fick’s Law did not account for that delay predicts constant release. The two data
points that were practically on top of one another indicated the point at which the
niosomes were not breaking and was where the theoretical model failed. Figure 38
illustrates the experimental and theoretical concentrations for 5mM.

Figure 38. Experimental and Theoretical Concentration of Dye Using Fick's First
Law of Diffusion (5mM)

The conclusion is the same. The theoretical model predicted moderately well, but did not
predict the constant concentration in the niosome when they were not breaking. The two
data points with the same concentration in niosome were the point at which the niosome
was not releasing dye. Fick’s First Law did not model this occurrence well. The
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behavior was repeated when the experimental and theoretical concentrations were plotted
for the 14mM in Figure 39.

Figure 39. Experimental and Theoretical Concentration of Dye Using Fick's First
Law of Diffusion (14mM)

The pattern was repeated in this plot that showed that Fick’s model did not model well
for the system when the niosomes were not breaking. It was very obvious in this plot
because very early on in the 14mM experiment did the niosomes stop breaking. For the
remainder of the experiment, they mostly did not want to break (or had mostly broken) as
indicated by the practically constant concentration in the niosome of the experimental
points.

Figure 40 illustrates the experimental and theoretical concentration for the

5mM/PBS experiment:
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y = -0.0022x +
0.0276
R2 = 0.9608

Figure 40. Experimental and Theoretical Concentration of Dye Using Fick's First
Law of Diffusion (5mM/PBS)

The plot indicates that Fick’s First Law of Diffusion did model this system very well.
The r2 value for the experimental data was 0.9608. The system was modeled well
because the release of dye from the niosome was slow and gradual. Since the PBS was
not causing the niosomes to burst, there was not a sudden change in concentration
followed by a period of niosomes not bursting. In this experiment, dye was gradually
being released from the niosome over an extended amount of time, and it was indicated
that Fick’s Law was a good model for this system.
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7.5.

Experimental Flux

7.5.1. Membrane

Fick’s First Law of Diffusion was not able to model the concentration in the
medium well. This was due to the dynamics of the system that were not accounted for in
the equation. Fick’s Law can be used with the experimental data to obtain the actual flux
at each time. The fluxes for 4mM, 5mM, and 14mM are shown in Figure 41.

Figure 41. Flux vs. Time in Membrane (4mM, 5mM, and 14mM)

The plot indicates that for all experiments the flux decreased as the concentration
gradient between the membrane and medium deceased.

At the beginning of the

experiment the niosomes first released a large amount of their dye. The concentration in
the membrane was high in the beginning of the experiment. As time went on, the dye
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diffused across the cellulose membrane the concentration between the two sides “evened”
out. Although there were some niosomes still bursting over time, the concentration
gradient was more even now and continued to decrease as dye went into the medium and
increased the concentration there.

Figure 42 illustrates the flux for the 5mM and

5mM/PBS.

Figure 42. Flux vs. Time in Membrane (5mmM and 5mM/PBS)

The plot indicates that the flux of 5mM/PBS was practically constant which indicates that
the niosomes were not dramatically breaking and releasing dye, causing a major
concentration gradient. The flux was influenced by the concentration gradient and was
constant/steady if there was not a major change in concentration. The PBS was not
breaking the niosomes and therefore, the concentration gradient in the membrane and
medium was always steady. The 5mM behaved as previously described: decreased as
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the concentration gradient decreased and increased as the concentration in the membrane
increased at 72 hours due to the shift in niosomes breaking and the momentarily higher
number of moles in the medium than membrane when the system was readjusting to this
change.
7.5.2. Niosome

The fluxes of dye from the niosome are shown in Figure 43 for 4mM, 5mM, and
14mM.

Figure 43. Flux vs. Time in Niosome (4mM, 5mM, and 14mM)

Figure 43 indicates the flux was initially very high as the concentration gradient was very
high. The flux decreased over time as the concentration gradient deceased. The steep
slope at the beginning indicates that this was the time when the niosomes initially burst
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due to their contact with water. The flux remained constant because the niosomes were
either not breaking or were releasing dye very slowly at a constant rate. The flux of 5mM
and 5mM/PBS is shown in Figure 44.

Figure 44. Flux vs. Time in Niosome (5mM and 5mM/PBS)

This plot indicates that the release from the niosomes in the 5mM/PBS was relatively
constant. There were not significant changes in the flux which meant that the dye from
the niosomes was only being release over time and was not induced by the PBS. The flux
was relatively constant because the difference inside and outside of the niosome
(gradient) remained the same throughout the experiment. The low flux meant that there
was not dye being released. The flux for the 5mM dye started high and decrease over
time as the concentration gradient decreased. There was no indication that the niosomes
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were bursting or had the need to burst. The flux was gradual and was only being released
constantly as the stability of the niosomes weakened over time.

7.6.

Predicted Concentration of Dye Over Time

7.6.1. Membrane

The concentration in the membrane and the concentration in the medium were predicted
for different times. All the plots were graphed on a log-scale to illustrate better the
behavior of the system. Figure 45 shows the results for 4mM.

Figure 45. Predicted Concentration of Dye Over Time for the Membrane System
Plotted on the Log-Scale (4mM)
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Figure 45 indicates that the concentrations were predicted well at the beginning of the
experiment.

It was clear that the predicted times agreed at the beginning of the

experiment with the experimental data. Figure 46 illustrates the same plot for the 5mM.

Figure 46. Predicted Concentration of Dye Over Time for the Membrane System
Plotted on the Log-Scale (5mM)

Figure 46 indicates Fick’s First Law predicted the concentration well at the beginning of
the experiment. After 72 hours, there was the shift in breaking niosomes and therefore a
shift in the normal behavior of the concentration in the membrane. The predicted plot
wanted to keep decreasing, even after 72 hours, but experimental data indicated that it did
not decrease there but rather increased and then continued to decrease until it reached
equilibrium with the medium. The niosomes were breaking at a lower rate and thus a less
concentration change occurred as indicated by the more steady concentration data in the
membrane as opposed to the sharp decline in the predicted line. There was perhaps a
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different model that could predict this behavior; however, this is for the future. Figure 47
illustrates the predicted concentration in the membrane and concentration in the medium
for the 14mM.

Figure 47. Predicted Concentration of Dye Over Time for the Membrane System
Plotted on the Log-Scale (14mM)

Figure 47 indicates that Fick’s First Law predicted the concentration moderately well at
the beginning of the experiment for the 14mM. The data points at the beginning were
slightly different than the predicted values (error bars were plotted to illustrate the
discrepancy) due to the difference in the average diffusion coefficient used to calculate
the predicted values and the actual diffusion coefficients used to calculate the
experimental values. The experimental diffusion coefficients varied slightly from one
time-run to the next. The predicted concentrations used an average diffusion coefficient
in their calculations which explains for the slight variation.
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The 4mM and 5mM

diffusion coefficient per experiment must have been relatively close to the average
diffusion coefficient that went into calculating the predicted values because those
experimental points were very close to the predicted points.

The theoretical

concentrations deviated at 72 hours, which indicates that the concentration in the
membrane was not decreasing as fast as the predicted values were. The concentration
decreased only slightly because it was through this time interval that the niosomes were
breaking at a very slow rate. Future work may be spent on finding a model that would
predict this behavior. Figure 48 illustrates the predicted concentration in the membrane
and concentration in the medium for 5mM/PBS.

Figure 48. Predicted Concentration of Dye Over Time for the Membrane System
Plotted on the Log-Scale (5mM/PBS)

Figure 48 indicates that the predicted concentration fitted well to the experimental
concentrations over the entire time interval. This would be correct because the PBS
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system was somewhat stable, meaning that there were no bursting niosomes or changes in
bursting niosomes. The concentration in the membrane steadily deceased over time,
while the concentration in the medium steadily increased over time as the dye from the
niosome was slowly being released over time. The plot supports the fact that PBS did not
affect the release of the niosome and a simple system such as this can be predicted well
with Fick’s First Law for many different times.
7.6.2. Niosome

The predicted concentration of dye in the niosome and concentration of dye
released into the membrane were plotted for 4mM in Figure 49.

Figure 49. Predicted Concentration Over Time for the Niosome System Plotted on
the Log-Scale (4mM)
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The plot indicates that the concentrations can be predicted moderately well at the
beginning of the experiment. Error points were plotted and indicated the error in the
average diffusion coefficient that was used to calculate the predicted concentration and
the actual diffusion coefficient obtained for each time-run experiment. The model did not
indicate the point at which the niosomes were not breaking as seen as the relatively
constant behavior of the experimental data points. Figure 50 illustrates the predicted
concentrations for 5mM.

Figure 50. Predicted Concentration of Dye Over Time for the Niosome System
Plotted on the Log-Scale (5mM)

The plot shows a moderately well fit at the beginning of the experiment, but did not
predict well the point at which the niosomes are not breaking. That point was indicated
by the data points that were constant over a specific period of time. The rate of breaking
was constant and slower and so the concentration in the niosomes slowly decreased over
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time; Fick’s Law predicted a steadier, steeper decline. A better model is needed that
describes this behavior. Error in the diffusion coefficient was indicated by the error data
points. Figure 51 illustrates the same graph for 14mM.

Figure 51. Predicted Concentration of Dye Over Time for the Niosome System
Plotted on the Log-Scale (14mM)

The plot follows the same pattern as the 4mM and 5mM. The predicted concentrations
did not fit the experimental data well where the niosomes were not breaking. The
predicted curve assumed that the release had a relatively constant behavior, but in reality,
it did not.

Error points were plotted indicating the error in the average diffusion

coefficient used to calculate the predicted line and the actual diffusion coefficient used to
calculate the experimental concentrations at each time-run experiment. Again, a better
model is needed to predict the dynamics of the system. Figure 52 illustrates the same
plot for the 5mM/PBS.
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Figure 52. Predicted Concentration of Dye Over Time for the Niosome System
Plotted on the Log-Scale (5mM/PBS)

The plot indicates that the predicted model fits the experimental data very well. Fick’s
First Law worked well with the PBS system because dye was being slowly diffused from
the niosome over a long period of time, but there was no sudden release of dye that
caused the system to behavior differently. The PBS system resulted in a stable system in
which the niosomes were not breaking, but dye was slowly being released through natural
causes.
7.7.

Release Rate of Dye from Niosomes

The release rate of dye from the niosomes was important to study because it
provided information on how the dye will behave over time. The maximum release rate
was determined and adjusted to control for the desired time and amount of released drug.
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The dye was present in one of three areas: entrapped in the niosomes, free dye in the
cellulose membrane, or free dye in the medium. The release rate of the niosomes was
determined from a total mole balance on the system in which the free dye in the cellulose
membrane and the free dye in the medium was calculated based on measured data.
Figure 53 illustrates the release rate of dye from the niosomes for the 4mM, 5mM, and
14mM.

Figure 53. Release Rate of Dye from Niosomes (4mM, 5mM, and 14mM)

The release rate was plotted on a scale that was normalized by the initial concentration.
The data for the 4mM, 5mM, and 14mM had been normalized so that a clear comparison
could be made between the three experiments. The plot indicates that the 4mM and
14mM data points are extremely close to one another. The 5mM also followed a similar
behavior, although a measurement at three hours was not made for this experiment. The
151

data indicates that most of the dye from the niosomes was released during the first ten
hours of the experiment, in all three cases. It appeared that after the initial release of the
dye from the niosomes, there was little or no change in the rate of release from the
niosomes. It is important to note, however, that experimental measurements indicate that
there are still niosomes that are in tact at the end of the experiment that have not released
dye. This was based on the fact that there is a change in concentration before and after
the TX-100 detergent was added, which indicated that there was still a small amount of
dye in the niosomes that were not broken by the influence of the osmotic pressure
difference in the niosomes and water. The size of the niosomes may play an important
role in the study of this system. Larger niosomes were less stable than smaller niosomes
and were the majority of niosomes that initially burst. The smaller, more stable niosomes
may “survive” the length of the experiment and were why we saw a change in
concentration even at the end. The data after the initial release of dye was still somewhat
unclear. The experimental data dipped into the negative and back into the positive for
some points. Error bars were plotted and an average behavior trend was illustrated. The
concentration data indicates that the rate of release should be zero for a period of time
and then will be constant. Even though the rate of release was small, it was constant and
would cause a change in the concentration as presented earlier in the concentration data.
The release rate for the 5mM in water solutions and 5mM/PBS is plotted in Figure
54.
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Figure 54. Release Rate of Dye vs. Time (5mM and 5mM/PBS)

It is indicated that the release from the niosomes in the PBS was very much lower than
the release of the dye from the niosomes in the water solutions. This means that the
water induced breaking of the niosomes, while the PBS stabilized the niosomes. The
niosomes will break in a similar aqueous environment, while in a buffer solution will
remain moderately stable.
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Chapter Eight
Conclusion

There are several conclusions that can be made based on the experiments
performed and the results obtained in this thesis:
1. It is clear that the PBS retain the stability of the niosomes.
2. The water does break the niosomes very fast initially.
3. The system was able to be characterized.
4. Diffusion data is all that is needed to characterize the system.
5. The dye from the membrane diffuses into the medium.
6. A hydrogel membrane that behaves similar to PBS is needed to stabilize the
release of dye from the niosomes.
The experiments performed in this thesis provide important information on the behavior
of the system. In these experiments, the behavior of dye, encapsulated in non-ionic
surfactant vesicles, through a cellulose membrane into a beaker of medium was studied.
The initial concentration of the dye encapsulated in the niosomes was varied from 4mM,
5mM, and 14mM. The concentration was kept constant and the medium in which it was
diffused into was changed. These experiments led to several conclusions about the
system. It is very clear that PBS retains the stability of the niosomes. The PBS does not
have any affect on the breaking of the niosomes as seen by the constant flux,
concentration in the niosome did not significantly decrease over time, and the moles or
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concentration in the medium did not increase significantly over time. The water does
break the niosomes very fast initially as indicated by the high increase in moles at the
beginning of the experiment, the initial decrease in concentration in niosomes, and the
significant increase in concentration in the medium. The release rate of the niosomes
also indicates that most of the dye entrapped in the niosomes is released during the first
ten hours of the experiment. Information on what is exactly happening in the system
based on the data is known. Water initially rushes in and breaks the niosomes. The
concentration in the niosomes decrease, the moles in the membrane increase but the
concentration will decrease as dye leaves the membrane and water comes in, and the
concentration and moles in the medium increase. There is a point in the experiment in
which the concentration in the niosome is constant and then slowly decreases. This can
be explained by several reasons: the data does not give a true perspective of what is
occurring due to the independent systems taken, the smaller, more stable niosomes will
break later in time, or the concentration differential in the niosome and membrane may
promote release. This point of no release is delayed in time and occurs for a longer
period of time from the 4mM, 5mM, and 14mM. This could be due to the stability of
smaller niosomes in higher concentrations or the fact that higher concentrations take
longer for the concentration differential to decrease enough for breaking to occur again.
The dye from the membrane is still diffusing into the medium during this point of
niosomes not breaking because the concentration in the medium is still increasing.
Fick’s First Law of Diffusion predicts well for the membrane system because
even though there are changes in the rate of the niosomes breaking, the diffusion between
the membrane and medium is not effected by that. Although there are fluctuations in the
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gradient due to the niosomes, the system remains relatively simple and will follow Fick’s
First Law. Fick’s First Law does not predict the niosome diffusion/breaking well because
it does not account for the point of no niosomes breaking/release of dye. A different
model will be needed. The model therefore does not predict time well for the niosome
system because it does not recognize this shift.
The objectives to the project changed as more information was made available
and different failures resulted in other successes. The first objective of this project was to
study the behavior of the release of the 5(6)-carboxyfluorescein from the niosomes. This
was successfully accomplished by running the experiments and calculating moles,
concentration, and flux to study the behavior of the system as a whole. The system was
separated into two sub-systems and the behavior of each was obtained. A diffusion
model was able to predict the behavior of one of the sub-systems and found that another
model was needed to fit the other sub-system. The concentration in the niosomes was
changed and the type of medium in which the niosomes were diffused was changed in
order to observe the behavior of the system under these different conditions. The second
objective of this project was to run the system with in vitro experiments. This goal was
also accomplished. It is desired to run the entire system in vitro in the future with the
hydrogel, but this project just focused on the niosomes alone. In these experiments, as
many parameters as possible were set to in vitro conditions such as the membrane, the
dye size, the dye concentration, and the pH of the medium. The future will allow for
more accurately run the experiment in vitro by setting other parameters such as
temperature. The third objective of this project was to look ahead to the future of the
system. This goal was accomplished by investigating the different types of hydrogels and
156

proposing a hydrogel that has the potential to be compatible with the system. The future
of this project was determined as we found out more information about the niosome
system and were able to apply this information to the future design of the smartpackaging system. For example, the high concentrations in the niosomes will result in
high concentrations outside of the niosomes for a longer period of time. It would perhaps
be suggested to use a smaller concentration so that there is not all of this released dye
floating around for several hours that could possible cause exposure and toxicity to other
organs. Water should also be present to induce the bursting of the niosomes; otherwise, it
will take a very long time for the dye to be released naturally. Suggested future work has
also be included and is presented in Chapter Nine.
The smart-packing system has the potential to be a novel approach to drug
delivery. The idea to have two control mechanisms is very attractive when over-exposure
and increased toxicity in the body is a major problem. This project has begun the process
for designing this system, and the results can provide us with valuable information as to
the behavior of our vesicles. The future of the project will lie in incorporating the second
control mechanism and optimizing the properties of both. The investigation of one of the
fundamental components has been performed and there is optimism about the success of
the system.
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Chapter Nine
Future Work

The information presented in this thesis can provide valuable insight into the
direction that this project will go towards.

The study of the release rate of 5(6)-

carboxyfluorescein dye from niosomes in a dialysis membrane allows the understanding
of the behavior of a drug in a stand alone niosome. However, this is just the beginning of
our “smart-packaging” system. The future of the system is still yet to be seen, and there
are still pieces of the puzzle that must be scrutinized and incorporated into the whole.
This chapter focuses on the future of the project by presenting the anticipated studies to
be conducted. Several future goals of the project will be presented, as well as tasks that
must be performed to achieve those goals. Specific attention will be spent on describing
the Surface Force Apparatus, as this will be a significant component in future studies.
Attention will also be devoted to the Attenuated Total Reflection Fourier Transform
Infrared technique. It is important to note that by the nature of research there is a good
chance that these anticipated studies may be altered or a new course may be needed. As
far as a PhD project is concerned, it is the hope that many of these analyses will be
conducted; however, they should not be strictly interpreted at this time.
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9.1.

Future Goals of Project

9.1.1. Future Goal One

The first goal for the future work of this project is to continue to study the
characteristics of the behavior of the dye within the niosomes alone. Although this may
seem tedious and redundant, it is important to understand this behavior as conditions in
the system change. The system was studied as the concentration of the dye within the
niosomes was changed, as well as with changing the bulk solution to PBS; however, it is
important to study the behavior of the release rate of the dye from the niosomes as
environmental factors changes as well. The incorporation of the niosomes into the
hydrogel network is eagerly anticipated, but it is desired to build a strong foundation on
the understanding of the niosome component before a second component is added to our
system. Currently, the proposed system studied in this thesis is moderately simple
consisting of just the niosomes; however, when the system will be built upon by adding
more complications, it will be advantageous to have a solid understanding of the
niosomes system alone.
9.1.2. Future Goal Two

The second goal for the future work of this project is to develop the hydrogel
membrane that will be used in the system. This is crucial for the future of this project
because the hydrogel composes the second element of the “smart-packaging” system.
The hydrogel must be developed in such a way that its properties compliment the
behavior of the niosome component but do not greatly interfere with it.

The two

components must be designed in such a way that neither one stands alone, but either one
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does not prohibit the unique characteristics of the other. The hydrogel is very important
in the system because it is the second control mechanism for drug delivery. A hydrogel
system will be designed that will be biocompatible, biodegradable, pH and temperature
sensitive, effective in controlling the release of the drug, and be alterable for
optimization. Once the hydrogel of choice is decided upon, the next goal in conjunction
with the hydrogel is to incorporate the niosomes into the network. It is desired to confirm
that the two units “fit” together, meaning that based on the theoretical and experimental
information obtained for the two units alone, they are actually compatible with one
another and will release the drug in a controlled manner. It is important to show that
these two components actually work together and their properties can be furthered
studied.
9.1.3. Future Goal Three

The achievement of incorporating the niosome and hydrogel together to form a
drug release system (see Goal Two) will lead to the third goal. The third goal for the
future of this project is to now study the interactions between the niosome and hydrogel
in detail.

Now that the system is established and know that it is going to work, the

interaction between the two will be studied. This information is important because it will
allow for the understanding of what properties govern the behavior of the system, what
properties may be altered to improve the system, and what the optimal operating
conditions of the system are. It is important to understand the structure of the hydrogel
network and its mechanical properties such as its swelling behavior, the stiffness, the
cross-link density (if applicable), the thickness, its elasticity, and its dynamic response.
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In conjunction with the mentioned properties, the normal forces between the hydrogel
may also be of interest. The preparation conditions of the niosomes and hydrogels, the
chemical composition of the niosomes and hydrogels, and the tribological behavior of the
system could also be studied. These are just to name a few properties that could be
chosen to be studied. The studies for the future work of this project are not limited to just
these parameters and will not necessarily include an analysis on all of the ones mentioned
above. Other properties that could be of interest include the adhesion behavior of the
hydrogel and the niosomes within the hydrogel. Chemical reactions occurring in the
system may also be of interest for the future work. It is desired to show that for a
particular hydrogel with a particular crosslink density and embedded with a specific
composite niosome, this is what will happen.
9.1.4. Future Goal Four

The fourth goal for the future work of this project is to design a drug delivery
system that will be able to be tested in vivo in an animal rabbit model. It is desired to
optimize the control of the release of the system so that the actual outcomes in a
biological model can be studies. The long-range goal of the project is to design a system
that may be used in human beings for the treatment of brain cancer. The goal to test the
system in an animal rabbit model first so that it will give a better understanding of how
the in vitro studies actually compare to the system’s behavior in vivo experiments. This
goal is optimistically lofty, considering all of the work that needs to be done to get to this
point, so it is safe to say that this goal will remain in the far distant future but will remain
important in the back of our minds as to remind us what we are striving to attain.
161

9.2.

Future Tasks for Project

9.2.1. Future Task One

The first task for the future of this project will attempt to address the first future
goal of the project: to continue to study the characteristics of the niosomes alone. It is
desired to observe the behavior of the release of the dye from the niosomes as
environmental conditions are changed such as temperature and pH. The goal would be to
ultimately inject the system into the human brain, and by altering sensitive conditions
such as the temperature and pH, obtain a better idea of how the system will behavior once
implanted in our target system. Understanding how the niosomes and dye behave under
certain temperatures and pHs will allow for the determination of what conditions will
work and what conditions will not work. The determination of how extreme temperature
or pH changes drastically alter the release of the dye, the integrity of the niosomes, and
the optimal operating range is feasible. Base concentrations can be changed to work with
and hold that concentration constant while we change the other conditions. It is also
possible to change the temperature and pH for different concentrations if needed.
9.2.2. Future Task Two

The second task for the future of this project will attempt to address the second
future goal of the project: to develop a hydrogel system that will be used in the system.
A literature search has already been conducted on several different types of polymer
hydrogels that are available. The hydrogel system that is believed to have the most
potential for use in biomedical applications was presented in this thesis: the chitosan/βglycerophosphate hydrogel. The first observation would be the under workings of this
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hydrogel in the lab such as method of synthesis, the ease of synthesis, the temperature
and pH sensitivity, and other properties that will help for the determination if this is, in
fact, an acceptable hydrogel to use. Once that is determined, the incorporation of the
niosomes into the hydrogel will be done. Based on the literature, the chitosan hydrogel
will begin to gel via physical alterations and the niosomes will be entrapped within the
three dimensional network. Since a crosslinking agent is not needed for the formation of
the chitosan hydrogel, the crosslinking density is something that may not be easily
controlled for. The chitosan will form its own cross-linking density based on ionic
crosslinking (see Section 2.2.4). However, other properties of the hydrogel can be
studied such as the effect the chitosan deacetylation has on the release rate of the drug
and the composition of the chitosan and β-glycerophosphate. These are all suggestions
that may be desired to observe. However, it is important to note that they may not be
necessary or required to study based on the literature and other concrete data that has
been previously generated.
9.2.3. Future Task Three

The third task for the future of this project will attempt to address the third goal of
this project: to study the interactions between the niosomes and the hydrogel. The main
approach that will be taken will make use of the Surface Force Apparatus, or commonly
called the SFA. The SFA is an instrument that is used to measure the forces between two
surfaces and can provide information on the surface interactions, structural information
about the two samples, and other interfacial properties [142]. A detailed description of
the SFA will be provided in Section 9.3. There are three main properties that influence
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the performance of the components of a hydrogel: their mechanical strength, their surface
friction, and their response kinetics [143]. The SFA will allow for application and
measurement of the shear and normal forces between two surfaces as a function of the
distance of separation between the two to the ±1 Å. The normal and shear forces will
depend strongly on the structure of the hydrogel.

The SFA will allow for the

determination of the force profiles of the empty and niosome-embedded hydrogels. It
will help to determine how the normal and adhesive forces are affected by solvent
conditions, crosslink density (if applicable), thickness, and the ionic or hydrophobic
constituents in the hydrogel. It can provide information on the friction coefficients and
dissipation effects between the hydrogel and niosome and how they will affect the
properties of the network. The SFA can also provide insight into effect that surface
chemistry, roughness, and confinement have on the swelling behavior of the gel. The
effect of changing certain ambient conditions such as temperature, pH, and solvent ionic
strength have on the response of the hydrogel can also be observed [143].
The SFA will allow for the determination of the structure of our hydrogel network
and how it behaves under certain conditions. It will allow for the determination of the
surface forces of the hydrogel and compare that with the surface forces of the hydrogel
and the niosomes. The cushioning and stiffness of our hydrogel can be determined and
compared with the cushioning and stiffness of the hydrogel with the niosomes. The SFA
will use a friction device and a bimorph slider. An optical multiple beam interferometry
(MBI) technique will provide data on the physical characteristics of the hydrogel network
such as their thickness, their elastic modulus, and their normal and lateral interaction
forces. The amount of force required to compress the hydrogel can be determined which
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will provide insight into the swelling and elasticity of the system. Recovery times of the
hydrogels can be found which will provide information on the dynamic response of the
system. The SFA is also a good tool for measuring adhesion forces. The SFA will be a
powerful tool in the study of our “smart-packaging” system. The information obtained
from the SFA will allow us to determine the behavior of the system and thus, dictate the
alteration and design of the final system.

An Attenuated Total Reflection Fourier

Transform Infrared (ATR-FTIR) technique will also be used to determine the surface
reactions of our system. It will allow us to obtain a surface analysis between the empty
hydrogel and the hydrogel with the niosomes. The ATR-FTIR data will depend on how
much force was used to compress the system and will be based off of the SFA
measurements. The SFA can determine the surface forces of the system, and the ATRFTIR can provide information on the surface interactions of the sample. For each surface
force associated with each altered system, a different set of surface interactions will be
obtained. Both techniques will be discussed in Section 9.3.
9.2.4. Future Task Four

The fourth task for the future of this project will attempt to address the fourth goal
of this project: to test the smart-packaging system in vivo experiments using animal rabbit
models. This will be achieved by taking all of the data collected, and presenting the
optimal system to the surgeons at the Moffitt Cancer Center and Research Institute. It is
interest to test the system in animal models so the effects it will have once exposed to
actual physiological conditions can be determined. It is impossible to mimic the entire
environment of the body in vitro, so in vivo experiments will allow for the determination
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of how well the system will stand up in the “real world.” The survival times of the
animal models and any adverse side effects they may experience will be observed. Based
on the information obtained from the in vivo experiments, the system will be able to be
fine tuned so that it could possibly one day be used in actual human beings.

9.3.

SFA and ATR-FTIR

The surface force apparatus, as discussed earlier, is an instrument that can be used to
study the surface interactions of polymer systems, biological systems, and molecular
systems in various environments. The simplest way to measure the adhesion between
two solid surfaces is to measure the deflection of a spring that one surface is suspended
from and observe the force required to separate the two bodies [144]. In short, the SFA
will measure the attractive and repulsive intermolecular forces between two layers
supported on a solid (or soft) substrate as a function of surface separation. The surfaces
can be brought into contact with one another or can be separated by using highly
controlled micrometers and piezoelectric displacement transducers. The deflection of a
spring supporting one of the surfaces is used to determine the forces between them. A
detailed description of the SFA will be presented here.
Direct force measurements are often very straightforward, however, the problem
with surface force measurements comes when there are very weak forces at very small
surface separations that must be controlled and measured within 0.1 nm [142]. The first
direct measurements were attractive van der Waals forces made by Derjaguin and
coworkers [145, 146] between a convex lens and a flat glass surface vacuum [142]. The
simplest way to measure the force as a function of surface separation is to move the base
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of a force-measuring spring by a set amount, δDo, and observing if the spring deflects by
δDs, if there is indeed a force between the two surfaces [144]. The surface separation will
change by δD, and the three distance changes can be related by the following equation
[144]:

δDs = δDo − δD

Eqn. 45

and the force differential between the initial and final separation can be represented by
[144]:

δF = K sδDs

Eqn. 46

where Ks is the stiffness of the force-measuring spring (spring constant).

The

measurement of the forces between two flat surfaces is extremely hard due to the rigorous
effort to perfectly align the surfaces for reliable angstrom measurements [144]. It is
much easier to measure the forces between two curved surfaces such as two spheres, a
sphere and a flat surface, or two crossed cylinders [144]. The formula for the general
force law is:

F ( D) = −

∂W ( D )
∂D

Eqn. 47

The Derjaguin approximation is used to relate the force, F(D), measured between two
curved surfaces with the energy per unit area, E(D), between two flat surfaces at a
distance, D, apart from each other [144]. The surface forces depend on the geometry of
the surfaces in contact, and for two spheres in contact with one another, the Derjaguin
approximation would take the following form [142]:
⎛ RR ⎞
F ( D ) = 2π ⎜⎜ 1 2 ⎟⎟ E ( D )
⎝ R1 + R2 ⎠
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Eqn. 48

where R1 and R2 are the radii of the spheres in contact with one another. For the case of
two cylinders, the Derjaguin approximation becomes [142]:
F ( D) =

2π R1 R2 W ( D)
sin(θ )

Eqn. 49

where D is much smaller than R1 or R2. For the case where R1 = R2, the formula for the
Derjaguin approximation would be as follows [144]:
E ( D) =

F ( D)
2πr

Eqn. 50

The Derjaguin approximation can be applied to ay force law including attractive,
repulsive, or oscillatory forces [142].

The only requirement is that the range of

interaction, or separation between the two surfaces, is much less that the radii of the
spheres [142]. The Derjaguin approximation can be used to derive the interaction energy
for two planar surfaces if the easier to measure forces between two curved surfaces are
known.
The SFA was developed to measure the interactions between dynamic and static
surfaces in vapors or liquids with precision down to the Angstrom level [142]. Previous
techniques developed by Tabor and Winterton (1969) [147] and Israelachvili and Tabor
(1972, 1973) [148, 149] measured the van der Waals forces between smooth mica in air
or in a vacuum. The techniques were in agreement with the Lifshitz theory of van der
Waals forces as small as 1.5 nm separations [142]. The techniques were improved upon
to include measurements in liquids. The SFA that we will be using is one such apparatus.
The SFA can directly measure the force between two surfaces in controlled vapor
or immersed in liquids [150, 151]. Figure 55 illustrates a basic SFA.
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Figure 55. Basic SFA (Mark 4 Model)

The distance resolution is about 0.1 nm and has a force sensitivity of about 10-8 N.
Israelachvili (1992) [142] provides a detail description of how the SFA works. The SFA
consists of two curved mica surfaces that are molecularly smooth with a radius of about 1
cm and a thickness of about 2 μm. The mica sheets are transparent, which allow a beam
of light to pass through the mica and onto the sample.

The interaction forces are

measured by force-measuring springs. The mica surfaces are oriented in a cross cylinder
manner, which would be similar to contacting a sphere and a flat surface or contacting
two spheres. An optical technique is used to measure the distance of separation between
the two surfaces from microns to molecular levels. The optical technique uses multiple
beam interference fringes, or Fringes of Equal Chromatic Order (FECO) to determine this
distance. The mica surfaces are coated with a layer of pure silver and glued silver side
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down onto the silica discs. A light is passed up through the two surfaces, where the beam
is forced onto the beam of a grating spectrometer. Figure 56 illustrates this procedure.

Figure 56. The Path of Light Through the Mica Surfaces and to the Spectrograph in
an SFA

The FECO fringes can provide information on the distance between the two surfaces
(usually to better than 0.1 nm), the exact shape of the two surfaces, and the refractive
index of the material between them based on the fringes positions and shapes. The
shapes of the fringes also allow for the determination of the radii of the surfaces and any
deformation in the surfaces that may occur due to the interaction [144]. The multiple
beam interference fringes allow for the surface separation to be measured to ± 1 Ǻ [144].
A three-stage mechanism is used to control the distance between the surfaces. A coarse
control can control for positioning within 1 μm, a medium control can position distances
within 1 nm, and a piezoelectric crystal tube can position distances to 0.1 nm by
vertically expanding or contracting by about 1 nm per volt applied axially across its
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cylindrical wall [142].

The force measurements can be made by the expansion or

contraction of the piezoelectric crystal by a specific quantity. The measurements are then
able to be taken optically by observing how much the two surfaces have moved. The
force difference between the initial and final positions can be determined by multiplying
the difference in how much the two surfaces have moved by the stiffness of the spring. A
full force law can be determined for any distance and for both repulsive and attractive
forces. A single-cantilever or a double-cantilever fixed-stiffness spring can be used as
the force measuring spring, and the stiffness of the spring can be adjusted and changed
during the experiment by a factor of 1000 [142].
The force between any other curved surfaces can be scaled by R once the force as
a function of D is determined for the two surfaces. The Derjaguin approximation can be
used to relate the interfacial (or adhesion) energy E per unit area between two flat
surfaces. The SFA has been used to measure the basic interactions, between surfaces in
both aqueous and nonaqueous solutions, and includes van der Waals forces, electrostatic
double-layer forces, oscillatory forces, repulsive hydration forces, attractive hydrophobic
forces, steric interactions in polymer systems, capillary forces, and adhesion forces [142].
The use of the SFA has been extended to measurements of dynamic interactions and
time-dependent effects [152-154], shear and friction forces [155], and the fusion of lipid
bilayers [156].
The SFA has been used to study the forces between a mica surfaces coated with
lipid bilayers [157]. The forces between two bilayers absorbed onto the mica surface
have shown to correlate well to larger vesicles without undulation forces [157]. The SFA
can be used to measure the magnitude, range, and origin of the forces that control for
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vesicle stability [157]. For our system, the SFA will allow us to determine how much
force is needed to compress the hydrogel and what the strength of the hydrogel is. We
will be able to compare the forces in the hydrogel alone with the forces that are present
when the niosomes are added to the network. A certain force will be associated with
each manipulated hydrogel (i.e. crosslinking density if applicable, composition of
components, amount of components, etc.), and we will be able to determine which
system will work best for our drug delivery. We will also be able to gain other important
information from the SFA about our system and ultimately be able to gather this
knowledge and present an optimized system to Moffitt.
We are also interested in using ATR-FTIR techniques to study the surface
interactions of our sample. Other analytical surface techniques that have previously been
used include X-ray and UV photoelectron spectroscopy, electron energy loss
spectroscopy, Auger electron spectroscopy, low-energy electron diffraction, field
emission microscopy, field ionization spectroscopy, scanning tunneling spectroscopy,
and atomic force microscopy [158]. The problem with these techniques is that they
require the use of an ultra-high vacuum which can change the surface characteristics of
the sample [158].

Other techniques have show similar setbacks.

ATR-FTIR is a

technique that has shown to not alter the surface interactions of the sample to be studied
[159]. ATR-FTIR is a specific form of a Fourier Transform technique. A FT technique
applies the principles of infrared spectroscopy (IR) which is to pass an infrared light
through a sample and observing what part of the light is absorbed by the sample at a
particular frequency [159].

FTIR has improved most aspects of traditional IR
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spectroscopy through the use of an interferometer.

Figure 57 illustrates a typical

Michelson interferometer [158].

Figure 57. Schematic of a Michelson Interferometer

The interferometer consists of two mirrors that are perpendicular to one another: one
mirror that is able to move and one mirror that is stationary. The mirrors are bisected by
a beam splitting mirror, or a semi-reflecting mirror. The beam splitter splits the beam
from the source. One beam is sent to the fixed mirror where it is reflected and sent back
to the beam splitter. The two beams interfere on recombination. The beam is controlled
by the movable mirror and leaves the interferometer to go to the detector (interferogram).
The detector receives a signal from the intensity of the combined beams as a function of
the position of the mirror. The intensity is converted into a spectrum by a Fourier
transform function. There are several steps that must be taken in order to obtain an IR
transmission spectrum. A interferogram must be obtained for both a beam with and
without a sample and be translated from interferograms into spectra of the source with
and without sample absorption [159].
173

ATR-FTIR has been successful in measuring the diffusion in polymers [160]
based on its robust, noninvasive, in situ technique. ATR-FTIR is a reliable method for
short-time data that is easy to use and comparably inexpensive against other techniques
such as NMR spectroscopy. ATR-FTIR is unique from other techniques in that it is able
to distinguish between chemical species by providing molecular-molecular differences
between solute and polymer through the absorption of light at different wavelengths
[160].

Shifts in the IR spectrum can also allow the determination of chemical

interactions between the solute and the polymer. ATR involves the passing of a beam of
light through a dense material where a rarer medium reflects the light at the interface
[160]. The attenuated terms derives from the process of the rare medium absorbing light
at the interface [160]. For ATR, a special ATR crystal is placed in optical contact with a
sample [159]. The ATR crystal has a high refractive index. The spectrometer uses
mirrors to focus an IR beam onto the beveled (inclined) edge of ATR element where it is
reflected and absorbed through the crystal and another set of mirrors sends the signal to a
detector. ATR is based on that fact that some radiation will penetrate some of the sample
(evanescent wave) even though most internal reflection occurs at the sample-crystal
interface. The distance of penetration depends on the wavelength of the incident light
[158]. The sample will interact with the evanescent wave and the sample will absorb
radiation [159]. This radiation resembles the transmission spectrum for the sample. The
interface is where chemical bonds from the existence of solute molecules in the polymer
(or change in the polymer due to interactions with solute molecules) are measured
through the evanescent wave [160]. Figure 58 illustrates the simple ATR process [158]
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while Figure 59 illustrates a FTIR spectrometer and ATR attachment for the
measurement of diffusion in polymers [159].

Figure 58. Scheme of an ATR

Figure 59. Schematic of the FTIR Spectrometer and ATR Attachment for the
Measurement of Diffusion in a Polymer

The ATR spectrum will depend on several factors including the angle of the incoming
radiation, the wavelength of the radiation, and the sample and ATR crystal’s refractive
indexes [159]. ATR is a fast technique to obtain IR spectrum that will not harm the
sample There is usually no sample preparation required; however, attention must be
spent on the sample to ATR crystal optical contact. The FTIR-ATR can be used for a
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variety of pharmaceutical applications including characterizing the structure and
properties of biological systems, studying noninvasive drug release, measuring drug
release from polymer systems, investigating drug penetration into artificial and biological
membranes, and characterizing interactions between drugs and synthetic macromolecules
[159].

9.3.

Closing Remarks on Future Work

The future work of this project is very promising for the development and
investigation of the “smart-packaging” system. The scope of this project has just begun
to uncover the properties of the system, and the future work of the project will begin to
build on this information. The future will also see the incorporation of the hydrogel
polymer, the essential second component to the system. The interactions, compatibility,
and behavior of the system will be explored with such tools as the Surface Force
Apparatus and the Attenuated Total Reflection Fourier Transform Infrared technique.
The SFA will allow us to compare the surface forces of our empty hydrogel with that of
our hydrogel with the niosomes embedded within its network.

The surface force

information will allow us to determine properties such as elasticity, swelling behavior,
dynamic response times, and other properties that will ultimately go into the final design
of the system. This information is important because it will allow us to know the exact
the behavior the system under certain conditions so that we may present our data to
Moffitt for future investigations.

The ATR-FTIR will also be a powerful tool in

obtaining information about the surface interactions of the system. We will be able to
determine the surface characteristics when a particular force is applied to the system. We
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will be able to determine any changes in the surface interactions between the niosome
and hydrogel while maintaining the integrity of the system. The information obtained
from these studies will allow use to present our data to surgeons at the Moffitt Research
and Cancer Institute. We will be able to tell them how the system will behave and
hopefully run the system in vivo to determine the behavior in an actual biological model.
The ultimate goal of the system is to be administered intracavitary to brain tumor patients
to increase survival time and decrease adverse side effects. The information and analyses
proposed in this thesis and future work section all aspire towards the understanding and
improvement of our system to attain this goal.
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Appendix A. Approximate Sizes of Quanta

Table 23. Various Types of Radiation and Corresponding Sizes of Quanta

[134]
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Appendix B. Density (g/ml) Calculation for 4mM, 5mM, 14mM, and 5mM/PBS

Table 24. Density Calculations (g/ml)

Time
3
6
9
12
24
72
144

4mM

5mM

14mM

5mM/PBS

Beaker
g/ml

Membrane
g/ml

Beaker
g/ml

Membrane
g/ml

Beaker
g/ml

Membrane
g/ml

Beaker
g/ml

Membrane
g/ml

0.980
0.981
0.981
0.987
0.986
-

1.02
1.00
1.03
1.03
1.05
-

0.980
0.990
0.986
0.980
0.990

1.04
1.01
1.015
1.015
1.065

0.985
0.986
0.986
0.986
0.987
0.986
-

1.055
1.015
1.02
1.015
1.02
1.005

0.993
0.993
0.990

1.023
1.025
1.03
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Appendix C. Intensity Measurements

Table 25. Intensity Measurements for 4mM
Time
(hr)
0
3
6
9
24

Beaker (before TX)
1 ml from beaker
0
92.60
99.55
142.9
236.9

0
93.68
99.20
142.2
235.5

0
92.39
98.16
141.0
236.3

Beaker (after TX)
1 ml sample + 10 µl
TX
0
94.87
91.80
141.2
225.1

0
93.58
91.71
139.8
224.5

0
93.54
91.55
141.1
223.8

Membrane (before)
990 PBS + 10 µl
sample
132.9
194.9
184.4
183.4
136.7

130.0
194.8
184.3
183.5
164.3

130.4
196.9
184.7
183.1
163.0

Membrane (before)
990 PBS + 10 µl
sample + 10 µl TX
337.5
286.0
264.4
265.2
238.6

333.5
282.5
261.2
264.9
236.1

335.1
288.1
264.2
263.0
236.1

Table 26. Intensity Measurements for 5mM
Time
(hr)
0
6
12
24
72
144

Beaker (before TX)
1 ml from beaker
0
43.17
67.54
85.15
187.4
189.1

0
43.91
67.18
85.96
187.5
191.8

0
43.80
68.40
85.66
187.1
190.6

Beaker (after TX)
1 ml sample + 10 µl
TX
0
62.29
96.77
109.6
206.1
190.9

0
63.17
95.99
110.2
205.8
198.1

0
63.08
97.01
108.9
208.7
191.9

Membrane (before)
990 PBS + 10 µl
sample
79.56
88.26
90.76
95.67
77.69
115.0

78.36
86.76
89.61
95.46
77.55
115.5

80.82
87.63
90.04
94.25
77.90
115.4

Membrane (before)
990 PBS + 10 µl
sample + 10 µl TX
219.8
189.5
182.5
190.2
127.8
125.7

221.2
189.2
179.1
183.5
126.1
151.9

222.3
192.2
177.9
182.2
127.1
151.8

Table 27. Intensity Measurements for 14mM
Time
(hr)
0
3
6
9
12
24
72

Beaker (before TX)
1 ml from beaker
0
124.5
123.1
209.3
155.1
182.0
225.8

0
124.7
123.9
208.3
157.9
183.2
223.2

0
121.8
120.9
208.6
156.4
183.5
226.2

Beaker (after TX)
1 ml sample + 10 µl
TX
0
121.9
116.0
215.5
146.8
179.9
212.0

0
121.9
114.7
216.7
148.7
182.1
213.4

0
122.3
117.1
217.8
147.4
182.5
213.1

Membrane (before)
990 PBS + 10 µl
sample
74.72
117.7
110.0
100.2
94.81
81.37
58.3

76.23
118.0
109.3
100.1
94.90
82.31
58.0

77.62
119.0
111.2
101.0
94.98
82.40
59.6

Membrane (before)
990 PBS + 10 µl
sample + 10 µl TX
191.9
159.7
155.8
144.6
137.1
125.2
106.0

194.5
160.4
154.8
143.0
135.7
125.1
105.3

195.1
159.5
154.6
142.4
136.5
126.7
108.5

It is important to note that these are the intensity reading for 14mM; however, the actual
intensity readings are not indicative of the absolute intensity as it is related to 4mM,
5mM, and 5mM/PBS. The samples in 14mM required dilution due to their high
concentrations. The sample concentrations for the membrane were cut in half twice. For
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t=0, 3, 6, 9, and 12 hours, the sample concentrations for the beaker were cut in half. For
t=24 and 72 hours, the sample concentrations for the beaker were cut in half twice.

Table 28. Intensity Measurements for 5mM/PBS
Time
(hr)
0
24
72
144

Beaker (before TX)
1 ml from beaker
0
42.54
38.84
41.46

0
42.53
39.13
40.89

0
42.73
37.67
41.03

Beaker (after TX)
1 ml sample + 10 µl
TX
0
44.18
37.15
39.15

0
44.49
37.18
38.43

0
44.31
36.69
38.64

198

Membrane (before)
990 PBS + 10 µl
sample
113.2
120.1
125.5
149.8

114 9
120.2
125.1
150.7

113.6
120.7
125.9
149.1

Membrane (before)
990 PBS + 10 µl
sample + 10 µl TX
269.0
259.7
243.7
2323.2

269.4
259.0
241.3
227.6

269.6
262.0
243.8
229.0

Appendix D. Material Safety Data Sheets

D.1. Phosphate Buffer Saline MSDS

MATERIAL SAFETY DATA SHEET
Date Printed: 02/15/2006
Date Updated: 01/27/2006
Version 1.5
Section 1 - Product and Company Information
Product Name PHOSPHATE BUFFERED SALINE, PH 7.4,
TRU- MEASURE CHEMICAL
Product Number P3813
Brand SIGMA
Company Sigma-Aldrich
Street Address 3050 Spruce Street
City, State, Zip, Country SAINT LOUIS MO 63103 US
Technical Phone: 800-325-5832
Emergency Phone: 314-776-6555
Fax: 800-325-5052
Section 2 - Composition/Information on Ingredient
Substance Name CAS # SARA 313
PHOSPHATE BUFFERED SALINE (SOLID) None No
Ingredient Name CAS # Percent SARA 313
SODIUM CHLORIDE 7647-14-5 83.8 No
DI-SODIUM HYDROGEN PHOSPHATE ANHYDROUS 7558-79-4 12 No
POTASSIUM PHOSPHATE, MONOBASIC 7778-77-0 2 No
POTASSIUM CHLORIDE 7447-40-7 2 No
Section 3 - Hazards Identification
EMERGENCY OVERVIEW
Caution: Avoid contact and inhalation. Target organ(s): Heart.
HMIS RATING
HEALTH: 1*
FLAMMABILITY: 0
REACTIVITY: 0
NFPA RATING
HEALTH: 1
FLAMMABILITY: 0
REACTIVITY: 0
*additional chronic hazards present.
For additional information on toxicity, please refer to Section 11.
Section 4 - First Aid Measures
ORAL EXPOSURE
If swallowed, wash out mouth with water provided person is
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conscious. Call a physician.
INHALATION EXPOSURE
If inhaled, remove to fresh air. If breathing becomes difficult,
call a physician.
DERMAL EXPOSURE
In case of contact, immediately wash skin with soap and copious
amounts of water.
EYE EXPOSURE
In case of contact with eyes, flush with copious amounts of
water for at least 15 minutes. Assure adequate flushing by
separating the eyelids with fingers. Call a physician.
Section 5 - Fire Fighting Measures
FLASH POINT
N/A
AUTOIGNITION TEMP
N/A
FLAMMABILITY
N/A
EXTINGUISHING MEDIA
Suitable: Noncombustible. Use extinguishing media appropriate to
surrounding fire conditions.
FIREFIGHTING
Protective Equipment: Wear self-contained breathing apparatus
and protective clothing to prevent contact with skin and eyes.
Specific Hazard(s): Emits toxic fumes under fire conditions.
Section 6 - Accidental Release Measures
PROCEDURE(S) OF PERSONAL PRECAUTION(S)
Exercise appropriate precautions to minimize direct contact with
skin or eyes and prevent inhalation of dust.
METHODS FOR CLEANING UP
Sweep up, place in a bag and hold for waste disposal. Avoid
raising dust. Ventilate area and wash spill site after material
pickup is complete.
Section 7 - Handling and Storage
HANDLING
User Exposure: Avoid inhalation. Avoid contact with eyes, skin,
and clothing. Avoid prolonged or repeated exposure.
STORAGE
Suitable: Keep tightly closed.
Section 8 - Exposure Controls / PPE
ENGINEERING CONTROLS
Safety shower and eye bath. Mechanical exhaust required.
PERSONAL PROTECTIVE EQUIPMENT
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Respiratory: Use respirators and components tested and approved under appropriate
government standards such as NIOSH (US) or CEN
(EU). Respiratory protection is not required. Where protection
from nuisance levels of dusts are desired, use type N95 (US) or
type P1 (EN 143) dust masks.
Hand: Protective gloves.
SIGMA - P3813 www.sigma-aldrich.com Page 2
Eye: Chemical safety goggles.
GENERAL HYGIENE MEASURES
Wash thoroughly after handling.
Section 9 - Physical/Chemical Properties
Appearance Physical State: Solid
Property Value At Temperature or Pressure
pH N/A
BP/BP Range N/A
MP/MP Range N/A
Freezing Point N/A
Vapor Pressure N/A
Vapor Density N/A
Saturated Vapor Conc. N/A
SG/Density N/A
Bulk Density N/A
Odor Threshold N/A
Volatile% N/A
VOC Content N/A
Water Content N/A
Solvent Content N/A
Evaporation Rate N/A
Viscosity N/A
Surface Tension N/A
Partition Coefficient N/A
Decomposition Temp. N/A
Flash Point N/A
Explosion Limits N/A
Flammability N/A
Autoignition Temp N/A
Refractive Index N/A
Optical Rotation N/A
Miscellaneous Data N/A
Solubility N/A
N/A = not available
Section 10 - Stability and Reactivity
STABILITY
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Stable: Stable.
Materials to Avoid: Strong oxidizing agents, Strong acids.
HAZARDOUS DECOMPOSITION PRODUCTS
Hazardous Decomposition Products: Nature of decomposition products
not known.
HAZARDOUS POLYMERIZATION
Hazardous Polymerization: Will not occur
Section 11 - Toxicological Information
ROUTE OF EXPOSURE
Skin Contact: May cause skin irritation.
Skin Absorption: May be harmful if absorbed through the skin.
Eye Contact: May cause eye irritation.
Inhalation: Material may be irritating to mucous membranes and
upper respiratory tract. May be harmful if inhaled.
SIGMA - P3813 www.sigma-aldrich.com Page 3
Ingestion: May be harmful if swallowed.
TARGET ORGAN(S) OR SYSTEM(S)
Heart.
SIGNS AND SYMPTOMS OF EXPOSURE
Ingestion of large amounts causes vomiting and diarrhea.
Dehydration and congestion may occur in internal organs.
Hypertonic salt solutions can produce inflammatory reactions in
the gastrointestinal tract.
Section 12 - Ecological Information
No data available.
Section 13 - Disposal Considerations
APPROPRIATE METHOD OF DISPOSAL OF SUBSTANCE OR PREPARATION
Contact a licensed professional waste disposal service to dispose
of this material. Dissolve or mix the material with a combustible
solvent and burn in a chemical incinerator equipped with an
afterburner and scrubber. Observe all federal, state, and local
environmental regulations.
Section 14 - Transport Information
DOT
Proper Shipping Name: None
Non-Hazardous for Transport: This substance is
considered to be non-hazardous for transport.
IATA
Non-Hazardous for Air Transport: Non-hazardous for air
transport.
Section 15 - Regulatory Information
EU ADDITIONAL CLASSIFICATION
S: 22-24/25
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Safety Statements: Do not breathe dust. Avoid contact with skin
and eyes.
US CLASSIFICATION AND LABEL TEXT
US Statements: Caution: Avoid contact and inhalation. Target
organ(s): Heart.
UNITED STATES REGULATORY INFORMATION
SARA LISTED: No
CANADA REGULATORY INFORMATION
WHMIS Classification: This product has been classified in
accordance with the hazard criteria of the CPR, and the MSDS
contains all the information required by the CPR.
DSL: No
NDSL: No
Section 16 - Other Information
DISCLAIMER
For R&D use only. Not for drug, household or other uses.
WARRANTY
SIGMA - P3813 www.sigma-aldrich.com Page 4
The above information is believed to be correct but does not
purport to be all inclusive and shall be used only as a guide. The
information in this document is based on the present state of our
knowledge and is applicable to the product with regard to
appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Sigma-Aldrich Inc.,
shall not be held liable for any damage resulting from handling or
from contact with the above product. See reverse side of invoice
or packing slip for additional terms and conditions of sale.
Copyright 2006 Sigma-Aldrich Co. License granted to make unlimited
paper copies for internal use only.
SIGMA - P3813 www.sigma-aldrich.com Page 5
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D.2. Triton-X 100

Material Safety Data Sheet
Triton X-100
ACC# 24515
Section 1 - Chemical Product and Company Identification
MSDS Name: Triton X-100
Catalog Numbers: BP151-100, BP151-500, NC9269787, XXBP15120LI
Synonyms: Polyethylene glycol p-tert-octylphenyl ether; Poly(oxy-1,2-ethanediyl),
alpha-[4-(1,1,3,3-tetramethylbutyl)phenyl]-omega-hydroxy-; Poly(oxyethylene) p-tertoctylphenyl ether.
Company Identification:
Fisher Scientific
1 Reagent Lane
Fair Lawn, NJ 07410
For information, call: 201-796-7100
Emergency Number: 201-796-7100
For CHEMTREC assistance, call: 800-424-9300
For International CHEMTREC assistance, call: 703-527-3887
Section 2 - Composition, Information on Ingredients

CAS#
9002-93-1

Chemical Name
Ethoxylated p-tert-octylphenol

Percent
100

EINECS/ELINCS
unlisted

Section 3 - Hazards Identification

EMERGENCY OVERVIEW
Appearance: clear to slightly hazy liquid.
Warning! May cause allergic skin reaction. May cause eye and skin irritation. May cause
respiratory and digestive tract irritation. May be harmful if swallowed. The toxicological
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properties of this material have not been fully investigated.
Target Organs: Eyes.
Potential Health Effects
Eye: Causes severe eye irritation. Causes redness and pain. Risk of serious damage to
eyes.
Skin: May cause skin irritation. May cause skin sensitization, an allergic reaction, which
becomes evident upon re-exposure to this material.
Ingestion: May cause gastrointestinal irritation with nausea, vomiting and diarrhea. May
be harmful if swallowed.
Inhalation: May cause respiratory tract irritation. The toxicological properties of this
substance have not been fully investigated.
Chronic: Repeated exposure may cause sensitization dermatitis.
Section 4 - First Aid Measures

Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally
lifting the upper and lower eyelids. Get medical aid.
Skin: Immediately flush skin with plenty of water for at least 15 minutes while removing
contaminated clothing and shoes. Get medical aid if irritation develops or persists. Wash
clothing before reuse.
Ingestion: Do not induce vomiting. If victim is conscious and alert, give 2-4 cupfuls of
milk or water. Get medical aid. Wash mouth out with water.
Inhalation: Remove from exposure and move to fresh air immediately. If not breathing,
give artificial respiration. If breathing is difficult, give oxygen. Get medical aid if cough
or other symptoms appear.
Notes to Physician: Treat symptomatically and supportively.
Section 5 - Fire Fighting Measures

General Information: As in any fire, wear a self-contained breathing apparatus in
pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
During a fire, irritating and highly toxic gases may be generated by thermal
decomposition or combustion. Vapors may be heavier than air. They can spread along the
ground and collect in low or confined areas. Runoff from fire control or dilution water
may cause pollution.
Extinguishing Media: Water or foam may cause frothing. Use water spray, dry chemical,
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carbon dioxide, or chemical foam.
Flash Point: 288 deg C ( 550.40 deg F) Autoignition Temperature: Not available.
Explosion Limits, Lower:Not available.
Upper: Not available.
NFPA Rating: (estimated) Health: 2; Flammability: 1; Instability: 0
Section 6 - Accidental Release Measures

General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks: Absorb spill with inert material (e.g. vermiculite, sand or earth), then place
in suitable container. Avoid runoff into storm sewers and ditches which lead to
waterways. Clean up spills immediately, observing precautions in the Protective
Equipment section. Provide ventilation.
Section 7 - Handling and Storage

Handling: Wash thoroughly after handling. Avoid breathing dust, vapor, mist, or gas.
Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid
ingestion and inhalation. Use with adequate ventilation.
Storage: Do not store in direct sunlight. Store in a tightly closed container. Store in a
cool, dry, well-ventilated area away from incompatible substances.
Section 8 - Exposure Controls, Personal Protection

Engineering Controls: Facilities storing or utilizing this material should be equipped with
an eyewash facility and a safety shower. Use adequate ventilation to keep airborne
concentrations low.
Exposure Limits
Chemical Name
ACGIH
Ethoxylated p-tertnone listed
octylphenol
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NIOSH

OSHA - Final PELs

none listed

none listed
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OSHA Vacated PELs: Ethoxylated p-tert-octylphenol: No OSHA Vacated PELs are
listed for this chemical.
Personal Protective Equipment
Eyes: Wear chemical splash goggles.
Skin: Wear appropriate protective gloves to prevent skin exposure.
Clothing: Wear appropriate protective clothing to prevent skin exposure.
Respirators: Follow the OSHA respirator regulations found in 29 CFR 1910.134 or
European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149
approved respirator if exposure limits are exceeded or if irritation or other symptoms are
experienced.
Section 9 - Physical and Chemical Properties

Physical State: Liquid
Appearance: clear to slightly hazy
Odor: aromatic odor
pH: 6-8
Vapor Pressure: < 1 mm Hg @ 20
Vapor Density: 7.11 (Air=1)
Evaporation Rate:Negligible.
Viscosity: 240 cP at 25 deg C
Boiling Point: 270 deg C
Freezing/Melting Point:7 deg C
Decomposition Temperature:Not available.
Solubility: Soluble in water.
Specific Gravity/Density: 1.082
Molecular Formula:C14H22O.(C2H4O)n
Molecular Weight:206.1534
Section 10 - Stability and Reactivity

Chemical Stability: Stable under normal temperatures and pressures.
Conditions to Avoid: Light, exposure to air, exposure to moist air or water.
Incompatibilities with Other Materials: Oxidizing agents, strong reducing agents, strong
acids.
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Hazardous Decomposition Products: Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Will not occur.
Section 11 - Toxicological Information

RTECS#:
CAS# 9002-93-1: MD0907700; YM0616666; YM0683332
LD50/LC50:
CAS# 9002-93-1:
Draize test, rabbit, eye: 10 uL/24H Moderate;
Draize test, rabbit, skin: 500 uL/24H Mild;
Oral, rat: LD50 = 1800 mg/kg;
Oral, rat: LD50 = 3800 mg/kg;
Oral, rat: LD50 = 1900 mg/kg;
.
Carcinogenicity:
CAS# 9002-93-1: Not listed by ACGIH, IARC, NTP, or CA Prop 65.
Epidemiology: No information found.
Teratogenicity: No information found.
Reproductive Effects: No information found.
Mutagenicity: No data available.
Neurotoxicity: No information found.
Other Studies:
Section 12 - Ecological Information

Ecotoxicity: No data available. Fish-toxicity: Bluegill TL(96H): Dynamic Bioassay: >10
mg/l Static Bioassay: 12 mg/l
Environmental: No information available.
Physical: No information available.
Other: No information available.
Section 13 - Disposal Considerations
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Chemical waste generators must determine whether a discarded chemical is classified as
a hazardous waste. US EPA guidelines for the classification determination are listed in 40
CFR Parts 261.3. Additionally, waste generators must consult state and local hazardous
waste regulations to ensure complete and accurate classification.
RCRA P-Series: None listed.
RCRA U-Series: None listed.
Section 14 - Transport Information

Shipping Name:

US DOT
Not regulated as a hazardous
material

Canada TDG
No information available.

Hazard Class:
UN Number:
Packing Group:

Section 15 - Regulatory Information

US FEDERAL
TSCA
CAS# 9002-93-1 is listed on the TSCA inventory.
Health & Safety Reporting List
None of the chemicals are on the Health & Safety Reporting List.
Chemical Test Rules
None of the chemicals in this product are under a Chemical Test Rule.
Section 12b
None of the chemicals are listed under TSCA Section 12b.
TSCA Significant New Use Rule
None of the chemicals in this material have a SNUR under TSCA.
CERCLA Hazardous Substances and corresponding RQs
None of the chemicals in this material have an RQ.
SARA Section 302 Extremely Hazardous Substances
None of the chemicals in this product have a TPQ.
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SARA Codes
CAS # 9002-93-1: immediate.
Section 313 No chemicals are reportable under Section 313.
Clean Air Act:
This material does not contain any hazardous air pollutants.
This material does not contain any Class 1 Ozone depletors.
This material does not contain any Class 2 Ozone depletors.
Clean Water Act:
None of the chemicals in this product are listed as Hazardous Substances under the
CWA.
None of the chemicals in this product are listed as Priority Pollutants under the CWA.
None of the chemicals in this product are listed as Toxic Pollutants under the CWA.
OSHA:
None of the chemicals in this product are considered highly hazardous by OSHA.
STATE
CAS# 9002-93-1 is not present on state lists from CA, PA, MN, MA, FL, or NJ.
California Prop 65
California No Significant Risk Level: None of the chemicals in this product are listed.
European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols:
XN
Risk Phrases:
R 22 Harmful if swallowed.
R 41 Risk of serious damage to eyes.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately with plenty of
water and seek medical advice.
S 39 Wear eye/face protection.
WGK (Water Danger/Protection)
CAS# 9002-93-1: 1
Canada - DSL/NDSL
CAS# 9002-93-1 is listed on Canada's DSL List.
Canada - WHMIS
This product has a WHMIS classification of D2B.
This product has been classified in accordance with the hazard criteria of the Controlled
Products Regulations and the MSDS contains all of the information required by those
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regulations.
Canadian Ingredient Disclosure List
CAS# 9002-93-1 is listed on the Canadian Ingredient Disclosure List.
Section 16 - Additional Information

MSDS Creation Date: 6/25/1999
Revision #3 Date: 10/13/2003

The information above is believed to be accurate and represents the best information
currently available to us. However, we make no warranty of merchantability or any other
warranty, express or implied, with respect to such information, and we assume no
liability resulting from its use. Users should make their own investigations to determine
the suitability of the information for their particular purposes. In no event shall Fisher be
liable for any claims, losses, or damages of any third party or for lost profits or any
special, indirect, incidental, consequential or exemplary damages, howsoever arising,
even if Fisher has been advised of the possibility of such damages.
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